Antibodies specific for immunoglobulin-like transcript 3 (ILT3) and uses thereof

Abstract
Humanized, non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), also known as Leukocyte immunoglobulin-like receptor subfamily B member 4 (LILRB4), are described.
Description
REFERENCE TO SEQUENCE LISTING SUBMITTED ELECTRONICALLY

The sequence listing of the present application is submitted electronically via EFS-Web as an ASCII formatted sequence listing with a file name “24530US_NP_SEQTXT_05NOVEMBER2018.txt”, creation date of Nov. 5, 2018, and a size of 376 Kb. This sequence listing submitted via EFS-Web is part of the specification and is herein incorporated by reference in its entirety.


BACKGROUND OF THE INVENTION
(1) Field of the Invention

The present invention provides non-promiscuous monoclonal antibodies specific for immunoglobulin-like transcript 3 (ILT3), an inhibitory receptor expressed on the surface of myeloid immune cells.


(2) Description of Related Art

Immunoglobulin-like transcript 3 (ILT3), designated CD85 k and also known as Leukocyte Immunoglobulin-Like Receptor subfamily B member 4 (LILRB4) and Leukocyte Immunoglobulin-like Receptor 5 (LIR-5), is a type I membrane protein that contains cytoplasmic immunoreceptor tyrosine-based inhibition motif (ITIM) motifs and is involved in the down-regulation of immune responses (Cella et al., J Exp Med. 185 (10): 1743-51 (1997); Samaridis et Eur J Immunol. 27 (3): 660-665 (1997). Expression of ILT3 is up-regulated on tolerogenic dendritic cells. This gene is a member of the leukocyte immunoglobulin-like receptor (LIR) family, which is found in a gene cluster at chromosomal region 19q13.4. The encoded protein belongs to the subfamily B class of LIR receptors, which contain two or four extracellular immunoglobulin domains, a transmembrane domain, and two to four ITIMs. ILT3 is selectively expressed by myeloid antigen presenting cells (APCs) such as monocytes, macrophages, and dendritic cells, e.g., monocyte-derived dendritic cells differentiated in the presence of IL-10 or vitamin D3. ILT3 consists of 447 amino acids with a predicted molecular mass of about 47 kD. The amino terminal portion of ILT3 begins with a hydrophobic signal peptide of 23 amino acids followed by an extracellular domain composed of two C2 type immunoglobulin superfamily domains and having the amino acid sequence set forth in SEQ ID NO: 1 less the C-terminal His Tag. (The Rhesus monkey ILT3 extracellular domain has the amino acid sequence set forth in SEQ ID NO: 2). The putative transmembrane domain of ILT3 consists of 21 amino acids, followed by a long cytoplasmic region of 167 amino acids, which is characterized by the presence of motifs spaced by 26 amino acid residues and are reminiscent of the ITIM motifs identified in KIRs (natural-killer cell Ig receptors) as binding sites for protein tyrosine phosphatase SHP-1. ILT3 is expressed on immune cells where it binds to MHC class I molecules on antigen-presenting cells and transduces a negative signal that inhibits stimulation of an immune response. The receptor can also function in antigen capture and presentation. ILT3 is thought to control inflammatory responses and cytotoxicity to help focus the immune response and to limit auto-reactivity. Multiple transcript variants encoding different isoforms of ILT3 have been identified.


Patent publications that disclose use of an antibody for modulating ILT3 activity with applications for inhibiting transplant rejection or for use in treatments for cancer or infectious diseases include U.S. Pub. Nos. 20090202544, 20150110714, 20150139986, and 20170267759; and, Intl. Pub. Nos. WO2013043569, WO2013181438, WO2014116846, WO2016049641, WO2016127427, WO2018089300, and WO2018148494. Of interest is Intl. Pub. No. WO2017015227, which discloses CD166, also known as lymphocyte cell adhesion molecule (ALCAM), as a ligand for ILT3 and provides methods for treating cancer comprising in some embodiments an antibody against CD166 or ALCAM. Also of interest are U.S. Pat. Nos. 7,777,008 and 8,901,281, which disclose monoclonal antibody 9B11 for use in various treatments where it is desirable to upregulate the immune system for anti-cancer treatments and to downregulate the immune system for inhibiting transplant rejection.


While the patent publications disclose anti-ILT3 antibodies, in some instances no specific antibody is disclosed or specific antibodies are disclosed, which in some cases are shown to be promiscuous and cross-react with one or more ILT3-related receptors such as LILRA6 and ILT8. Promiscuous anti-ILT3 antibodies may have off-target effects, which may have undesirable effects that contraindicate its use for therapeutic applications. Therefore there is a need for antibodies and antigen binding fragments that specifically bind ILT3 and have no measurable promiscuity towards other related receptors.


BRIEF SUMMARY OF THE INVENTION

The present invention provides monoclonal antibodies and antigen binding fragments that bind specifically to immunoglobulin-like transcript 3 (ILT3) with no measurable binding to closely related proteins (e.g., ILT5, ILT7, ILT8, or ILT11) as determined by (i) a cell ELISA using 10 μg/mL antibody or antigen binding fragment or (ii) Biacore using 10 μg/mL antibody or antigen binding fragment. In particular embodiments, the antibodies and antigen binding fragments specifically bind to both human ILT3 and Rhesus monkey ILT3. These antibodies and antigen binding fragments are capable of antagonizing ILT3 activity thereby enhancing dendritic cell activation and T cell priming. Tolerized dendritic cells and myeloid-derived suppressor cells (MDSCs) are also responsive to these antibodies. Furthermore, in vivo studies of these antibodies in humanized NSG™ mouse model systems (The Jackson Laboratories, Bar Harbor, Me.) show that these antibodies may have the ability to reduce tumor burden and shift cellular phenotypes to a more activated state.


In clinical trial samples, ILT3 expression, like PD-L1, LAG3, and the GEP signature, was found to be associated with responsiveness to the anti-PD-1 antibody, pembrolizumab. Soluble ILT3 in circulation is also increased in certain cancer types. Taken together, the anti-ILT3 antibodies of the present invention may be useful for treating particular cancers either as a monotherapy treatment or in combination with an anti-PD-1 and/or anti-PD-L1 antibody to enhance responsiveness to the anti-PD-1 or anti-PD-L1 antibody, particularly in cancer treatments in which the cancer is non-responsive to anti-PD-1 or anti-PD-L1 monotherapies. In particular embodiments, the present invention provides chimeric or humanized anti-ILT3 antibodies. In certain embodiments, the antibodies may be fully human antibodies that compete with the antibodies disclosed herein for binding to the ILT3 epitope disclosed herein.


The present invention provides an antibody or antigen binding fragment comprising one, two, or three complementarity determining regions (CDRs) of a heavy chain variable VH domain having heavy chain complementarity determining region (HC-CDR) 1, 2, and 3 and one, two, or three CDRs of a light chain variable domain VL having LC-CDR1, 2, and 3, wherein the antibody or antigen binding fragment is capable of specifically binding human ILT3 wherein the the binding of the antibody or antigen binding fragment may be determined by cell ELISA or Biacore.


In a further embodiment, the antibody or antigen binding fragment binds to an epitope on the human ILT3 or competes with an antibody disclosed for binding to an epitope on the human ILT3, wherein the epitope comprises at least one amino acid within one or more of the amino acid sequences set forth in the group consisting of SEQ ID NOs:3, 4, 5, 6, 7, and 8. In further embodiments, the antibody or antigen binding fragment binds to an epitope on the human ILT3 or competes with an antibody disclosed for binding to an epitope on the human ILT3, wherein the epitope comprises one or more of the amino acid sequences set forth in the group consisting of SEQ ID NOs:3, 4, 5, 6, 7, and 8. In further embodiments, the antibody or antigen binding fragment binds to an epitope on the human ILT3 or competes with an antibody disclosed for binding to an epitope on the human ILT3, wherein the epitope comprises the amino acid sequences set forth in the group consisting of SEQ ID NOs:3, 4, 5, 6, 7, and 8. In particular embodiments, the epitope is determined by hydrogen deuterium exchange mass spectrometry (HDX-MS) analysis.


The present invention further provides an antibody or antigen binding fragment that binds human ILT3 comprising a heavy chain (HC) wherein the heavy chain variable domain (VH) comprises a heavy chain complementarity determining region (HC-CDR) 3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 49, 57, 65, 73, 81, 89, 97, and 105, or having an amino acid sequence that has 3, 2, or 1 differences with an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 49, 57, 65, 73, 81, 89, 97, and 105. In some embodiments the amino acid sequence differences are conservative changes/substitutions. In particular embodiments, the antibody or antigen binding fragment that binds human ILT3 comprises a heavy chain (HC) wherein the heavy chain variable domain (VH) comprises a heavy chain complementarity determining region (HC-CDR) 3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 49, 57, 65, 73, 81, 89, 97, and 105, or having an amino acid sequence that has 3, 2, or 1 differences with an amino acid sequence selected from the group consisting of SEQ ID NO: 23, 49, 57, 65, 73, 81, 89, 97, and 105. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment, the antibody or antigen binding fragment binds to an epitope on the human ILT3 or competes with an antibody disclosed for binding to an epitope on the human ILT3, wherein the epitope comprises at least one amino acid from one or more of the amino acid sequences set forth in in the group consisting of SEQ ID NO: 3, 4, 5, 6, 7, and 8. In further embodiments, the antibody or antigen binding fragment binds to an epitope on the human ILT3 or competes with an antibody disclosed for binding to an epitope on the human ILT3, wherein the epitope comprises one or more of the amino acid sequences set forth in SEQ ID NOs:3, 4, 5, 6, 7, and 8. In further embodiments, the antibody or antigen binding fragment binds to an epitope on the human ILT3 or competes with an antibody disclosed for binding to an epitope on the human ILT3, wherein the epitope comprises the amino acid sequences set forth in SEQ ID NOs:3, 4, 5, 6, 7, and 8. In particular embodiments, the epitope is determined by hydrogen deuterium exchange mass spectrometry (HDX-MS) analysis.


The present invention further provides an antibody or antigen binding fragment that binds human ILT3 comprising (a) an HC having a variable domain (VH) comprising a variable domain complementarity determining region (HC-CDR) 1 having the amino acid sequence set forth in SEQ ID NO: 17, 47, 55, 63, 71, 79, 87, 95, or 103; an HC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 18, 48, 56, 64, 72, 80, 88, 96, or 104; and an HC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 23, 49, 57, 65, 73, 81, 89, 97, or 105; and, variants thereof wherein one or more of the HC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof; and (b) a light chain (LC) having variable domain (VL) comprising a variable domain complementarity determining region (LC-CDR) 1 having the amino acid sequence set forth in SEQ ID NO: 27, 50, 58, 66, 74, 82, 90, 98, or 106; an LC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 43, 51, 59, 67, 75, 83, 91, 99, or 107; and an LC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 44, 60, 68, 76, 84, 92, 100, or 108; and, variants thereof wherein one or more of the LC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody or antigen binding fragment, HC-CDR1 has the amino acid sequence set forth in SEQ ID NO:17; HC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 19, 20, or 21; HC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 23; and LC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 34, 35, 36, 37, 38, 39, 40, 41, or 42; LC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 43; and, LC-CDR3 has the amino acid sequence set forth in SEQ ID NO:44; and, variants thereof wherein one or more of the HC-CDRs and LC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody or antigen binding fragment, HC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 17; HC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 20; and HC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 23; and LC-CDR1 having the amino acid sequence set forth in SEQ ID NO: 41; LC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 43; and, LC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 44; and, variants thereof wherein one or more of the HC-CDRs and LC-CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody or antigen binding fragment, the antibody or antigen binding fragment comprises (a) a VH having a framework selected from the group consisting of human VH1, VH2, VH3, VH4, VH5, and VH6 family and variants thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof; and, (b) a VL having a framework selected from the group consisting of human Vκ1, Vκ2, Vκ3, Vκ4, Vκ5, Vκ6, Vλ2, Vλ3, Vλ4, Vλ5, Vλ6, Vλ7, Vλ8, Vλ9, and Vλ10 family and variants thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In particular embodiments, the antibody or antigen binding fragment comprises (a) a VH having a human VH1 family framework or variant thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof; and, (b) a VL having a human Vκ5 family framework or variant thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody, the antibody comprises a human IgG1, IgG2, IgG3, or IgG4 HC constant domain or variant thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human IgG1, IgG2, IgG3, or IgG4 isotype HC constant domain. In particular aspects, the constant domain may comprise a C-terminal lysine or may lack a C-terminal lysine or a C-terminal glycine-lysine dipeptide.


In particular embodiments, the heavy chain constant domain is of the human IgG1 isotype, which has been modified to have reduced or minimal effector function. In further aspects, the minimal effector function results from an effector-less Fc mutation, which may comprise or consist of the mutation N297A or D265A/N297A as identified using Kabat numbering in which case the minimal effector function results from aglycosylation (see for example, the amino acid sequence shown in SEQ ID NO: 211 wherein the N297A mutation corresponds to amino acid position 180; a D265A mutation, if present, would correspond to amino acid position 148). In particular aspects, the IgG1 has been modified to comprise or consist of an L234A, an L235A, and a D265S mutation as identified using Kabat numbering to render the Fc effector-less (see for example the amino acid sequence shown in SEQ ID NO: 12 or 13 wherein the L234A, L235A, and D265S mutations correspond to amino acid positions 117, 118, and 148, respectively).


In a further aspect, the HC constant domain is of the human IgG4 isotype and which isotype further includes a substitution of the serine residue at position 228 (EU numbering) with proline, which corresponds to position 108 of SEQ ID NO: 9 or 10 (Serine at position 108).


In a further embodiment of the antibody or antigen binding fragment, the antibody comprises a human kappa or lambda LC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa or lambda LC constant domain.


In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody or antigen binding fragment, the antibody comprises (i) a VH having a framework selected from the human VH1, VH2, VH3, VH4, VH5, and VH6 family and a human IgG1 or IgG4 HC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human IgG1 or IgG4 isotype HC constant domain; and, (ii) and a VL having a framework selected from the human Vκ1, Vκ2, Vκ3, Vκ4, Vκ5, Vκ6, Vλ1, Vλ2, Vλ3, Vλ4, Vλ5, Vλ6, Vλ7, Vλ8, Vλ2, and Vλ10 family and a human kappa or lambda LC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa or lambda LC constant domain. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody or antigen binding fragment, the antibody comprises (i) a VH having a human VH2 family framework and a VL having a human Vκ5 family framework; (ii) a human IgG1 or IgG4 HC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human IgG1 or IgG4 isotype HC constant domain; and, (iii) a human kappa LC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa LC constant domain. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody or antigen binding fragment, the antibody comprises (i) a VH having a human VH1 family framework and a human VL having a human Vκ5 family framework; (ii) a human IgG4 HC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human IgG4 isotype HC constant domain; and, (iii) a human kappa LC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa LC constant domain. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In a further embodiment of the antibody or antigen binding fragment, the antibody or antigen binding fragment comprises a VH and a VL having the amino acid sequences set forth in SEQ ID NO: 15 and SEQ ID NO: 16, respectively; SEQ ID NO: 45 and SEQ ID NO: 46, respectively; SEQ ID NO: 53 and SEQ ID NO: 54, respectively; SEQ ID NO: 61 and SEQ ID NO: 62, respectively; SEQ ID NO: 69 and SEQ ID NO: 70, respectively; SEQ ID NO: 77 and SEQ ID NO: 78, respectively; SEQ ID NO: 85 and SEQ ID NO: 86, respectively; SEQ ID NO: 93 and SEQ ID NO: 94, respectively; or SEQ ID NO: 101 and SEQ ID NO: 102, respectively.


In a further embodiment of the antibody or antigen binding fragment, the antibody or antigen binding fragment comprises a VH having the amino acid sequence set forth in SEQ ID NO: 117, 118, 119, 123, 124, or 125 and a VL having the amino acid sequence set forth in SEQ ID NO: 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, or 141.


In a further embodiment of the antibody or antigen binding fragment, the antibody or antigen binding fragment comprises a VH having the amino acid sequence set forth in SEQ ID NO: 118 and a VL having the amino acid sequence set forth in SEQ ID NO: 140.


In a further embodiment of the antibody, the antibody comprises an HC constant domain comprising the amino acid sequence set forth in SEQ ID NO: 9, 10, 11, 12, or 13. In particular aspects, the HC constant domain comprising the amino acid sequence set forth in SEQ ID NOs: 9, 11, 12, or 13 may lack a C-terminal lysine or a C-terminal glycine-lysine dipeptide. In particular embodiments, the HC constant domain comprises the amino acid sequence set forth in SEQ ID NO: 10.


In a further embodiment of the antibody, the antibody comprises an LC constant domain comprising the amino acid sequence set forth in SEQ ID NO: 14.


In a further embodiment of the antibody, the antibody comprises an HC comprising the amino acid sequence of SEQ ID NO: 142, 143, 144, 148, 149, 150, 167, 168, 169, 170, 174, 175, 176, 177, 178, 182, 183, 184, 185, 186, 187, 191, 192, or 193. In particular aspects, the HC comprising the amino acid sequence set forth in SEQ ID NOs: 142, 143, 144, 148, 149, 150, 167, 168, 169, 170, 174, or 175, may lack a C-terminal lysine or a C-terminal glycine-lysine dipeptide. In particular embodiments, the HC comprises the amino acid sequence set forth in SEQ ID NO: 143 or 177. In particular embodiments, the HC set forth in SEQ ID NO: 177 further lacks a C-terminal glycine.


In a further embodiment of the antibody, the antibody comprises an LC comprising the amino acid sequence set forth in SEQ ID NO: 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, or 166. In particular embodiments, the LC comprises the amino acid set forth in SEQ ID NO: 165.


In a further embodiment of the antibody, the antibody comprises an HC having the amino acid sequence set forth in SEQ ID NO:143 and an LC comprising the amino acid sequence set forth in SEQ ID NO:165. In particular aspects, the HC comprising the amino acid sequence set forth in SEQ ID NO: 143 lacks a C-terminal lysine or a C-terminal glycine-lysine dipeptide.


The present invention further provides a chimeric, humanized, or recombinant human antibody or antigen binding fragment that binds to an epitope on a human ILT3, wherein the epitope comprises at least one amino acid within the amino acid sequences set forth in the group consisting of SEQ ID NOs:3, 4, 5, 6, 7, and 8. In a further embodiment, the chimeric, humanized, or recombinant human antibody or antigen binding fragment binds to an epitope on a human ILT3 comprising the amino acid sequences set forth in SEQ ID NOs: 3, 4, 5, 6, 7, and 8. In these embodiments, the epitope is determined by hydrogen deuterium exchange mass spectrometry (HDX-MS) analysis.


The present invention further provides a chimeric, humanized, or recombinant human antibody or antigen binding fragment that binds ILT3 wherein the binding cross-blocks or competes with the binding of an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO: 15 and a light chain having the amino acid sequence shown in SEQ ID NO: 16. In a further embodiment, the chimeric, humanized, or recombinant human antibody or antigen binding fragment that cross-blocks or competes with an antibody comprising a heavy chain having the amino acid sequence set forth in SEQ ID NO: 15 and a light chain having the amino acid sequence shown in SEQ ID NO: 16 binds an epitope on ILT3 that comprises the amino acid sequences set forth in SEQ ID NOS: 3, 4, 5, 6, 7, and 8.


The present invention further provides a composition comprising one or more of any one of the antibody or antigen binding fragment disclosed or claimed herein and a pharmaceutically acceptable carrier.


The present invention further provides a method for treating a cancer in a subject comprising administering to the subject an effective amount of an antibody or antigen binding fragment disclosed or claimed herein sufficient to treat the cancer in the subject.


In a further embodiment, the cancer is pancreatic cancer, melanomas, breast cancer, lung cancer, head and neck cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.


The present invention further provides a method for treatment of a cancer in a subject comprising administering to the subject concurrently or consecutively an antibody or antigen binding fragment disclosed herein in combination with one or more inhibitors or antagonists of PD-1, PD-L1 and/or PD-L2. In one embodiment, the antagonist of PD-1 is an antibody or antigen binding fragment thereof that binds to human PD-1 and blocks the binding of PD1 to human PD-L1 and PD-L2. In one embodiment, the antagonist of PD-L1 or PD-L2 is an antibody or antigen binding fragment thereof that binds to human PD-L1 or PD-L2 and blocks the binding of human PD-L1 or PD-L2 PD1.


In a further embodiment, the anti PD1 antagonist is an anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or pidilizumab and the PD-L1 inhibitor is durvalumab, atezolizumab, avelumab, YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105.


The present invention further provides an antibody or antigen binding fragment disclosed or claimed herein for treatment of cancer in a subject.


In a further embodiment, the cancer is pancreatic cancer, melanomas, breast cancer, lung cancer, head and neck cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.


The present invention further provides an antibody or antigen binding fragment disclosed or claimed herein for treatment of a cancer in a subject wherein the treatment further comprises one or more inhibitors or antagonists of PD-1, PD-L1 and/or PD-L2.


In one embodiment, the antagonist of PD-1 is an antibody or antigen binding fragment thereof that binds to human PD-1 and blocks the binding of PD1 to PD-L1 and PD-L2.


In one embodiment, the antagonist of PD-L1 or PD-L2 is an antibody or antigen binding fragment thereof that binds to human PD-L1 or PD-L2 and blocks the binding of human PD-L1 or PD-L2 PD1.


In a further embodiment, the anti-PD-1 antibody is nivolumab, pembrolizumab, cemiplimab, or pidilizumab and the PD-L1 inhibitor is durvalumab, atezolizumab, avelumab, YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105.


The present invention further provides for use of an antibody or antigen binding fragment disclosed or claimed herein for the treatment of a cancer.


The present invention further provides for use of an antibody or antigen binding fragment disclosed or claimed herein for the manufacture of a medicament for the treatment of a cancer.


In a further embodiment, the cancer is pancreatic cancer, melanomas, breast cancer, lung cancer, head and neck cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer, peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, or cancer of hematological tissues.


The present invention further provides a composition comprising any one of the aforementioned antibodies or antigen binding fragments and a pharmaceutically acceptable carrier. In particular embodiments, the composition comprises a mixture of antibodies comprising a heavy chain having a C-terminal lysine and antibodies comprising a heavy chain lacking a C-terminal lysine. In particular embodiments, the composition comprises an antibody disclosed herein wherein the predominant antibody form comprises a heavy chain having a C-terminal lysine. In particular embodiments, the composition comprises an antibody disclosed herein wherein the predominant antibody form comprises a heavy chain lacking a C-terminal lysine. In particular embodiments, the composition comprises an antibody disclosed herein wherein about 100% of the antibodies in the composition comprise a heavy chain lacking a C-terminal lysine.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1A, FIG. 1B, FIG. 1C, FIG. 10, FIG. 1E, and FIG. 1F show a comparison of the selectivity of several of the anti-ILT3 antibodies disclosed herein to monoclonal antibody 9B11 and mouse IgG1 (mIGgG1) using a cell-based ELISA format. CHO-K1 cells expressing human ILT3 (FIG. 1A), Rhesus monkey ILT3 (FIG. 1B), human ILT5 (FIG. 1C), human ILT7 (FIG. 10), human ILT8 (FIG. 1E), or human ILT11 (FIG. 1F) were each tested with monoclonal antibody p40B5 (LB179.40B5.1A1), p49C6 (LB181.49C6.1A1), and p52B8 lb181.52B8.1B1); antibody 9B11 (U.S. Pat. No. 7,777,008 as having the amino acid sequences of SEQ ID NO: 33 (light chain) and SEQ ID NO: 34 (heavy chain)), and mouse IgG1.



FIG. 2A shows data characteristics on binding affinity, isoelectric point, purity of monomer species, and thermal stability measurements for variants of mAb 10. Terms: “huILT3” refers to human ILT3; “rhILT3” refers to Rhesus monkey ILT3; “pI” refers to isoelectric point; “Tm” refers to temperature mid-point of a thermal unfolding curve; “Tagg” refers to mid-point of a thermal aggregation curve; “SEC” refers size-exclusion ultra-high performance liquid chromatography).



FIG. 2B shows the relationship of SEC purity and melting temperature of humanized light chain variants of mAb 10 (M64V VH1 IgG4). VL1-VL8 refer to variants having the amino acid sequence set forth in SEQ ID NOs: 126-133, respectively.



FIG. 3A shows a deuterium labeling difference heatmap of the human ILT3 extracellular domain amino acid residues that are bound by Chimeric Anti-ILT3 52B8 mouse 52B8 VH parental/human IgG4 (S228P): mouse 52B8 parental VL/human Kappa antibody (“c58B2”; mAb 73). These six peptide domains, which comprise the epitope bound by the antibody(residues 18-23 (ISWGNS; SEQ ID NO: 3), residues 64-69 (IPSMTE; SEQ ID NO: 4), residues 96-101 (MTGAYS; SEQ ID NO: 5), residues 124-131 (QSRSPMDT; SEQ ID NO: 6), residues 152-159 (AQQHQAEF; SEQ ID NO: 7) and residues 184-187 (LLSH; SEQ ID NO: 8)), are located near the border of the D1 and D2 domains of the ILT3 extracellular domain. The amino acid sequence of human extracellular domain with C-terminal His Tag is set forth in SEQ ID NO: 1.



FIG. 3B shows a first view and a second view of a surface structure model of the extracellular domain of human ILT3. The dark region of the model shows the location of the six peptide domains comprising the human ILT3-His epitope bound by c58B8 (mAb 73).



FIG. 3C is a ribbon diagram showing the placement of the epitope on the ILT3 extracellular domain: ISWGNS (SEQ ID NO: 3), IPSMTE (SEQ ID NO: 4), MTGAYS (SEQ ID NO: 5), QSRSPMDT (SEQ ID NO: 6), AQQHQAEF (SEQ ID NO: 7) and LLSH (SEQ ID NO: 8).



FIG. 3D shows a deuterium labeling difference heatmap of the human ILT3 extracellular domain amino acid residues that are bound by antibody ZM4.1.



FIG. 3E shows a deuterium labeling difference heatmap of the human ILT3 extracellular domain amino acid residues that are bound by antibody DX446



FIG. 3F shows a deuterium labeling difference heatmap of the human ILT3 extracellular domain amino acid residues that are bound by antibody DX439.



FIG. 3G shows a deuterium labeling difference heatmap of the human ILT3 extracellular domain amino acid residues that are bound by antibody 9B11.



FIG. 4 shows free c52B8 (mAb 73) concentrations in blood after multiple doses in humanized tumor models (Panc08.13 and SK-MEL-5). Free c52B8 concentrations are expressed by circles and squares. Dashed lines indicate simulated historical antibody levels after IV bolus administration of 1, 3, 10, or 30 mg/kg of humanized IgG4 in C57BL/6J mice.



FIG. 5A shows a human dendritic cell (DC) functional assay demonstrating anti-ILT3 antibody chimeric antibodies in which the VH and VL from p52B8 fused to IgG4 Fc (c52B8; mAb 73), IgG1 Fc (mAb 78), or IgG1 (N297A) Fc (mAb 76) had comparable ability to activate dendritic cells (DCs). Human immature DCs were prepared and differentiated into CD11c+ dendritic cells with GM-CSF (1000 U/mL) and IL-4 (1000 U/mL) over 5 days. These cells were treated with IL-10, LPS (a grain negative bacterial cell wall component and a TLR4 ligand (Raetz et al. Ann. Rev. Biochem 71: 635-700 (2002)), and varying concentrations of the indicated antibodies for 42 hours. The data shown are mean and s.d of two technical replicates. This experiment is representative of four independent studies. Control IgGs had no effect (not shown).



FIG. 5B and FIG. 5C show that humanized 52B8 (lot 26AVY; mAb 46) is indistinguishable from c52B8 (mAb 73) in the human DC functional assay using DCs from two different healthy human donors. The data shown are mean and s.d. of two technical replicates. The data shown are representative of three independent studies using these two donors.



FIG. 6A and FIG. 6B show that anti-ILT3 antibody c52B8 (mAb 73) and humanized anti-ILT3 antibody 52B8 (mAb 46; lot 26AVY) reduce suppressive capacity of myeloid-derived suppressor cells (MDSCs). The T cell suppression assay was conducted with a T cell to MDSC ratio of 4:1. The data shown are means and s.d. of three technical replicates at the level of the T cell assay step. The experiment shown is representative of two independent studies using PBMCs from the same two donors with qualitatively similar results.



FIG. 7 shows c52B8 inhibits growth of SK-MEL-5 tumors in SK-MEL-5 human-NSG mice bearing SK-MEL-5 subcutaneous tumors. Animals were randomized to treatment on the basis of tumor volume on day 21 post-implantation and dosed s.c. with 20 mg/kg of c52B8 or isotype control once weekly beginning on day 21. Data shown in the top panel are means and std. error (nine per group). Individual animal tumor growth curves are shown in the middle and bottom panels. Body weight decreased to a similar degree in both control and 52B8 groups. This study is representative of three independent studies.



FIG. 8A, FIG. 8B, FIG. 8C, and FIG. 8D show the effect of c52B8 in tumor growth and immune activation in SK-MEL-5 hu-NSG model. FIG. 8A shows a tumor growth curve; FIG. 8B shows CyTOF quantification of TILs collected 7 days after the 2nd dose: % CD4+ T regulatory cells and CD69 expression levels on CD4+ T cells; FIG. 8C shows sHLA-G levels in blood plasma harvested at the end of the study; FIG. 8D shows IHC analysis of human CD3+ T cells infiltration in the tumor, 4 tumors in each group.



FIG. 9A, FIG. 9B, FIG. 9C, and FIG. 9D show the effect of a c52B8 and pembrolizumab combination in Panc 08.13 human-NSG mice. FIG. 9A shows a tumor growth curve; FIG. 9B shows CyTOF quantification of % Tregs and CD69 expression levels on CD4+ T cells from tumors harvested at the end of the study; FIG. 9C shows plasma sHLA-G levels in terminal blood samples; FIG. 9D shows plasma IFN7 and IL-8 levels in terminal blood samples quantitated using 10 plex MSD (Meso Scale Discovery).



FIG. 10 shows that humanized anti-ILT3 antibody 52B8 (mAb 46) reduces the suppressive capacity of MDSCs to an extent comparable to chimeric anti-ILT3 antibody c52B8 (mAb 73) in an MDSC/T cell suppression assay at a 4:1 ratio of T cell to MDSC.



FIG. 11 shows the effect of the humanized anti-ILT3 antibody 52B8 (mAb 46) and pembrolizumab combination in an MDSC/T cell suppression assay at either a 4:1 or 8:1 ratio of T cell to MDSC using MDSC cells obtained from human donor D001003835.



FIG. 12 shows the effect of the humanized anti-ILT3 antibody 52B8 (mAb 46) and pembrolizumab combination in an MDSC/T cell suppression assay at an 8:1 ratio of T cell to MDSC using MDSC cells obtained from human donor D001003180.



FIG. 13 shows the effect of the humanized anti-ILT3 antibody 52B8 (mAb 46) and pembrolizumab combination in an MDSC/T cell suppression assay at an 4:1 ratio of T cell to MDSC using MDSC cells obtained from human donor D001003507.



FIG. 14 shows the effect of the humnized anti-ILT3 antibody 52B8 (mAb 46) and pembrolizumab combination in an MDSC/T cell suppression assay at an 8:1 ratio of T cell to MDSC using MDSC cells obtained from human donor D001003428.



FIG. 15 shows the effect humanized anti-ILT3 antibody 52B8 (mAb 46) and pembrolizumab combination in a mixed lymphocyte reaction of IL-10-polarized human monocyte-derived dendritic cells and allogenic CD8+ T cells, incubated for four days followed by measurement of interferon gamma (IFNγ) in the culture supernatant as a read out of T cell activation.





DETAILED DESCRIPTION OF THE INVENTION

The present invention provides non-promiscuous monoclonal antibodies specific for human immunoglobulin-like transcript 3 (ILT3), an inhibitory receptor expressed on the surface of myeloid immune cells.


Definitions

The term “immunoglobulin-like transcript 3” (abbreviated herein as “ILT3”, and also known as LIR-5, LILRB4, or CD85 k), as used herein and unless otherwise indicated, refers to the human member of the ILT3 family, which is selectively expressed by myeloid antigen presenting cells (APCs) such as monocytes, macrophages, and dendritic cells, e.g., monocyte-derived dendritic cells differentiated in the presence of IL-10 or vitamin D3.


As used herein, “antibody” refers to an entire immunoglobulin, including recombinantly produced forms and includes any form of antibody that exhibits the desired biological activity. Thus, it is used in the broadest sense and specifically covers, but is not limited to, monoclonal antibodies (including full length monoclonal antibodies), polyclonal antibodies, multi specific antibodies (e.g., bispecific antibodies), humanized antibodies, fully human antibodies, biparatopic antibodies, humanized camelid heavy chain antibodies, and non-human/human chimeric antibodies. “Parental antibodies” are antibodies obtained by exposure of an immune system to an antigen prior to modification of the antibodies for an intended use, such as humanization of a non-human antibody for use as a human therapeutic antibody.


An “antibody” refers, in one embodiment, to a glycoprotein comprising at least two heavy chains (HCs) and two light chains (LCs) inter-connected by disulfide bonds, or an antigen binding portion thereof. Each heavy chain is comprised of a heavy chain variable region or domain (abbreviated herein as VH) and a heavy chain constant region or domain. In certain naturally occurring IgG, IgD and IgA antibodies, the heavy chain constant region is comprised of three domains, CH1, CH2 and CH3. In certain naturally occurring antibodies, each light chain is comprised of a light chain variable region or domain (abbreviated herein as VL) and a light chain constant region or domain. The light chain constant region is comprised of one domain, CL. The human VH includes six family members: VH1, VH2, VH3, VH4, VH5, and VH6 and the human VL family includes 16 family members: Vκ1, Vκ2, Vκ3, Vκ4, Vκ5, Vκ6, Vλ1, Vλ2, Vλ3, Vλ4, Vλ5, Vλ6, Vλ7, Vλ8, Vλ9, and Vλ10. Each of these family members can be further divided into particular subtypes.


The VH and VL regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDR), interspersed with regions that are more conserved, termed framework regions (FR). Each VH and VL is composed of three CDR regions and four FR regions, arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. The variable regions of the heavy and light chains contain a binding domain that interacts with an antigen. The constant regions of the antibodies may mediate the binding of the immunoglobulin to host tissues or factors, including various cells of the immune system (e.g., effector cells) and the first component (C1q) of the classical complement system. The assignment of amino acids to each domain is, generally, in accordance with the definitions of Sequences of Proteins of Immunological Interest, Kabat, et al.; National Institutes of Health, Bethesda, Md.; 5th ed.; NIH Publ. No. 91-3242 (1991); Kabat (1978) Adv. Prot. Chem. 32:1-75; Kabat, et al., (1977) J. Biol. Chem. 252:6609-6616; Chothia, et al., (1987) J Mol. Biol. 196:901-917 or Chothia, et al., (1989) Nature 342:878-883.


In general, while an antibody comprises six CDRs, three on the VH and three on the VL, the state of the art recognizes that in most cases, the CDR3 region of the heavy chain is the primary determinant of antibody specificity, and examples of specific antibody generation based on CDR3 of the heavy chain alone are known in the art (e.g., Beiboer et al., J. Mol. Biol. 296: 833-849 (2000); Klimka et al., British J. Cancer 83: 252-260 (2000); Rader et al., Proc. Natl. Acad. Sci. USA 95: 8910-8915 (1998); Xu et al., Immunity 13: 37-45 (2000). See Kabat et al. (1991) Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, Md. (defining the CDR regions of an antibody by sequence); see also Chothia and Lesk (1987) J. Mol. Biol. 196: 901-917 (defining the CDR regions of an antibody by structure).


The following general rules shown in Table 1 may be used to identify the CDRs in an antibody sequence. There are rare examples where these virtually constant features do not occur; however, the Cys residues are the most conserved feature.










TABLE 1







Light chain



CDR1



Start
About amino acid residue 24


Residue before
Usually a Cys


Residue after
Usually a Trp. Typically Trp-Tyr-Gln, but also, Trp-Leu-Gln, Trp-



Phe-Gln, or Trp-Tyr-Leu


Length
10 to 17 amino acid residues


Light chain



CDR2



Start
Usually 16 amino acid residues after the end of CDR1


Residues before
Generally Ile-Tyr, but also, Val-Tyr, Ile-Lys, or Ile-Phe


Length
Usually seven amino acid residues


Light chain



CDR3



Start
Usually 33 amino acid residues after end of CDR2


Residue before
Usually Cys


Residues after
Usually Phe-Gly-Xaa-Gly (SEQ ID NO: 221)


Length
Seven to 11 amino acid residues


Heavy chain



CDR1



Start
About amino acid residue 26 (usually four amino acid residues after a



Cys) [Chothia/AbM defintion]; Kabat definition starts five amino acid



residues later


Residues before
Usually Cys-Xaa-Xaa-Xaa (SEQ ID NO: 222)


Residues after
Usually a Trp. Typically Trp-Val, but also, Trp-Ile or Trp-Ala


Length
10 to 12 amino acid residues [AbM definition]; Chothia definition



excludes the last four amino acid residues


Heavy chain



CDR2



Start
Usually 15 amino acid residues after the end of Kabat/AbM



definition) of heavy chain CDR1


Residues before
Typically Leu-Glu-Trp-Ile-Gly (SEQ ID NO: 223), but a number of



variations


Residues after
Lys/Arg-Leu/Ile/Val/Phe/Thr/Ala-Thr/Ser/Ile/Ala


Length
Kabat definition 16 to 19 amino acid residues; AbM (and recent



Chothia) definition ends seven amino acid residues earlier


Heavy chain



CDR3



Start
Usually 33 amino acid residues after end of heavy chain CDR2



(usually two amino acid residues after a Cys)


Residues before
Usually Cys-Xaa-Xaa (typically Cys-Ala-Arg)


Residues after
Usually Trp-Gly-Xaa-Gly (SEQ ID NO: 224)


Length
Three to 25 amino acid residues









In general, the basic antibody structural unit comprises a tetramer. Each tetramer includes two identical pairs of polypeptide chains, each pair having one “light” chain (about 25 kDa) and one “heavy” chain (about 50-70 kDa). The amino-terminal portion of each chain includes a variable region of about 100 to 110 or more amino acids primarily responsible for antigen recognition. The carboxy-terminal portion of the heavy chain may define a constant region primarily responsible for effector function of the antibody. Typically, human light chains are classified as kappa and lambda light chains. Furthermore, human heavy chains are typically classified as mu, delta, gamma, alpha, or epsilon, and define the antibody's isotype as IgM, IgD, IgG, IgA, and IgE, respectively. Within light and heavy chains, the variable and constant regions are joined by a “J” region of about 12 or more amino acids, with the heavy chain also including a “D” region of about 10 more amino acids. See generally, Fundamental Immunology, Ch. 7 (Paul, W., ed., 2nd ed. Raven Press, N.Y. (1989).


The heavy chain of an antibody may or may not contain a terminal lysine (K) residue, or terminal glycine and lysine (GK) residues. Thus, in particular embodiments of the anti-ILT3 antibodies herein comprising a heavy chain constant region amino acid sequence shown herein lacking a terminal lysine but terminating with a glycine residue further include embodiments in which the terminal glycine residue is also lacking. This is because the terminal lysine and sometimes glycine and lysine together may be cleaved during expression of the antibody or cleaved off when introduced into the human body with no apparent adverse effect on antibody efficacy, stability, or immunogenicity. In some cases cases, the nucleic acid molecule encoding the heavy chain may purposely omit the codons encoding the terminal lysine or the codons for the terminal lysine and glycine.


As used herein, “antigen binding fragment” refers to fragments of antibodies, i.e. antibody fragments that retain the ability to bind specifically to the antigen bound by the full-length antibody, e.g. fragments that retain one or more CDR regions. Examples of antibody binding fragments include, but are not limited to, Fab, Fab′, F(ab′)2, and Fv fragments; diabodies; single-chain antibody molecules, e.g., scFv; nanobodies and multispecific antibodies formed from antibody fragments.


As used herein, a “Fab fragment” is comprised of one light chain and the CH1 and variable regions of one heavy chain. The heavy chain of a Fab molecule cannot form a disulfide bond with another heavy chain molecule. A “Fab fragment” can be the product of papain cleavage of an antibody.


As used herein, a “Fab′ fragment” contains one light chain and a portion or fragment of one heavy chain that contains the VH domain and the CH1 domain and also the region between the CH1 and CH2 domains, such that an interchain disulfide bond can be formed between the two heavy chains of two Fab′ fragments to form a F(ab′)2 molecule.


As used herein, a “F(ab′)2 fragment” contains two light chains and two heavy chains containing the VH domain and a portion of the constant region between the CH1 and CH2 domains, such that an interchain disulfide bond is formed between the two heavy chains. An F(ab′)2 fragment thus is composed of two Fab′ fragments that are held together by a disulfide bond between the two heavy chains. An “F(ab′)2 fragment” can be the product of pepsin cleavage of an antibody.


As used herein, an “Fv region” comprises the variable regions from both the heavy and light chains, but lacks the constant regions.


These and other potential constructs are described in Chan & Carter (2010) Nat. Rev. Immunol. 10:301. These antibody fragments are obtained using conventional techniques known to those with skill in the art, and the fragments are screened for utility in the same manner as are intact antibodies. Antigen-binding portions can be produced by recombinant DNA techniques, or by enzymatic or chemical cleavage of intact immunoglobulins.


As used herein, an “Fc” region contains two heavy chain fragments comprising the CH2 and CH3 domains of an antibody. The two heavy chain fragments are held together by two or more disulfide bonds and by hydrophobic interactions of the CH3 domains.


As used herein, a “diabody” refers to a small antibody fragment with two antigen-binding sites, which fragments comprise a heavy chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH—VL or VL—VH). By using a linker that is too short to allow pairing between the two domains on the same chain, the domains are forced to pair with the complementarity domains of another chain and create two antigen-binding sites. Diabodies are described more fully in, e.g., EP 404,097; WO 93/11161; and Holliger et al. (1993) Proc. Natl. Acad. Sci. USA 90: 6444-6448. For a review of engineered antibody variants generally see Holliger and Hudson (2005) Nat. Biotechnol. 23:1126-1136.


As used herein, a “bispecific antibody” is an artificial hybrid antibody having two different heavy/light chain pairs and thus two different binding sites. For example, a bispecific antibody may comprise a first heavy/light chain pair comprising one heavy and one light chain of a first antibody comprising at least the six CDRs of an anti-ILT3 antibody disclosed herein or embodiments wherein one or more of the six CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof along with a second heavy/light chain pair comprising one heavy and one light chain of a second antibody having specificity for an antigen of interest other than ILT3. Bispecific antibodies can be produced by a variety of methods including fusion of hybridomas or linking of Fab′ fragments. See, e.g., Songsivilai, et al., (1990) Clin. Exp. Immunol. 79: 315-321, Kostelny, et al., (1992) J Immunol. 148:1547-1553. In addition, bispecific antibodies may be formed as “diabodies” (Holliger, et al., (1993) PNAS USA 90:6444-6448) or as “Janusins” (Traunecker, et al., (1991) EMBO J. 10:3655-3659 and Traunecker, et al., (1992) Int. J. Cancer Suppl. 7:51-52).


As used herein, “isolated” antibodies or antigen-binding fragments thereof are at least partially free of other biological molecules from the cells or cell cultures in which they are produced. Such biological molecules include nucleic acids, proteins, lipids, carbohydrates, or other material such as cellular debris and growth medium. An isolated antibody or antigen-binding fragment may further be at least partially free of expression system components such as biological molecules from a host cell or of the growth medium thereof. Generally, the term “isolated” is not intended to refer to a complete absence of such biological molecules or to an absence of water, buffers, or salts or to components of a pharmaceutical formulation that includes the antibodies or fragments.


As used herein, a “monoclonal antibody” refers to a population of substantially homogeneous antibodies, i.e., the antibody molecules comprising the population are identical in amino acid sequence except for possible naturally occurring mutations that may be present in minor amounts. In contrast, conventional (polyclonal) antibody preparations typically include a multitude of different antibodies having different amino acid sequences in their variable domains that are often specific for different epitopes. The modifier “monoclonal” indicates the character of the antibody as being obtained from a substantially homogeneous population of antibodies, and is not to be construed as requiring production of the antibody by any particular method. For example, the monoclonal antibodies to be used in accordance with the present invention may be made by the hybridoma method first described by Kohler et al. (1975) Nature 256: 495, or may be made by recombinant DNA methods (see, e.g., U.S. Pat. No. 4,816,567). The “monoclonal antibodies” may also be isolated from phage antibody libraries using the techniques described in Clackson et al (1991) Nature 352: 624-628 and Marks et al. (1991) J. Mot Biol. 222: 581-597, for example. See also Presta (2005) J. Allergy Clin. Immunol. 116:731.


As used herein, a “chimeric antibody” is an antibody having the variable domain from a first antibody and the constant domain from a second antibody wherein (i) the first and second antibodies are from different species (U.S. Pat. No. 4,816,567; and Morrison et al., (1984) Proc. Natl. Acad. Sci. USA 81: 6851-6855) or (ii) the first and second antibodies are from different isotypes, e.g., variable domain from an IgG1 antibody and the constant domains from an IgG4 antibody). In one aspect, the variable domains are obtained from a non-human antibody such as a mouse antibody (the “parental antibody”), and the constant domain sequences are obtained from a human antibody. In a further aspect, the variable domains are humanized variable domains from a mouse antibody and the constant domains of a human antibody.


As used herein, a “humanized antibody” refers to forms of antibodies that contain sequences from both human and non-human (e.g., murine, rat) antibodies. In general, the humanized antibody will comprise all of at least one, and typically two, variable domains, in which the hypervariable loops correspond to those of a non-human immunoglobulin, and all or substantially all of the framework (FR) regions are those of a human immunoglobulin sequence. The humanized antibody may optionally comprise at least a portion of a human immunoglobulin constant region (Fc).


“Humanization” (also called Reshaping or CDR-grafting) is now a well-established technique for reducing the immunogenicity of monoclonal antibodies (mAbs) from xenogeneic sources (commonly rodent) and for improving the effector functions (ADCC, complement activation, C1q binding). The engineered mAb is engineered using the techniques of molecular biology, however simple CDR-grafting of the rodent complementarity-determining regions (CDRs) into human frameworks often results in loss of binding affinity and/or specificity of the original mAb. In order to humanize an antibody, the design of the humanized antibody includes variations such as conservative amino acid substitutions in residues of the CDRs, and back substitution of residues from the rodent mAb into the human framework regions (back mutations). The positions can be discerned or identified by sequence comparison for structural analysis or by analysis of a homology model of the variable regions' 3D structure. The process of affinity maturation has most recently used phage libraries to vary the amino acids at chosen positions. Similarly, many approaches have been used to choose the most appropriate human frameworks in which to graft the rodent CDRs. As the datasets of known parameters for antibody structures increases, so does the sophistication and refinement of these techniques. Consensus or germline sequences from a single antibody or fragments of the framework sequences within each light or heavy chain variable region from several different human mAbs can be used. Another approach to humanization is to modify only surface residues of the rodent sequence with the most common residues found in human mAbs and has been termed “resurfacing” or “veneering.” Often, the human or humanized antibody is substantially non-immunogenic in humans.


As used herein, “non-human amino acid sequences” with respect to antibodies or immunoglobulins refers to an amino acid sequence that is characteristic of the amino acid sequence of a non-human mammal. The term does not include amino acid sequences of antibodies or immunoglobulins obtained from a fully human antibody library where diversity in the library is generated in silico (See for example, U.S. Pat. No. 8,877,688 or 8,691,730).


As used herein, “effector functions” refer to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC); Fc receptor binding; antibody-dependent cell-mediated cytotoxicity (ADCC); phagocytosis; down regulation of cell surface receptors (e.g. B cell receptor); and B cell activation.


As used herein, “conservatively modified variants” or “conservative substitution” refers to substitutions of amino acids with other amino acids having similar characteristics (e.g. charge, side-chain size, hydrophobicity/hydrophilicity, backbone conformation and rigidity, etc.), such that the changes can frequently be made without altering the biological activity of the protein. Those of skill in this art recognize that, in general, single amino acid substitutions in non-essential regions of a polypeptide do not substantially alter biological activity (see, e.g., Watson el al. (1987) Molecular Biology of the Gene, The Benjamin/Cummings Pub. Co., p. 224 (4th Ed.)). In addition, substitutions of structurally or functionally similar amino acids are less likely to disrupt biological activity. Exemplary conservative substitutions are set forth in Table 2.











TABLE 2






Original
Conservative



residue
substitution








Ala (A)
Gly; Ser



Arg (R)
Lys; His



Asn (N)
Gln; His



Asp (D)
Glu; Asn



Cys (C)
Ser; Ala



Gln (Q)
Asn



Glu (E)
Asp; Gln



Gly (G)
Ala



His (H)
Asn; Gln



Ile (I)
Leu; Val



Leu (L)
Ile; Val



Lys (K)
Arg; His



Met (M)
Leu; Ile; Tyr



Phe (F)
Tyr; Met; Leu



Pro (P)
Ala



Ser (S)
Thr



Thr (T)
Ser



Trp (W)
Tyr; Phe



Tyr (Y)
Trp; Phe



Val (V)
Ile; Leu









As used herein, the term “epitope” or “antigenic determinant” refers to a site on an antigen (e.g., ILT3) to which an immunoglobulin or antibody specifically binds. Epitopes within protein antigens can be formed both from contiguous amino acids (usually a linear epitope) or noncontiguous amino acids juxtaposed by tertiary folding of the protein (usually a conformational epitope). Epitopes formed from contiguous amino acids are typically, but not always, retained on exposure to denaturing solvents, whereas epitopes formed by tertiary folding are typically lost on treatment with denaturing solvents. A contiguous linear epitope comprises a peptide domain on an antigen comprising at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids. A noncontiguous conformational epitope comprises one or more peptide domains or regions on an antigen bound by an antibody interspersed by one or more amino acids or peptide domains not bound by the antibody, each domain independently comprises at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 amino acids. Methods for determining what epitopes are bound by a given antibody (i.e., epitope mapping) are well known in the art and include, for example, immunoblotting and immunoprecipitation assays, wherein overlapping or contiguous peptides (e.g., from ILT3) are tested for reactivity with a given antibody (e.g., anti-ILT3 antibody). Methods of determining spatial conformation of epitopes include techniques in the art and those described herein, for example, x-ray crystallography, two-dimensional nuclear magnetic resonance, and HDX-MS (see, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66, G. E. Morris, Ed. (1996)).


The term “epitope mapping” refers to the process of identifying the molecular determinants on the antigen involved in antibody-antigen recognition using techniques in the art and those described herein, for example, x-ray crystallography, two-dimensional nuclear magnetic resonance, and Hydrogen-Deuterium-Exchange-with-Mass-Spectroscopy (HDX-MS).


The term “binds to the same epitope” with reference to two or more antibodies means that the antibodies bind to the same segment of amino acid residues or combinations of segments of amino acids, as determined by a given method. Techniques for determining whether antibodies bind to the “same epitope on ILT3” with the antibodies described herein include, for example, epitope mapping methods, such as, x-ray analyses of crystals of antigen:antibody complexes, which provides atomic resolution of the epitope, and HDX-MS. Other methods that monitor the binding of the antibody to antigen fragments (e.g. proteolytic fragments) or to mutated variations of the antigen where loss of binding due to a modification of an amino acid residue within the antigen sequence is often considered an indication of an epitope component (e.g. alanine scanning mutagenesis—Cunningham & Wells (1985) Science 244:1081). In addition, computational combinatorial methods for epitope mapping can also be used. These methods rely on the ability of the antibody of interest to affinity isolate specific short peptides from combinatorial phage display peptide libraries.


Antibodies that “compete with another antibody for binding to a target such as ILT3” refer to antibodies that inhibit (partially or completely) the binding of the other antibody to the target, i.e., ILT3. Whether two antibodies compete with each other for binding to a target, i.e., whether and to what extent one antibody inhibits the binding of the other antibody to a target, may be determined using known competition experiments. In certain embodiments, an antibody competes with, and inhibits binding of another antibody to a target by at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90% or 100%. The level of inhibition or competition may be different depending on which antibody is the “blocking antibody” (i.e., the cold antibody that is incubated first with the target). Competition assays can be conducted as described, for example, in Ed Harlow and David Lane, Cold Spring Harb Protoc; 2006; doi:10.1101/pdb.prot4277 or in Chapter 11 of “Using Antibodies” by Ed Harlow and David Lane, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., USA 1999. Competing antibodies bind to the same epitope, an overlapping epitope or to adjacent epitopes (e.g., as evidenced by steric hindrance).


Other competitive binding assays include: solid phase direct or indirect radioimmunoassay (RIA), solid phase direct or indirect enzyme immunoassay (EIA), sandwich competition assay (see Stahli et al., Methods in Enzymology 9:242 (1983)); solid phase direct biotin-avidin EIA (see Kirkland et al., J. Immunol. 137:3614 (1986)); solid phase direct labeled assay, solid phase direct labeled sandwich assay (see Harlow and Lane, Antibodies: A Laboratory Manual, Cold Spring Harbor Press (1988)); solid phase direct label RIA using 1-125 label (see Morel et al., Mol. Immunol. 25(1):7 (1988)); solid phase direct biotin-avidin EIA (Cheung et al., Virology 176:546 (1990)); and direct labeled RIA. (Moldenhauer et al., Scand. J. Immunol. 32:77 (1990)).


As used herein, “specifically binds” refers, with respect to an antigen or molecule such as human ILT3, to the preferential association of an antibody or other ligand, in whole or part, with human ILT3 and not to other molecules, particularly molecules found in human blood or serum. Antibodies typically bind specifically to their cognate antigen with high affinity, reflected by a dissociation constant (KD) of 10−7 to 10−11 M or less. Any KD greater than about 10−6 M is generally considered to indicate nonspecific binding. As used herein, an antibody that “specifically binds” or “binds specifically” to human ILT3 refers to an antibody that binds to the human ILT3 with high affinity, which means having a KD of 10−7 M or less, in particular embodiments a KD of 10−8 M or less, or 5×10−9 M or less, or between 10−8 M and 10−11 M or less, but does not bind with measurable binding to closely related proteins such as human ILT5, human ILT7, human ILT8, and human ILT11 as determined in a cell ELISA or Biacore assay using 10 μg/mL antibody.


As used herein, an antigen is “substantially identical” to a given antigen if it exhibits a high degree of amino acid sequence identity to the given antigen, for example, if it exhibits at least 80%, at least 90%, at least 95%, at least 97%, or at least 99% or greater amino acid sequence identity to the amino acid sequence of the given antigen. By way of example, an antibody that binds specifically to human ILT3 may also cross-react with ILT3 from certain non-human primate species (e.g., rhesus monkey or cynomolgus monkey).


As used herein, “isolated nucleic acid molecule” means a DNA or RNA of genomic, mRNA, cDNA, or synthetic origin or some combination thereof which is not associated with all or a portion of a polynucleotide in which the isolated polynucleotide is found in nature, or is linked to a polynucleotide to which it is not linked in nature. For purposes of this disclosure, it should be understood that “a nucleic acid molecule comprising” a particular nucleotide sequence does not encompass intact chromosomes. Isolated nucleic acid molecules “comprising” specified nucleic acid sequences may include, in addition to the specified sequences, coding sequences for up to ten or even up to twenty or more other proteins or portions or fragments thereof, or may include operably linked regulatory sequences that control expression of the coding region of the recited nucleic acid sequences, and/or may include vector sequences.


As used herein, “treat” or “treating” means to administer a therapeutic agent, such as a composition containing any of the antibodies or antigen binding fragments thereof of the present invention, internally or externally to a subject or patient having one or more disease symptoms, or being suspected of having a disease, for which the agent has therapeutic activity or prophylactic activity. Typically, the agent is administered in an amount effective to alleviate one or more disease symptoms in the treated subject or population, whether by inducing the regression of or inhibiting the progression of such symptom(s) by any clinically measurable degree. The amount of a therapeutic agent that is effective to alleviate any particular disease symptom may vary according to factors such as the disease state, age, and weight of the patient, and the ability of the drug to elicit a desired response in the subject. Whether a disease symptom has been alleviated can be assessed by any clinical measurement typically used by physicians or other skilled healthcare providers to assess the severity or progression status of that symptom. The term further includes a postponement of development of the symptoms associated with a disorder and/or a reduction in the severity of the symptoms of such disorder. The terms further include ameliorating existing uncontrolled or unwanted symptoms, preventing additional symptoms, and ameliorating or preventing the underlying causes of such symptoms. Thus, the terms denote that a beneficial result has been conferred on a human or animal subject with a disorder, disease or symptom, or with the potential to develop such a disorder, disease or symptom.


As used herein, “treatment,” as it applies to a human or veterinary subject, refers to therapeutic treatment, as well as diagnostic applications. “Treatment” as it applies to a human or veterinary subject, encompasses contact of the antibodies or antigen binding fragments of the present invention to a human or animal subject.


As used herein, “therapeutically effective amount” refers to a quantity of a specific substance sufficient to achieve a desired effect in a subject being treated. For instance, this may be the amount necessary to inhibit activation of ILT3 or the amount necessary for enhanced pembrolizumab responsiveness when co-administered with pembrolizumab.


As used herein the term “PD-1” refers to the programmed Death 1 (PD-1) protein, an inhibitory member of the extended CD28/CTLA-4 family of T cell regulators (Okazaki et al. (2002) Curr Opin Immunol 14: 391779-82; Bennett et al. (2003) J. Immunol. 170:711-8). Other members of the CD28 family include CD28, CTLA-4, ICOS and BTLA. The PD-1 gene encodes a 55 kDa type I transmembrane protein (Agata et al. (1996) Int Immunol. 8:765-72). Two ligands for PD-1 have been identified, PD-L1 (B7-H1) and PD-L2 (B7-DC), that have been shown to downregulate T cell activation upon binding to PD-1 (Freeman et al. (2000) J. Exp. Med. 192:1027-34; Carter et al. (2002) Eur. J. Immunol. 32:634-43). PD-1 is known as an immunoinhibitory protein that negatively regulates TCR signals (Ishida, Y. et al. (1992) EMBO J. 11:3887-3895; Blank, C. et al. (Epub 2006 Dec. 29) Immunol. Immunother. 56(5):739-745). The interaction between PD-1 and PD-L1 can act as an immune checkpoint, which can lead to, e.g., a decrease in tumor infiltrating lymphocytes, a decrease in T-cell receptor mediated proliferation, and/or immune evasion by cancerous cells (Dong et al. (2003) J. Mol. Med. 81:281-7; Blank et al. (2005) Cancer Immunol. Immunother. 54:307-314; Konishi et al. (2004) Clin. Cancer Res. 10:5094-100). Immune suppression can be reversed by inhibiting the local interaction of PD-1 with PD-L1 or PD-L2; the effect is additive when the interaction of PD-1 with PD-L2 is blocked as well (Iwai et al. (2002) Proc. Nat'l. Acad. Sci. USA 99:12293-7; Brown et al. (2003) J. Immunol. 170:1257-66).


Antibodies and Antigen Binding Fragments


The present invention provides isolated chimeric, humanized, and human antibodies and antigen binding fragments that specifically bind ILT3 and have no measurable binding to closely related proteins (e.g., ILT5, ILT7, ILT8, and ILT11) as determined in a cell ELISA or Biacore assay using 10 μg/mL antibody. The anti-ILT3 antibodies increase activity of antigen presenting cells and dendritic cells, reduce activity of monocyte repressors, and increase priming of T-cells. Thus, the present invention further includes the use of the anti-ILT3 antibodies in monotherapies for the treatment of cancers and for use in combination with anti-PD-1 or anti-PD-L1 antibodies, for either in a first line, second line, or third line therapy for the treatment of cancer.


An anti-ILT3 antibody includes any antibody disclosed herein by amino acid sequence and includes any antibody that comprises (i) at least one, two, three, four, five, or six CDRs of an antibody disclosed herein by amino acid sequence or (ii) has no CDR amino acid sequence disclosed herein but which binds the same epitope on ILT3 as an antibody disclosed herein by amino acid sequence and which may modulate ILT3 receptor signaling such that the antibody increases activity of antigen presenting cells and dendritic cells, reduces activity of monocyte repressors, and increases priming of T-cells. In particular aspects, the antibody has no measurable binding to human ILT5, human ILT7, human ILT8, and human ILT11 as determined in a cell ELISA or in a Biacore assay using 10 μg/mL of the antibody. The term specifically excludes antibodies comprising at least one CDR of antibody ZM4.1 or antibody 9B11 or any of the other antibodies disclosed in U.S. Pat. Nos. 7,777,008 and 8,901,281 or in U.S. Pub. Nos. 20090202544, 20150110714, 20150139986, and 20170267759; and, Intl. Pub. Nos. WO2013043569, WO2013181438, WO2014116846, WO2016049641, WO2016127427, WO2018089300, and WO2018148494.


An anti-ILT3 antigen binding fragment and the like includes any protein or peptide containing molecule that comprises (i) at least a portion of an anti-ILT3 antibody disclosed herein by amino acid sequence, (ii) at least one, two, three, four, five, or six CDRs of an antibody disclosed herein by sequence, or (iii) has no CDR amino acid sequence disclosed herein but which binds the same epitope on ILT3 as an anti-ILT3 antibody disclosed herein by amino acid sequence, and which may modulate ILT3 receptor signaling such that the antigen binding fragment increases activity of antigen presenting cells and dendritic cells, reduces activity of monocyte repressors, and increases priming of T-cells. In particular aspects, the antigen binding fragment has no measurable binding to human ILT5, human ILT7, human ILT8, and human ILT11 as determined in a cell ELISA or in a Biacore assay using 10 μg/mL of the anti-ILT3 antigen binding fragment. The term specifically excludes antigen binding fragments comprising at least one CDR of antibody ZM4.1 or antibody 9B11 or any of the other antibodies disclosed in U.S. Pat. Nos. 7,777,008 and 8,901,281 or U.S. Pub. Nos. 20090202544, 20150110714, 20150139986, and 20170267759; and, Intl. Pub. Nos. WO2013043569, WO2013181438, WO2014116846, WO2016049641, WO2016127427, WO2018089300, and WO2018148494.


In a further embodiment, an anti-ILT3 antibody includes any antibody that comprises (i) at least HC-CDR3 of an antibody disclosed herein by amino acid sequence or (ii) has no H3-CDR3 amino acid sequence disclosed herein but which binds the same epitope on ILT3 as an antibody disclosed herein by amino acid sequence and which may modulate ILT3 receptor signaling such that the antibody increases activity of antigen presenting cells and dendritic cells, reduces activity of monocyte repressors, and increases priming of T-cells. In particular aspects, the antibody has no measurable binding to human ILT5, human ILT7, human ILT8, and human ILT11 as determined in a cell ELISA or in a Biacore assay using 10 μg/mL of the antibody. The term specifically excludes antibodies comprising at least one CDR of antibody ZM4.1 or antibody 9B11 or any of the other antibodies disclosed in U.S. Pat. Nos. 7,777,008 and 8,901,281 or in U.S. Pub. Nos. 20090202544, 20150110714, 20150139986, and 20170267759; and, Intl. Pub. Nos. WO2013043569, WO2013181438, WO2014116846, WO2016049641, WO2016127427, WO2018089300, and WO2018148494.


An anti-ILT3 antigen binding fragment and the like includes any protein or peptide containing molecule that comprises (i) at least a portion of an anti-ILT3 antibody disclosed herein by amino acid sequence, (ii) at least the HC-CDR3 of an antibody disclosed herein by sequence, or (iii) has no HC-CDR3 amino acid sequence disclosed herein but which binds the same epitope on ILT3 as an anti-ILT3 antibody disclosed herein by amino acid sequence, and which may modulate ILT3 receptor signaling such that the antigen binding fragment increases activity of antigen presenting cells and dendritic cells, reduces activity of monocyte repressors, and increases priming of T-cells. In particular aspects, the antigen binding fragment has no measurable binding to human ILT5, human ILT7, human ILT8, and human ILT11 as determined in a cell ELISA or in a Biacore assay using 10 μg/mL of the anti-ILT3 antigen binding fragment. The term specifically excludes antigen binding fragments comprising at least one CDR of antibody ZM4.1 or antibody 9B11 or any of the other antibodies disclosed in U.S. Pat. Nos. 7,777,008 and 8,901,281 or U.S. Pub. Nos. 20090202544, 20150110714, 20150139986, and 20170267759; and, Intl. Pub. Nos. WO2013043569, WO2013181438, WO2014116846, WO2016049641, WO2016127427, WO2018089300, and WO2018148494.


In particular embodiments, the anti-ILT3 antibody is a human or humanized anti-ILT3 antibody or antigen binding fragment or a chimeric anti-ILT3 antibody or antigen binding fragment that comprises HC-CDR3 of an anti-ILT3 antibody molecule disclosed herein or an H3-CDR3 shown in Table 3.


In particular embodiments, the anti-ILT3 antibody is a human or humanized anti-ILT3 antibody or antigen binding fragment or a chimeric anti-ILT3 antibody or antigen binding fragment that comprises HC-CDR1, HC-CDR2, HC-CDR3, LC-CDR1, LC-CDR2, and LC-CDR3 of an anti-ILT3 antibody molecule disclosed herein or in Table 3.















TABLE 3









Seq

Seq

Seq


mAb
HC-CDR1
No.
HC-CDR2
No.
HC-CDR3
No.





52B8
NYGMS
17
TISGGGDYTMYPDSVRG
20
RLWFRSLYYAMDY
23





40A6
SYSIN
47
RFWYDEGIAYNLTLES
48
DRDTVGITGWFAY
49





16B1
NYCVN
55
RFWFDEGKAYNLTLES
56
DRDTVGITGWFAY
57





11D1
TYWIE
63
EILPGNGNTHFNENFKD
64
RRLGRGPFDF
65





17H12
NFDMA
71
SITYDGGSTSYRDSVKG
72
VESIATISTYFDY
73





37C8
SYCVN
79
RFWYDEGKVYNLTLES
80
DRDTMGITGWFAY
81





1G12
TYWIQ
87
EILPGSGTTNYNENFKG
88
RLGRGPFDY
89





20E4
SYSVN
95
RFWYDGGTAYNSTLES
96
DRDTMGITGWFAY
97





24A4
SYCVN
103
RFWYDEGKVYNLTLES
104
DRDTLGITGWFAY
105





mAb
LC-CDR1

LC-CDR2

LC-CDR3






52B8
RASEKVDSFGQSFMH
41
LTSNLDS
43
QQNNEDPYT
44





40A6
KASQSVGVNVD
50
GSANRHT
51
LQYGSVPYT
52





16B1
KASQSVGINVD
58
GSANRHT
59
LQYGSVPYT
60





11D1
KASQDINEYIG
66
YTSTLQS
67
LQYANPLPT
68





17H12
RASQSVSMSRYDLIH
74
RASDLAS
75
QQTRKSPPT
76





37C8
KASQSVGINVD
82
GSANRHT
83
LQYGSVPYT
84





1G12
EASQDINKHID
90
YASILQP
91
LQYDNLLPT
92





20E4
KASQSVGVNVD
98
GSANRHT
99
LQYGSVPYT
100





24A4
KASQSVGINVD
106
GSANRHT
107
LQYGSVPYT
108









In particular embodiments, the anti-ILT3 antibody is a human or humanized anti-ILT3 antibody or antigen binding fragment or a chimeric anti-ILT3 antibody or antigen binding fragment, in each case comprising a heavy chain variable domain (VH) having a heavy chain complementarity determining region (HC-CDR) 3 comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 49, 57, 65, 73, 81, 89, 97, and 105, or an amino acid sequence that has 3, 2, or 1 differences with an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 49, 57, 65, 73, 81, 89, 97, and 105. In a further embodiment, the antibody or antigen binding fragment binds to an epitope on the human ILT3, wherein the epitope comprises at least one amino acid from one or more of the amino acid sequences set forth in in the group consisting of SEQ ID NO: 3, 4, 5, 6, 7, and 8. In a further embodiment, the antibody or antigen binding fragment binds to an epitope on the human ILT3, wherein the epitope comprises the amino acid sequences set forth in in the group consisting of SEQ ID NO: 3, 4, 5, 6, 7, and 8. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In particular embodiments, the anti-ILT3 antibody is a humanized or chimeric anti-ILT3 antibody disclosed herein. In particular embodiments, the anti-ILT3 antibody is a human or humanized anti-ILT3 antibody or antigen binding fragment or a chimeric anti-ILT3 antibody or antigen binding fragment that binds the same epitope bound by an anti-ILT3 antibody disclosed herein or competes with the binding of an anti-ILT3 antibody disclosed herein and the antibody comprises less than three or none of the CDRs of an anti-ILT3 antibody disclosed herein.


The present invention further provides an antibody or antigen binding fragment comprising (i) at least the six complementary determining regions (CDRs) of an anti-immunoglobulin-like transcript 3 (ILT3) antibody or (ii) at least the six CDRs of an anti-ILT3 antibody wherein one or more of the six CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations; wherein the six CDRs of the anti-ILT3 antibody comprise a heavy chain (HC)-CDR1 having the amino acid sequence set forth in SEQ ID NO: 17, 47, 55, 63, 71, 79, 87, 95, or 103; an HC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 18, 48, 56, 64, 72, 80, 88, 96, or 104; an HC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 22, 49, 57, 65, 73, 81, 89, 97, or 105; a light chain (LC)-CDR1 having the amino acid sequence set forth in SEQ ID NO: 27, 50, 58, 66, 74, 82, 90, 98, or 106; an LC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 43, 51, 59, 67, 75, 83, 91, 99, or 107; and an LC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 44, 60, 68, 76, 84, 92, 100, or 108; and, wherein the antibody or antigen binding fragment specifically binds human or rhesus ILT3 or both human and rhesus ILT3. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In particular embodiments, the present invention provides an antibody or antigen binding fragment comprising the six CDRs of the anti-ILT3 antibody comprise a heavy chain (HC)-CDR1 having the amino acid sequence set forth in SEQ ID NO:17; an HC-CDR2 having the amino acid sequence set forth in SEQ ID NO:19, 20, or 21; an HC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 23, 24, 25, or 26; a light chain (LC)-CDR1 having the amino acid sequence set forth in SEQ ID NO: 34, 35, 36, 37, 38, 39, 40, 41, or 42; an LC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 43; and an LC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 44.


In particular embodiments, the present invention provides an antibody or antigen binding fragment comprising the six CDRs of the anti-ILT3 antibody having a heavy chain (HC)-CDR1 having the amino acid sequence set forth in SEQ ID NO: 17; an HC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 20; an HC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 23; a light chain (LC)-CDR1 having the amino acid sequence set forth in SEQ ID NO: 41; an LC-CDR2 having the amino acid sequence set forth in SEQ ID NO: 43; and an LC-CDR3 having the amino acid sequence set forth in SEQ ID NO: 44.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody or antigen binding fragment comprises a heavy chain variable domain (VH) having a framework selected from the human VH1, VH2, VH3, VH4, VH5, and VH6 family and variants thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof; and, (b) a light chain variable domain (VL) having a framework selected from the human Vκ1, Vκ2, Vκ3, Vκ4, Vκ5, Vκ6, Vλ1, Vλ2, Vλ3, Vλ4, Vλ5, Vλ6, Vλ7, Vλ8, Vλ9, and Vλ10 family and variants thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody comprises a human IgG1, IgG2, IgG3, or IgG4 heavy chain (HC) constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native IgG1, IgG2, IgG3, or IgG4 isotype.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody comprises a human kappa or lambda light chain constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa or lambda light chain domain.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody comprises (i) a human heavy chain variable domain (VH) having a framework selected from the human VH3 family and a human light chain variable domain (VL) having a framework selected from the human Vκ1, Vκ3, and Vκ4 family; (ii) a human IgG1 or IgG4 heavy chain (HC) constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native IgG1 or IgG4 isotype; and, (iii) a human kappa or lambda light chain constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa or lambda light chain domain. In particular embodiments the amino acid sequence differences are conservative changes/substitutions.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody or antigen binding fragment comprises a heavy chain variable domain (VH) and a light chain variable domain (VL) having the amino acid sequences set forth in SEQ ID NO: 15 and SEQ ID NO: 16, respectively; SEQ ID NO: 45 and SEQ ID NO: 46, respectively; SEQ ID NO: 53 and SEQ ID NO: 54, respectively; SEQ ID NO:61 and SEQ ID NO: 62, respectively; SEQ ID NO: 69 and SEQ ID NO: 70, respectively; SEQ ID NO:77 and SEQ ID NO: 78, respectively; SEQ ID NO: 85 and SEQ ID NO: 86, respectively; SEQ ID NO: 93 and SEQ ID NO: 94, respectively; or SEQ ID NO: 101 and SEQ ID NO: 102, respectively.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody or antigen binding fragment comprises a heavy chain variable domain (VH) having the amino acid sequence set forth in SEQ ID NO: 117, 118, 119, 120, 121, 122, 123, 124, or 125 and a light chain variable domain (VL) having the amino acid sequence set forth in SEQ ID NO: 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, or 141.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody or antigen binding fragment comprises a heavy chain variable domain (VH) having the amino acid sequence set forth in SEQ ID NO: 118 and a light chain variable domain (VL) having the amino acid sequence set forth in SEQ ID NO: 140.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein, the antibody comprises a heavy chain (HC) constant domain comprising the amino acid sequence set forth in SEQ ID NO: 9, 10, 11, 12, or 13 and variants of SEQ ID NO: 9, 11, 12, or 13 in which the HC lacks a C-terminal Lysine or glycine-lysine.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein, the antibody comprises a light chain (LC) constant domain comprising the amino acid sequence set forth in SEQ ID NO: 14.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein, the antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 142, 143, 144, 148, 149, 150, 167, 168, 169, 170, 174, 175, 176, 177, 178, 182, 183, 184, 185, 186, 187, 191, 192, or 193 and variants of an HC comprising the amino acid sequence of SEQ ID NO: 143, 144, 148, 149, 150, 167, 168, 169, 170, 174, or 175 in which the HC lacks a C-terminal Lysine or glycine-lysine.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein, the antibody comprises a light chain (LC) comprising the amino acid sequence set forth in SEQ ID NO: 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, or 166.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein, the antibody comprises a heavy chain (HC) comprising the amino acid sequence of SEQ ID NO: 142, 143, 144, 148, 149, 150, 167, 168, 169, 170, 174, 175, 176, 177, 178, 182, 183, 184, 185, 186, 187, 191, 192, or 193 and a light chain (LC) comprising the amino acid sequence set forth in SEQ ID NO: 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, or 166, and variants of an HC comprising the amino acid sequence of SEQ ID NO: 143, 144, 148, 149, 150, 167, 168, 169, 170, 174, or 175 in which the HC lacks a C-terminal Lysine or glycine-lysine.


In particular embodiments, the present invention provides an antibody selected from the antibodies presented in Table 4.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein, the antibody comprises a heavy chain (HC) having the amino acid sequence set forth in SEQ ID NO: 143 and a light chain (LC) comprising the amino acid sequence set forth in SEQ ID NO: 165 and variants in which the HC lacks a C-terminal Lysine or glycine-lysine.


In particular embodiments, the present invention provides the above antibody or antigen binding fragment wherein the antibody comprises a human IgG1, IgG2, IgG3, or IgG4 heavy chain (HC) constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native IgG1, IgG2, IgG3, or IgG4 isotype, and variants thereof in which the HC lacks a C-terminal Lysine or glycine-lysine.


In some embodiments, different constant domains may be fused to a VL and VH regions comprising the CDRs provided herein. In particular embodiments, the VH regions comprising the CDRs provided herein may be fused to a human IgG1, IgG2, IgG3, or IgG4 heavy chain (HC) constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native or wild-type IgG1, IgG2, IgG3, or IgG4 isotype, and variants thereof in which the HC lacks a C-terminal Lysine or glycine-lysine.


In particular embodiments, the anti-ILT3 antibody (or antigen binding fragment) has an altered effector function and may comprise a heavy chain constant domain other than native (wild-type) human IgG1, for example a human IgG1 that has mutations that abrogate or minimize one or more effector functions, including ability to bind complement, human IgG4, or a hybrid human IgG1/human IgG4, and variants thereof in which the HC lacks a C-terminal Lysine or glycine-lysine.


Although native human IgG1 antibodies provide for long half-life and for effector functions, such as complement activation and antibody-dependent cellular cytotoxicity, such activities may not be desirable for all uses of an antibody. Thus, in particular embodiments, it is desirable that the heavy chain constant domain or Fc have minimal or reduced effector function (“effector-less”). In those instances, the anti-ILT3 HC variable domain may be fused to a human IgG4 constant domain, which is generally known to be effector-less, or an IgG1 constant domain that has been mutated to be rendered effecter-less. These effector-less molecules have minimal or reduced binding to human FcγRIIIA, and FcγRIIA, and Fcγ.RI compared to the polypeptide comprising the wildtype IgG Fc region, wherein the affinity to each of human FcγRIIIA, and FcγRIIA, and FcγRI is reduced by 1.15-fold to 100-fold compared to the polypeptide comprising the wildtype IgG constant domain, and wherein the antibody-dependent cell-mediated cytotoxicity (ADCC) induced by said molecule is 0-20% of the ADCC induced by the polypeptide comprising the wild-type human IgG1 constant domain.


Therefore in particular embodiments, the present invention includes chimeric or humanized anti-ILT3 antibodies and antigen-binding fragments thereof that comprise a human IgG4 constant domain. In a further embodiment, the human IgG4 constant domain may be modified to differ from the native (wild-type) human IgG4 constant domain (Swiss-Prot Accession No. P01861.1) at a position corresponding to position 228 in the EU system and position 241 in the Kabat system in which the native serine at position 108 (Ser108) of the HC constant domain is replaced with proline (Pro), see for example SEQ ID NO: 9. This modification prevents formation of a potential inter-chain disulfide bond between the cysteine at position 106 (Cys106) and the cysteine at position 109 (Cys109), which correspond to positions Cys226 and Cys229 in the EU system and positions Cys239 and Cys242 in the Kabat system, which may interfere with proper intra-chain disulfide bond formation. See Angal et al. Mol. Imunol. 30:105 (1993); see also (Schuurman et. al., Mol. Immunol. 38: 1-8, (2001); SEQ ID NOs: 14 and 41). In particular embodiments, the human IgG4 constant domain may further include in addition to the S228P substitution an L235E substitution.


In another embodiment, the chimeric or humanized anti-ILT3 antibody may be fused to a modified human IgG1 constant domain, which has been modified to be effector-less. In one embodiment, the human IgG1 HC may include substitutions of human IgG2 HC residues at positions 233-236 and IgG4 HC residues at positions 327, 330, and 331 to greatly reduce ADCC and CDC (Armour et al., Eur J Immunol. 29(8):2613-24 (1999); Shields et al., J Biol Chem. 276(9):6591-604(2001)). In particular embodiments, the antibody comprises a human IgG1 heavy chain (HC) constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native IgG, which provides an antibody having reduced or minimal effector function. In particular aspects, the IgG1 has been modified to comprise or consist of an L234A, an L235A, and a D265S mutation to render the Fc effector-less. Other mutations that may be used to render an IgG1 Fc effector-less may be found in U.S. Pat. No. 8,969,526.


In another embodiment, the human IgG1 HC is modified to lack N-glycosylation of the asparagine (Asn) residue at around position 297 of the HC. The consensus sequence for N-glycosylation is Asn-Xaa-Ser/Thr (wherein Xaa is any amino acid except Pro); in IgG1 the N-glycosylation consensus sequence is Asn-Ser-Thr. The modification may be achieved by replacing the codon for the Asn at position 297 in the nucleic acid molecule encoding the HC with a codon for another amino acid, for example Gln. Alternatively, the codon for Ser may be replaced with the codon for Pro or the codon for Thr may be replaced with any codon except the codon for Ser, e.g. N297A or N297D Such modified IgG1 molecules have little or no detectable effector function. Alternatively, all three codons are modified.


In another embodiment, the human IgG1 constant domain is modified to include one or more amino acid substitutions selected from E233P, L234A, L235A, L235E, N297A, N297D, D265S, and P331S, wherein the residues are numbered according to the EU index of Kabat, and wherein said polypeptide exhibits a reduced affinity to the human FcγRIIIA and/or FcγRIIA and/or FcγRI compared to a polypeptide comprising the wildtype IgG constant domain region. In particular embodiments, the human IgG constant domain comprises substitutions of L234A, L235A, and D265S as illustrated by SEQ ID NO: 4, for example. In particular embodiments, the human IgG1 constant domain comprises an amino acid substitution at position Pro329 and at least one further amino acid substitution E233P, L234A, L235A, L235E, N297A, N297D, D265S, and P331S. These and other substitutions are disclosed in WO9428027; WO2004099249; WO20121300831, U.S. Pat. Nos. 9,708,406; 8,969,526; 9,296,815; Sondermann et al. Nature 406, 267-273 (20 Jul. 2000)).


In an embodiment of the invention, the anti-ILT3 antibodies or antigen binding fragments thereof include embodiments in which one or more of the six CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof comprise a full tetrameric structure having two light chains and two heavy chains, including constant regions. The variable regions of each light chain/heavy chain pair form the antibody binding site. Thus, in general, an intact antibody has two binding sites. Except in bispecific antibodies, the two binding sites are, in general, the same.


In specific embodiments, the present invention provides the anti-ILT3 antibodies shown in the Table 4. With the exception of those antibodies comprising a replacement of the tryptophan residue at position 101 of the VH, the antibodies disclosed herein bind the human ILT3.










TABLE 4








SEQ ID NO:










mAb

Heavy
Light


No.
Description
Chain
Chain













1
Humanized anti-ILT3 mAb (52B8 VH1/VL1) IgG4
142
151



S228P/Kappa




2
Humanized anti-ILT3 mAb (52B8 VH1/VL2) IgG4
142
152



S228P/Kappa




3
Humanized anti-ILT3 mAb (52B8 VH1/VL3) IgG4
142
153



S228P/Kappa




4
Humanized anti-ILT3 mAb (52B8 VH1/VL4) IgG4
142
154



S228P/Kappa




5
Humanized anti-ILT3 mAb (52B8 VH2/VL1) IgG4
148
151



S228P/Kappa




6
Humanized anti-ILT3 mAb (52B8 VH2/VL2) IgG4
148
152



S228P/Kappa




7
Humanized anti-ILT3 mAb (52B8 VH2/VL3) IgG4
148
153



S228P/Kappa




8
Humanized anti-ILT3 mAb (52B8 VH2/VL4) IgG4
148
154



S228P/Kappa




9
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL1)
143
151



IgG4 S228P/Kappa




10
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL2)
143
152



IgG4 S228P/Kappa




11
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL3)
143
153



IgG4 S228P/Kappa




12
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL4)
143
154



IgG4 S228P/Kappa




13
Humanized anti-ILT3 mAb (52B8 VH2 M64V/VL1)
149
151



IgG4 S228P/Kappa




14
Humanized anti-ILT3 mAb (52B8 VH2 M64V/VL2)
149
152



IgG4 S228P/Kappa




15
Humanized anti-ILT3 mAb (52B8 VH2 M64V/VL3)
149
153



IgG4 S228P/Kappa




16
Humanized anti-ILT3 mAb (52B8 VH2 M64V/VL4)
149
154



IgG4 S228P/Kappa




17
Humanized anti-ILT3 mAb (52B8 VH1 M64L/VL1)
144
151



IgG4 S228P/Kappa




18
Humanized anti-ILT3 mAb (52B8 VH1 M64L/VL2)
144
152



IgG4 S228P/Kappa




19
Humanized anti-ILT3 mAb (52B8 VH1 M64L/VL3)
144
153



IgG4 S228P/Kappa




20
Humanized anti-ILT3 mAb (52B8 VH1 M64L/VL4)
144
155



IgG4 S228P/Kappa




21
Humanized anti-ILT3 mAb (52B8 VH2 M64L/VL1)
150
151



IgG4 S228P/Kappa




22
Humanized anti-ILT3 mAb (52B8 VH2 M64L/VL2)
150
152



IgG4 S228P/Kappa




23
Humanized anti-ILT3 mAb (52B8 VH2 M64L/VL3)
150
153



IgG4 S228P/Kappa




24
Humanized anti-ILT3 mAb (52B8 VH2 M64L/VL4)
150
154



IgG4 S228P/Kappa




25
Humanized anti-ILT3 mAb ((52B8 VH1 M64V/VL2)
169
152



L234A L235A D265S) IgG1/Kappa




26
Humanized anti-ILT3 mAb ((52B8 VH1 M64V/VL5)
169
152



L234A L235A D265S) IgG1/Kappa




27
Humanized anti-ILT3 mAb ((52B8 VH1 M64V/VL6)
169
156



L234A L235A D265S) IgG1/Kappa




28
Humanized anti-ILT3 mAb ((52B8 VH1 M64V/VL7)
169
157



L234A L235A D265S) IgG1/Kappa




29
Humanized anti-ILT3 mAb ((52B8 VH1 M64V/VL8)
169
158



L234A L235A D265S) IgG1/Kappa




30
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL5)
143
155



IgG4 S228P/Kappa




31
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL6)
143
156



IgG4 S228P/Kappa




32
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL7)
143
157



IgG4 S228P/Kappa




33
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL8)
143
158



IgG4 S228P/Kappa




34
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101F/
145
152



VL2) IgG4 S228P/Kappa




35
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Y/
146
152



VL2) IgG4 S228P/Kappa




36
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Q/
147
152



VL2) IgG4 S228P/Kappa




37
Humanized anti-ILT3 mAb ((52B8 VH1 M64V W101F/
145
152



VL2) L234A L235A D265S) IgG1/Kappa




38
Humanized anti-ILT3 mAb ((52B8 VH1 M64V W101Y/
146
152



VL2) L234A L235A D265S) IgG1/Kappa




39
Humanized anti-ILT3 mAb ((52B8 VH1 M64V W101Q/
147
152



VL2) L234A L235A D265S) IgG1/Kappa




40
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL2
143
159



S35A) IgG4 S228P/Kappa




41
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL2
143
160



S35N) IgG4 S228P/Kappa




42
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL2
143
161



N34Q) IgG4 S228P/Kappa




43
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL2
143
162



N34D) IgG4 S228P/Kappa




44
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL5
143
163



S35A) IgG4 S228P/Kappa




45
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL5
143
164



S35N) IgG4 S228P/Kappa




46
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL5
143
165



N34Q) IgG4 S228P/Kappa




47
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL5
143
166



N34D) IgG4 S228P/Kappa




48
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101F/
145
155



VL5) IgG4 S228P/Kappa




49
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Y/
146
155



VL5) IgG4 S228P/Kappa




50
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Q/
147
155



VL5) IgG4 S228P/Kappa




51
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101F/
145
163



VL5 S35A) IgG4 S228P/Kappa




52
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101F/
145
164



VL5 S35N) IgG4 S228P/Kappa




53
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101F/
145
165



VL5 N34Q) IgG4 S228P/Kappa




54
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101F/
145
166



VL5 N34D) IgG4 S228P/Kappa




55
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Y/
146
163



VL5 S35A) IgG4 S228P/Kappa




56
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Y/
146
164



VL5 S35N) IgG4 S228P/Kappa




57
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Y/
146
165



VL5 N34Q) IgG4 S228P/Kappa




58
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Y/
146
166



VL5 N34D) IgG4 S228P/Kappa




59
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Q/
147
163



VL5 S35A) IgG4 S228P/Kappa




60
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Q/
147
164



VL5 S35N) IgG4 S228P/Kappa




61
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Q/
147
165



VL5 N34Q) IgG4 S228P/Kappa




62
Humanized anti-ILT3 mAb (52B8 VH1 M64V W101Q/
147
166



VL5 N34D) IgG4 S228P/Kappa




63
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL1
210
126



N34Q) IgG1 N297A/Kappa




64
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL2
210
127



IgG1 N297A/Kappa




65
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL2
210
161



N34Q) IgG1 N297A/Kappa




66
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL3
210
128



N34Q) IgG1 N297A/Kappa




67
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL4
210
129



N34Q) IgG1 N297A/Kappa




68
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL5
210
130



IgG1 N297A/Kappa




69
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL5
210
165



N34Q) IgG1 N297A/Kappa




70
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL6
210
131



N34Q) IgG1 N297A/Kappa




71
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL7
210
132



N34Q) IgG1 N297A/Kappa




72
Humanized anti-ILT3 mAb (52B8 VH1 M64V/VL8
210
133



N34Q) IgG1 N297A/Kappa




73
Chimeric anti-ILT3 52B8 mouse VH/human IgG4
113
116



(S228P):mouse VL/human Kappa




74
Chimeric anti-ILT3 52B8 mouse VH M64V/human IgG4
114
116



(S228P):mouse VL/human Kappa




75
Chimeric anti-ILT3 52B8 mouse VH M64L/human IgG4
115
116



(S228P):mouse VL/human Kappa




76
Chimeric anti-ILT3 52B8 mouse VH/human IgG1

116



(N297A):mouse VL/human Kappa
Residues





1-122 of





SEQ ID





NO: 113





And





SEQ ID





NO: 211



77
Chimeric anti-ILT3 52B8 mouse VH M64V/human IgG1
Residues
116



(N297A):mouse VL/human Kappa
1-122 of





SEQ ID





NO: 114





And





SEQ ID





NO: 211



78
Chimeric anti-ILT3 52B8 mouse VH/human IgG1:mouse
Residues
116



VL/human Kappa
1-122 of





SEQ ID





NO: 113





And





SEQ ID





NO: 11



79
Chimeric anti-ILT3 52B8 mouse VH M64V/human
Residues
116



IgG1:mouse VL/human Kappa
1-122 of





SEQ ID





NO: 113





And





SEQ ID





NO: 11



80
Chimeric anti-ILT3 40A6 rat VH/human IgG4
194
195



(S228P):rat VL/human Kappa




81
Chimeric anti-ILT3 16B1 rat VH/human IgG4
196
197



(S228P):rat VL/human Kappa




82
Chimeric anti-ILT3 11D1 mouse VH/human IgG4
198
199



(S228P):mouse VL/human Kappa




83
Chimeric anti-ILT3 17H12 rat VH/human IgG4
200
201



(S228P):rat VL/human Kappa




84
Chimeric anti-ILT3 37C8 rat VH/human IgG4
202
203



(S228P):rat VL/human Kappa




85
Chimeric anti-ILT3 IG12 mouse VH/human IgG4
203
205



(S228P):mouse VL/human Kappa




86
Chimeric anti-ILT3 20E4 rat VH/human IgG4
206
207



(S228P):rat VL/human Kappa




87
Chimeric anti-ILT3 24A4 rat VH/human IgG4
208
209



(S228P):rat VL/human Kappa




88
Chimeric anti-ILT3 40A6 rat VH/human IgG1
212
195



(N297A):rat VL/human Kappa




89
Chimeric anti-ILT3 16B1 rat VH/human IgG1
213
197



(N297A):rat VL/human Kappa




90
Chimeric anti-ILT3 11D1 mouse VH/human IgG1
214
199



(N297A):mouse VL/human Kappa




91
Chimeric anti-ILT3 17H12 rat VH/human IgG1
215
201



(N297A):rat VL/human Kappa




92
Chimeric anti-ILT3 37C8 rat VH/human IgG1
216
203



(N297A):rat VL/human Kappa




93
Chimeric anti-ILT3 IG12 mouse VH/human IgG1
217
205



(N297A):mouse VL/human Kappa




94
Chimeric anti-ILT3 20E4 rat VH/human IgG1
218
207



(N297A):rat VL/human Kappa




95
Chimeric anti-ILT3 24A4 rat VH/human IgG1
219
209



(N297A):rat VL/human Kappa




96
Chimeric anti-ILT3 40A6 rat VH/human IgG1
220
195



(N297A):rat VL/human Kappa









Epitope mapping by hydrogen-deuterium exchange mass spectrometry (HDX-MS) as described in Example 4 shows that the anti-ILT3 antibodies disclosed herein bind to an epitope on the extracellular domain near the border between the D1 and D2 domains of the extracellular domain of ILT3. The epitope identified using HDX-MS indicates that the epitope bound by the anti-ILT3 antibodies disclosed herein comprises or consists of at least one amino acid within one or more of the peptide domain amino acid sequences selected from the group consisting of SEQ ID NOs: 3, 4, 5, 6, 7, and 8. In a further embodiment, the epitope comprises or consists of one or more of the peptide domain amino acid sequences selected from the group consisting of SEQ ID NOs: 3, 4, 5, 6, 7, and 8. In certain embodiments, the epitope comprises or consists of at least one amino acid in each of the peptide domain amino acid sequences selected from the group consisting of SEQ ID NOs: 3, 4, 5, 6, 7, and 8 and identified in the HDX-MS. In particular embodiments, the epitope comprises or consists of one or more of the peptide domain amino acid sequences selected from the group consisting of SEQ ID NOs: 3, 4, 5, 6, 7, and 8. In particular embodiments, the epitope comprises or consists of the peptide domains shown in SEQ ID Nos: 3, 4, 5, 6, 7, and 8.


Thus, the present invention further provides a chimeric, humanized, or human antibody or antigen binding fragment that binds to an epitope on ILT3 wherein the epitope comprises or consists of at least one amino acid within one or more of the peptide domains comprising amino acid sequences shown by the amino acid sequences set forth in SEQ ID NOs: 3, 4, 5, 6, 7, and 8 as determined by hydrogen deuterium exchange mass spectrometry (HDX-MS) analysis.


In a further embodiment, the present invention further provides a chimeric, humanized, or human antibody or antigen binding fragment that binds to an epitope on ILT3 wherein the epitope comprises or consists of amino acids within the peptide domains shown in one or more of SEQ ID Nos: 3, 4, 5, 6, 7, and 8. In certain embodiments, the epitope comprises or consists of at least one amino acid in each of the peptide domains identified in the heat map determined by HDX-MS and shown in FIG. 3A.


The present invention further provides a chimeric, humanized, or human antibody or antigen binding fragment that cross-blocks the binding of an antibody comprising a heavy chain variable domain having the amino acid sequence set forth in SEQ ID NO: 15 and a light chain variable domain having the amino acid sequence shown in SEQ ID NO: 16 to an epitope on ILT3. In a further embodiment, the epitope comprises or consists of at least one amino acid within one or more of the peptide domains comprising or consisting of amino acid sequences shown by the amino acid sequences set forth in SEQ ID NOs: 3, 4, 5, 6, 7, and 8 as determined by hydrogen deuterium exchange mass spectrometry (HDX-MS) analysis. In a further embodiment, the epitope comprises or consists of amino acids within the peptide domains shown in one or more of SEQ ID NOs: 3, 4, 5, 6, 7, and 8. In certain embodiments, the epitope comprises or consists of at least one amino acid in each of the peptide domains identified in the HDX-MS.


The present invention further provides bispecific antibodies and antigen-binding fragments comprising a first antibody or antigen binding fragment that binds ILT3 and a second antibody or antigen binding fragment that binds a molecule other than ILT3, wherein the first antibody or antigen binding fragment comprises at least the amino acid sequence of an HC-CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 49, 57, 65, 73, 81, 89, 97, and 105, or having an amino acid sequence that has 3, 2, or 1 differences with an amino acid sequence selected from the group consisting of SEQ ID NO: 22, 49, 57, 65, 73, 81, 89, 97, and 105 and wherein the first antibody binds an ILT3 epitope comprising amino acids within the sequences of SEQ ID Nos: 3, 4, 5, 6, 7, and 8 and the second antibody binds a molecule other than ILT3, and methods of use thereof.


The present invention further provides bispecific antibodies and antigen-binding fragments comprising a first antibody or antigen binding fragment that binds ILT3 and a second antibody or antigen binding fragment that binds a molecule other than ILT3, wherein the first antibody or antigen binding fragment comprising at least the six CDRs of an anti-ILT3 antibody or embodiments thereof wherein one or more of the CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and wherein the first antibody binds an ILT3 epitope comprising amino acids within the sequences of SEQ ID NOs: 3, 4, 5, 6, 7, and 8 and the second antibody binds a molecule other than ILT3, and methods of use thereof.


The present invention further provides biparatopic antibodies (antibodies having binding specificity for different epitopes on the same antigen) having a first heavy/light chain pair of a first antibody that comprises at least an HC-CDR3 having an amino acid sequence selected from the group consisting of SEQ ID NOs: 22, 49, 57, 65, 73, 81, 89, 97, and 105, or having an amino acid sequence that has 3, 2, or 1 differences with an amino acid sequence selected from the group consisting of SEQ ID NOs: 22, 49, 57, 65, 73, 81, 89, 97, and 105, wherein the first heavy/light chain pair binds an ILT3 epitope comprising amino acids within the sequences of SEQ ID NOs: 3, 4, 5, 6, 7, and 8 and the second antibody binds a molecule other than ILT3 and a second heavy/light chain pair of a second antibody having specificity for an anti-ILT3 epitope that is different from the epitope recognized by the first heavy/light chain pair.


The present invention further provides biparatopic antibodies (antibodies having binding specificity for different epitopes on the same antigen) having first heavy/light chain pair of a first antibody that comprises at least the six CDRs of an anti-ILT3 antibody or embodiments thereof wherein one or more of the CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof wherein the first antibody binds an ILT3 epitope comprising amino acids within the sequences of SEQ ID NOs: 3, 4, 5, 6, 7, and 8, wherein the first heavy/light chain pair binds an ILT3 epitope comprising amino acids within the sequences of SEQ ID NOs: 3, 4, 5, 6, 7, and 8 and the second antibody binds a molecule other than ILT3 and a second heavy/light chain pair of a second antibody having specificity for an anti-ILT3 epitope that is different from the epitope recognized by the first heavy/light chain pair.


Pharmaceutical Compositions and Administration


To prepare pharmaceutical or sterile compositions of the anti-ILT3 antibodies or antigen binding fragments thereof, the antibody or antigen binding fragments thereof is admixed with a pharmaceutically acceptable carrier or excipient. See, e.g., Remington's Pharmaceutical Sciences and U.S. Pharmacopeia: National Formulary, Mack Publishing Company, Easton, Pa. (1984) and continuously updated on the Internet by the U.S. Pharmacopeial Convention (USP) 12601 Twinbrook Parkway, Rockville, Md. 20852-1790, USA.


Formulations of therapeutic and diagnostic agents may be prepared by mixing with acceptable carriers, excipients, or stabilizers in the form of, e.g., lyophilized powders, slurries, aqueous solutions or suspensions (see, e.g., Hardman, et al. (2001) Goodman and Gilman's The Pharmacological Basis of Therapeutics, McGraw-Hill, New York, N.Y.; Gennaro (2000) Remington: The Science and Practice of Pharmacy, Lippincott, Williams, and Wilkins, New York, N.Y.; Avis, et al. (eds.) (1993) Pharmaceutical Dosage Forms: Parenteral Medications, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Tablets, Marcel Dekker, NY; Lieberman, et al. (eds.) (1990) Pharmaceutical Dosage Forms: Disperse Systems, Marcel Dekker, NY; Weiner and Kotkoskie (2000) Excipient Toxicity and Safety, Marcel Dekker, Inc., New York, N.Y.).


In a further embodiment, a composition comprising an antibody or antibody fragment disclosed herein is administered to a subject in accordance with the Physicians' Desk Reference 2017 (Thomson Healthcare; 75st edition (Nov. 1, 2002)). Methods of administering antibody molecules are known in the art and are described below. Suitable dosages of the molecules used will depend on the age and weight of the subject and the particular drug used. Dosages and therapeutic regimens of the anti-ILT3 antibody or antigen binding fragment can be determined by a skilled artisan. In certain embodiments, the anti-ILT3 antibody or antigen binding fragment is administered by injection (e.g., subcutaneously or intravenously) at a dose of about 1 to 30 mg/kg, e.g., about 5 to 25 mg/kg, about 10 to 20 mg/kg, about 1 to 5 mg/kg, or about 3 mg/kg. In some embodiments, the anti-ILT3 antibody or antigen binding fragment is administered at a dose of about 1 mg/kg, about 3 mg/kg, or 10 mg/kg, about 20 mg/kg, about 30 mg/kg, or about 40 mg/kg. In some embodiments, the anti-ILT3 antibody or antigen binding fragment is administered at a dose of about 1-3 mg/kg, or about 3-10 mg/kg. In some embodiments, the anti-ILT3 antibody or antigen binding fragment is administered at a dose of about 0.5-2, 2-4, 2-5, 5-15, or 5-20 mg/kg. The dosing schedule can vary from e.g., once a week to once every 2, 3, or 4 weeks. In one embodiment, the anti-ILT3 antibody or antigen binding fragment is administered at a dose from about 10 to 20 mg/kg every other week.


The mode of administration can vary. Suitable routes of administration is preferably parenteral or subcutaneous. Other routes of administration may include oral, transmucosal, intradermal, direct intraventricular, intravenous, intranasal, inhalation, insufflation, or intra-arterial.


In particular embodiments, the anti-ILT3 antibodies or antigen binding fragments thereof can be administered by an invasive route such as by injection. In further embodiments of the invention, the anti-ILT3 antibodies or antigen binding fragments thereof, or pharmaceutical composition thereof, may be administered intravenously, subcutaneously, intraarterially, or by inhalation, aerosol delivery. Administration by non-invasive routes (e.g., orally; for example, in a pill, capsule or tablet) is also within the scope of the present invention.


Compositions can be administered with medical devices known in the art. For example, a pharmaceutical composition of the invention can be administered by injection with a hypodermic needle, including, e.g., a prefilled syringe or autoinjector.


The pharmaceutical compositions disclosed herein may also be administered with a needleless hypodermic injection device; such as the devices disclosed in U.S. Pat. Nos. 6,620,135; 6,096,002; 5,399,163; 5,383,851; 5,312,335; 5,064,413; 4,941,880; 4,790,824 or 4,596,556.


The pharmaceutical compositions disclosed herein may also be administered by infusion. Examples of well-known implants and modules form administering pharmaceutical compositions include: U.S. Pat. No. 4,487,603, which discloses an implantable micro-infusion pump for dispensing medication at a controlled rate; U.S. Pat. No. 4,447,233, which discloses a medication infusion pump for delivering medication at a precise infusion rate; U.S. Pat. No. 4,447,224, which discloses a variable flow implantable infusion apparatus for continuous drug delivery; U.S. Pat. No. 4,439,196, which discloses an osmotic drug delivery system having multi-chamber compartments. Many other such implants, delivery systems, and modules are well known to those skilled in the art.


The administration regimen depends on several factors, including the serum or tissue turnover rate of the therapeutic antibody, the level of symptoms, the immunogenicity of the therapeutic antibody, and the accessibility of the target cells in the biological matrix. Preferably, the administration regimen delivers sufficient therapeutic antibody to effect improvement in the target disease state, while simultaneously minimizing undesired side effects. Accordingly, the amount of biologic delivered depends in part on the particular therapeutic antibody and the severity of the condition being treated. Guidance in selecting appropriate doses of therapeutic antibodies is available (see, e.g., Wawrzynczak (1996) Antibody Therapy, Bios Scientific Pub. Ltd, Oxfordshire, UK; Kresina (ed.) (1991) Monoclonal Antibodies, Cytokines and Arthritis, Marcel Dekker, New York, N.Y.; Bach (ed.) (1993) Monoclonal Antibodies and Peptide Therapy in Autoimmune Diseases, Marcel Dekker, New York, N.Y.; Baert, et al. (2003) New Engi. J. Med. 348:601-608; Milgrom et al. (1999) New Engl. J. Med. 341:1966-1973; Slamon et al. (2001) New Engi. J. Med. 344:783-792; Beniaminovitz et al. (2000) New Engi. J. Med. 342:613-619; Ghosh et al. (2003) New Engl. J. Med. 348:24-32; Lipsky et al. (2000) New Engl. J. Med. 343:1594-1602).


Dosage regimens are adjusted to provide the optimum desired response (e.g., a therapeutic response). For example, a single bolus may be administered, several divided doses may be administered over time or the dose may be proportionally reduced or increased as indicated by the exigencies of the therapeutic situation. It is especially advantageous to formulate parenteral compositions in dosage unit form for ease of administration and uniformity of dosage. Dosage unit form as used herein refers to physically discrete units suited as unitary dosages for the subjects to be treated; each unit contains a predetermined quantity of active compound calculated to produce the desired therapeutic effect in association with the required pharmaceutical carrier. The specification for the dosage unit forms described herein are dictated by and directly dependent on (a) the unique characteristics of the antibody or antibody binding fragment and the particular therapeutic effect to be achieved, and (b) the limitations inherent in the art of compounding such an active molecules for the treatment of sensitivity in individuals. (see, e.g., Yang, et al. (2003) New Engl. J. Med. 349:427-434; Herold, et al. (2002) New Engl. J. Med. 346:1692-1698; Liu, et al. (1999) J. Neural. Neurosurg. Psych. 67:451-456; Portielji, et al. (20003) Cancer Immunol. Immunother. 52:133-144).


Use of the Anti-ILT3 Antibodies or Antigen Binding Fragments Disclosed Herein


The anti-ILT3 antibodies and antigen binding fragments disclosed herein being non-promiscuous for related ILTs may be used to specifically detect human ILT3 (e.g., in a biological sample, such as serum or plasma), using a conventional immunoassay, such as an enzyme linked immunosorbent assays (ELISA), an radioimmunoassay (RIA) or tissue immunohistochemistry. The invention thus provides a method for detecting human ILT3 in a biological sample comprising contacting a biological sample with an anti-ILT3 antibody or antigen binding fragment and detecting either the anti-ILT3 antibody or antigen binding fragment bound to human ILT3 or unbound anti-ILT3 antibody or antigen binding fragment disclosed herein, to thereby detect human ILT3 in the biological sample. The anti-ILT3 antibody or antigen binding fragment is directly or indirectly labeled with a detectable substance to facilitate detection of the bound or unbound anti-ILT3 antibody or antigen binding fragment disclosed herein. Suitable detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials and radioactive materials. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, β-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; and examples of suitable radioactive material include 125I, 131I, 35S, and 3H.


Alternative to labeling the anti-ILT3 antibody or antigen binding fragment, human ILT3 can be assayed in biological fluids by a competition immunoassay utilizing ILT3 standards labeled with a detectable substance and an unlabeled anti-human ILT3 anti-ILT3 antibody or antigen binding fragment disclosed herein. In this assay, the biological sample, the labeled ILT3 standards and the anti-ILT3 antibody or antigen binding fragment are combined and the amount of labeled ILT3 standard bound to the unlabeled anti-ILT3 antibody or antigen binding fragment disclosed herein is determined. The amount of human ILT3 in the biological sample is inversely proportional to the amount of labeled ILT3 standard bound to the anti-ILT3 antibody or antigen binding fragment.


An anti-ILT3 antibody or antigen binding fragment disclosed herein may also be used to detect ILT3 from a species other than humans, in particular ILT3 from primates (e.g., cynomolgus monkey or rhesus monkey).


Methods of Upmodulating Immune Responses In Vivo


The anti-ILT3 antibodies or antigen binding fragments disclosed herein may be used as immunostimulatory compositions, e.g., alone or as part of a vaccine or combination therapy, to promote B cell, and/or T cell activation, e.g., either Th1 or Th2 cell activation, in a subject. That is, the anti-ILT3 antibody or antigen binding fragment disclosed herein may serve as adjuvants used in combination with an antigen of interest to enhance an immune response to that antigen of interest in vivo. For example, to stimulate an antibody or cellular immune response to an antigen of interest (e.g., for vaccination purposes), the antigen and anti-ILT3 antibody or antigen binding fragment disclosed herein may be co-administered (e.g., co-administered at the same time in the same or separate compositions, or sequentially in time such that an enhanced immune response occurs). The antigen of interest and the anti-ILT3 antibody or antigen binding fragment disclosed herein may be formulated together into a single pharmaceutical composition or in separate compositions. In one embodiment, the antigen of interest and the anti-ILT3 antibody or antigen binding fragment disclosed herein are administered simultaneously to the subject. Alternatively, in certain situations it may be desirable to administer the antigen first and then the anti-ILT3 antibody or antigen binding fragment disclosed herein or vice versa (for example, in the case of an antigen that naturally evokes a Th1 response, it may be beneficial to first administer the antigen alone to stimulate a Th1 response and then administer an anti-ILT3 antibody or antigen binding fragment disclosed herein, alone or together with a boost of antigen, to shift the immune response to a Th2 response). In preferred embodiments, an anti-ILT3 antibody or antigen binding fragment disclosed herein is administered at the time of priming with antigen, i.e., at the time of the first administration of antigen. For example, day −3, −2, −1, 0, +1, +2, +3. A particularly preferred day of administration of an anti-ILT3 antibody or antigen binding fragment disclosed herein is day −1.


In one embodiment, an anti-ILT3 antibody or antigen binding fragment disclosed herein is administered with an antigen of interest. An antigen of interest is one to which an immune response is desired. For example, an antigen of interest is an antigen capable of stimulating immune protection in a subject against challenge by an infectious agent from which the antigen was derived. Further contemplated is administration of an anti-ILT3 antibody or antigen binding fragment disclosed herein to increase immune responses without having to administer an antigen.


Exemplary antigens of interest therefore include those derived from infectious agents, wherein an immune response directed against the antigen serves to prevent or treat disease caused by the agent. Such antigens include, but are not limited to, viral, bacterial, fungal or parasite proteins and any other proteins, glycoproteins, lipoprotein, glycolipids, and the like. Antigens of interest also include those which provide benefit to a subject which is at risk for acquiring or which is diagnosed as having a tumor. The subject is preferably a mammal and most preferably, is a human.


Typical antigens of interest may be classified as follows: protein antigens, such as ceruloplasmin and serum albumin; bacterial antigens, such as teichoic acids, flagellar antigens, capsular polysaccharides, and extra-cellular bacterial products and toxins; glycoproteins and glycolipids; viruses, such as animal, plant, and bacterial viruses; conjugated and synthetic antigens, such as protein/hapten conjugates, molecules expressed preferentially by tumors, compared to normal tissue; synthetic polypeptides; and nucleic acids, such as ribonucleic acid and deoxyribonucleic acid. The term “infectious agent,” as used herein, includes any agent which expresses an antigen, which elicits a host cellular immune response. Non-limiting examples of viral antigens which may be considered useful as include, but are not limited to, the nucleoprotein (NP) of influenza virus and the Gag proteins of HIV. Other heterologous antigens include, but are not limited to, HIV Env protein or its component parts gp120 and gp41, HIV Nef protein, and the HIV Pol proteins, reverse transcriptase and protease. In addition, other viral antigens such as Ebola virus (EBOV) antigens, such as, for example, EBOV NP or glycoprotein (GP), either full-length or GP deleted in the mucin region of the molecule (Yang et al., Nat Med 6:886 (2000), small pox antigens, hepatitis A, B or C virus, human rhinovirus such as type 2 or type 14, herpes simplex virus, poliovirus type 2 or 3, foot-and-mouth disease virus (FMDV), rabies virus, rotavirus, influenza virus, coxsackie virus, human papilloma virus (HPV), for example the type 16 papilloma virus, the E7 protein thereof, and fragments containing the E7 protein or its epitopes; and simian immunodeficiency virus (SIV) may be used. The antigens of interest need not be limited to antigens of viral origin. Parasitic antigens, such as, for example, malarial antigens are included, as are fungal antigens, bacterial antigens and tumor antigens. Examples of antigens derived from bacteria are those derived from Bordetella pertussis (e.g., P69 protein and filamentous haemagglutinin (FHA) antigens), Vibrio cholerae, Bacillus anthracis, and E. coli antigens such as E. coli heat labile toxin B subunit (LT-B), E. coli K88 antigens, and enterotoxigenic E. coli antigens. Other examples of antigens include Schistosoma mansoni P28 glutathione S-transferase antigens (P28 antigens) and antigens of flukes, mycoplasma, roundworms, tapeworms, Chlamydia trachomatis, and malaria parasites, e.g., parasites of the genus plasmodium or babesia, for example Plasmodium falciparum, and peptides encoding immunogenic epitopes from the aforementioned antigens.


By the term “tumor-related antigen,” as used herein, is meant an antigen which affects tumor growth or metastasis in a host organism. The tumor-related antigen may be an antigen expressed by a tumor cell, or it may be an antigen that is expressed by a non-tumor cell but when so expressed, promotes the growth or metastasis of tumor cells. The types of tumor antigens and tumor-related antigens include any known or heretofore unknown tumor antigen, including, without limitation, the bcr/abl antigen in leukemia, HPVE6 and E7 antigens of the oncogenic virus associated with cervical cancer, the MAGE1 and MZ2-E antigens in or associated with melanoma, and the MVC-1 and HER-2 antigens in or associated with breast cancer.


An infection, disease or disorder which may be treated or prevented by the administration of a composition comprising an anti-ILT3 antibody or antigen binding fragment disclosed herein includes any infection, disease or disorder wherein a host immune response acts to prevent the infection, disease or disorder. Diseases, disorders, or infection which may be treated or prevented by the administration of a composition comprising an anti-ILT3 antibody or antigen binding fragment disclosed herein include, but are not limited to, any infection, disease or disorder caused by or related to a fungus, parasite, virus, or bacteria, diseases, disorders or infections caused by or related to various agents used in bioterrorism, listeriosis, Ebola virus, SARS, small pox, hepatitis A, hepatitis B, hepatitis C, diseases and disorders caused by human rhinovirus, HIV and AIDS, Herpes, polio, foot-and-mouth disease, rabies, diseases or disorders caused by or related to: rotavirus, influenza, coxsackie virus, human papilloma virus, SIV, malaria, cancer, e.g., tumors, and diseases or disorders caused by or related to infection by Bordetella pertussis, Vibrio cholerae, Bacillus anthracis, E. coli, flukes, mycoplasma, roundworms, tapeworms, Chlamydia trachomatis, and malaria parasites, etc.


Immune Responses to Tumor Cells


Regulatory T cells play an important role in the maintenance of immunological self-tolerance by suppressing immune responses against autoimmune diseases and cancer. Accordingly, in one embodiment, upmodulating an immune response would be beneficial for enhancing an immune response in cancer. Therefore, the anti-ILT3 antibodies or antigen binding fragments disclosed herein may be used in the treatment of malignancies, to inhibit tumor growth or metastasis. The anti-ILT3 antibodies or antigen binding fragments disclosed herein may be administered systemically or locally to the tumor site.


In one embodiment, modulation of human ILT3 function may be useful in the induction of tumor immunity. An ILT3 binding molecule may be administered to a patient having tumor cells (e.g., sarcoma, melanoma, lymphoma, leukemia, neuroblastoma, carcinoma) to overcome tumor-specific tolerance in the subject.


As used herein, the term “neoplastic disease” is characterized by malignant tumor growth or in disease states characterized by benign hyperproliferative and hyperplastic cells. The common medical meaning of the term “neoplasia” refers to “new cell growth” that results as a loss of responsiveness to normal growth controls, e.g., neoplastic cell growth.


As used herein, the terms “hyperproliferative”, “hyperplastic”, malignant” and “neoplastic” are used interchangeably, and refer to those cells in an abnormal state or condition characterized by rapid proliferation or neoplasia. The terms are meant to include all types of hyperproliferative growth, hyperplastic growth, cancerous growths or oncogenic processes, metastatic tissues or malignantly transformed cells, tissues, or organs, irrespective of histopathologic type or stage of invasiveness. A “hyperplasia” refers to cells undergoing an abnormally high rate of growth. However, as used herein, the terms neoplasia and hyperplasia can be used interchangeably, as their context will reveal, referring generally to cells experiencing abnormal cell growth rates. Neoplasias and hyperplasias include “tumors,” which may be either benign, premalignant or malignant.


The terms “neoplasia,” “hyperplasia,” and “tumor” are often commonly referred to as “cancer,” which is a general name for more than 100 disease that are characterized by uncontrolled, abnormal growth of cells. Examples of cancer include, but are not limited to: breast; colon; non-small cell lung, head and neck; colorectal; lung; prostate; ovary; renal; melanoma; and gastrointestinal (e.g., pancreatic and stomach) cancer; and osteogenic sarcoma.


In one embodiment, the cancer is selected from the group consisting of: pancreatic cancer, melanomas, breast cancer, lung cancer, head and neck cancer, bronchus cancer, colorectal cancer, prostate cancer, pancreatic cancer, stomach cancer, ovarian cancer, urinary bladder cancer, brain or central nervous system cancer (e.g., gliobastoma), peripheral nervous system cancer, esophageal cancer, cervical cancer, uterine or endometrial cancer, cancer of the oral cavity or pharynx, liver cancer, kidney cancer, testicular cancer, biliary tract cancer, small bowel or appendix cancer, salivary gland cancer, thyroid gland cancer, adrenal gland cancer, osteosarcoma, chondrosarcoma, and cancer of hematological tissues.


Immune Responses to Infectious Agents


Upregulation of immune responses may be in the form of enhancing an existing immune response or eliciting an initial immune response. For example, enhancing an immune response by modulation of ILT3 may be useful in cases of viral infection. As the anti-ILT3 antibodies or antigen binding fragments disclosed herein may act to enhance immune responses, they would be therapeutically useful in situations where more rapid or thorough clearance of pathogenic agents, e.g., bacteria and viruses would be beneficial.


As used herein, the term “viral infection” includes infections with organisms including, but not limited to, HIV (e.g., HIV-1 and HIV-2), human herpes viruses, cytomegalovirus (esp. Human), Rotavirus, Epstein-Barr virus, Varicella Zoster Virus, hepatitis viruses, such as hepatitis B virus, hepatitis A virus, hepatitis C virus and hepatitis E virus, paramyxoviruses: Respiratory Syncytial virus, parainfluenza virus, measles virus, mumps virus, human papilloma viruses (for example HPV6, 11, 16, 18 and the like), flaviviruses (e.g. Yellow Fever Virus, Dengue Virus, Tick-borne encephalitis virus, Japanese Encephalitis Virus) or influenza virus.


As used herein, the term “bacterial infections” include infections with a variety of bacterial organisms, including gram-positive and gram-negative bacteria. Examples include, but are not limited to, Neisseria spp, including N. gonorrhea and N. meningitidis, Streptococcus spp, including S. pneumoniae, S. pyogenes, S. agalactiae, S. matins; Haemophilus spp, including H. influenzae type B, non typeable H. influenzae, H. ducreyi; Moraxella spp, including M. catarrhalis, also known as Branhamella catarrhalis; Bordetella spp, including B. pertussis, B. parapertussis and B. bronchiseptica; Mycobacterium spp., including M. tuberculosis, M bovis, M leprae, M avium, M paratuberculosis, M. smegmatis; Legionella spp, including L. pneumophila; Escherichia spp, including enterotoxic E. coli, enterohemorragic E. coli, enteropathogenic E. coli; Vibrio spp, including V. cholera, Shigella spp, including S. sonnei, S. dysenteriae, S. flexnerii; Yersinia spp, including Y. enterocolitica, Y. pestis, Y. pseudotuberculosis, Campylobacter spp, including C. jejuni and C. coli; Salmonella spp, including S. typhi, S. paratyphi, S. choleraesuis, S. enteritidis; Listeria spp., including L. monocytogenes; Helicobacter spp, including H. pylori; Pseudomonas spp, including P. aeruginosa, Staphylococcus spp., including S. aureus, S. epidermidis; Enterococcus spp., including E. faecalis, E. faecium; Clostridium spp., including C. tetani, C. botulinum, C. difficile; Bacillus spp., including B. anthracis; Corynebacterium spp., including C. diphtheriae; Borrelia spp., including B. burgdorferi, B. garinii, B. afzelii, B. andersonii, B. hermsii; Ehrlichia spp., including E. equi and the agent of the Human Granulocytic Ehrlichiosis; Rickettsia spp, including R. rickettsii; Chlamydia spp., including C. trachomatis, C. neumoniae, C. psittaci; Leptsira spp., including L. interrogans; Treponema spp., including T. pallidum, T. denticola, T. hyodysenteriae. Preferred bacteria include, but are not limited to, Listeria, mycobacteria, mycobacteria (e.g., tuberculosis), Anthrax, Salmonella and Listeria monocytogenes.


In another embodiment, T cells can be removed from a patient, and contacted in vitro with an anti-ILT3 antibody or antigen binding fragment disclosed herein, optionally with an activating signal (e.g., antigen plus APCs or a polyclonal antibody) and reintroduced into the patient.


The anti-ILT3 antibodies or antigen binding fragments disclosed herein may also be used prophylactically in vaccines against various pathogens. Immunity against a pathogen, e.g., a virus, could be induced by vaccinating with a viral protein along with an anti-ILT3 antibody or antigen binding fragment disclosed herein. Alternately, an expression vector that encodes genes for both a pathogenic antigen and anti-ILT3 antibody or antigen binding fragment disclosed herein, e.g., a vaccinia virus expression vector engineered to express a nucleic acid encoding a viral protein and a nucleic acid encoding an anti-ILT3 antibody or antigen binding fragment disclosed herein, may be used for vaccination. Pathogens for which vaccines may be useful include, for example, hepatitis B, hepatitis C, Epstein-Barr virus, cytomegalovirus, HIV-1, HIV-2, tuberculosis, malaria and schistosomiasis.


The present invention further encompasses an anti-ILT3 antibody or antigen binding fragment disclosed herein conjugated to a diagnostic or therapeutic agent. The anti-ILT3 antibody or antigen binding fragment disclosed herein can be used diagnostically to, for example, monitor the development or progression of a tumor as part of a clinical testing procedure to, e.g., determine the efficacy of a given treatment regimen. Detection may be facilitated by coupling the antibody to a detectable substance. Examples of detectable substances include various enzymes, prosthetic groups, fluorescent materials, luminescent materials, bioluminescent materials, radioactive materials, positron emitting metals using various positron emission tomographies, and nonradioactive paramagnetic metal ions. The detectable substance may be coupled or conjugated either directly to the binding molecule or indirectly, through an intermediate (such as, for example, a linker known in the art) using techniques known in the art. U.S. Pat. No. 4,741,900 discloses metal ions that may be conjugated to binding molecules. Examples of suitable enzymes include horseradish peroxidase, alkaline phosphatase, beta-galactosidase, or acetylcholinesterase; examples of suitable prosthetic group complexes include streptavidin/biotin and avidin/biotin; examples of suitable fluorescent materials include umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride or phycoerythrin; an example of a luminescent material includes luminol; examples of bioluminescent materials include luciferase, luciferin, and aequorin; and examples of suitable radioactive materials are 125I, 131I, and 99Tc.


Further, an anti-ILT3 antibody or antigen binding fragment disclosed herein may be conjugated to a therapeutic moiety such as a cytotoxin, e.g., a cytostatic or cytocidal agent, a therapeutic agent or a radioactive metal ion, e.g., alpha-emitters such as, for example, 213Bi. A cytotoxin or cytotoxic agent includes any agent that is detrimental to cells. Examples include paclitaxol, cytochalasin B, gramicidin D, ethidium bromide, emetine, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin and analogs or homologs thereof. Therapeutic agents include, but are not limited to, antimetabolites (e.g., methotrexate, 6-mercaptopurine, 6-thioguanine, cytarabine, 5-fluorouracil decarbazine), alkylating agents (e.g., mechlorethamine, thioepa chlorambucil, melphalan, camustine (BSNU) and lomustine (CCNU), cyclothosphamide, busulfan, dibromomannitol, streptozotocin, mitomycin C, and cis-dichlorodiamine platinum (II) (DDP) cisplatin), anthracyclines (e.g., daunorubicin (formerly daunomycin) and doxorubicin), antibiotics (e.g., dactinomycin (formerly actinomycin), bleomycin, mithramycin, and anthramycin (AMC)), and anti-mitotic agents (e.g., vincristine and vinblastine).


The present invention is further directed to therapies that involve administering an anti-ILT3 antibody or antigen binding fragment disclosed herein to an animal, preferably a mammal, and most preferably a human, patient for treating, detecting, and/or preventing one or more of the diseases, disorders, or conditions disclosed herein. Therapeutic compounds of the invention include, but are not limited to, anti-ILT3 antibody or antigen binding fragment disclosed herein. The anti-ILT3 antibody or antigen binding fragment disclosed herein may be used to treat, diagnose, inhibit or prevent diseases, disorders or conditions associated with aberrant activity of ILT3, including, but not limited to, any one or more of the diseases, disorders, or conditions described herein.


The anti-ILT3 antibody or antigen binding fragment disclosed herein may be advantageously utilized in combination with other monoclonal or chimeric binding molecules, or with lymphokines or hematopoietic growth factors (such as, e.g., IL-2, IL-3 and IL-7), for example, which serve to increase the number or activity of effector cells which interact with the binding molecules.


The anti-ILT3 antibody or antigen binding fragment disclosed herein may be administered alone or in combination with other types of treatments, e.g., immunostimulatory treatments or treatments designed to control the proliferation of a target of activated immune cells (e.g., cancer cells or pathogens). Exemplary therapies include e.g., radiation therapy, chemotherapy, hormonal therapy, immunotherapy and anti-tumor agents, antibiotics, and immunoglobulin.


An anti-ILT3 antibody or antigen binding fragment disclosed herein may be administered to a human subject for therapeutic purposes. Moreover, an anti-ILT3 antibody or antigen binding fragment disclosed herein may be administered to a non-human mammal expressing ILT3 with which the binding molecule cross-reacts (e.g., a primate) for veterinary purposes or as an animal model of human disease.


Combinations


The anti-ILT3 antibodies or antigen binding fragments herein may be used in unconjugated forms or conjugated to a second agent, e.g., a cytotoxic drug, radioisotope, or a protein, e.g., a protein toxin or a viral protein. This method includes: administering the anti-ILT3 antibodies or antigen binding fragments herein, alone or conjugated to a cytotoxic drug, to a subject requiring such treatment. The anti-ILT3 antibodies or antigen binding fragments herein may be used to deliver a variety of therapeutic agents, e.g., a cytotoxic moiety, e.g., a therapeutic drug, a radioisotope, molecules of plant, fungal, or bacterial origin, or biological proteins (e.g., protein toxins) or particles (e.g., a recombinant viral particles, e.g.; via a viral coat protein), or mixtures thereof.


Additional Combination Therapies


The anti-ILT3 antibodies or antigen binding fragments herein may be used in combination with other therapies. For example, the combination therapy may include a composition comprising an anti-ILT3 antibody or antigen binding fragment co-formulated with, and/or co-administered with, one or more additional therapeutic agents, e.g., one or more anti-cancer agents, cytotoxic or cytostatic agents, hormone treatment, vaccines, and/or other immunotherapies. In other embodiments, the anti-ILT3 antibody or antigen binding fragment is administered in combination with other therapeutic treatment modalities, including surgery, radiation, cryosurgery, and/or thermotherapy. Such combination therapies may advantageously utilize lower dosages of the administered therapeutic agents, thus avoiding possible toxicities or complications associated with the various monotherapies.


By “in combination with,” it is not intended to imply that the therapy or the therapeutic agents must be administered at the same time and/or formulated for delivery together, although these methods of delivery are within the scope described herein. The anti-ILT3 antibody or antigen binding fragment may be administered concurrently with, prior to, or subsequent to, one or more other additional therapies or therapeutic agents. The anti-ILT3 antibody or antigen binding fragment and the other agent or therapeutic protocol may be administered in any order. In general, each agent will be administered at a dose and/or on a time schedule determined for that agent. In will further be appreciated that the additional therapeutic agent utilized in this combination may be administered together in a single composition or administered separately in different compositions. In general, it is expected that additional therapeutic agents utilized in combination be utilized at levels that do not exceed the levels at which they are utilized individually. In some embodiments, the levels utilized in combination will be lower than those utilized individually.


In certain embodiments, an anti-ILT3 antibody or antigen binding fragment described herein is administered in combination with one or more check point inhibitors or antagonists of programmed death receptor 1 (PD-1) or its ligand PD-L1 and PD-L2. The inhibitor or antagonist may be an antibody, an antigen binding fragment, an immunoadhesin, a fusion protein, or oligopeptide. In some embodiments, the anti-PD-1 antibody is chosen from nivolumab (OPDIVO®, Bristol Myers Squibb, New York, N.Y.), pembrolizumab (KEYTRUDA®, Merck Sharp & Dohme Corp, Kenilworth, N.J. USA), cetiplimab (Regeneron, Tarrytown, N.Y.) or pidilizumab (CT-011). In some embodiments, the PD-1 inhibitor is an immunoadhesin (e.g., an immunoadhesin comprising an extracellular or PD-1 binding portion of PD-L1 or PD-L2 fused to a constant region (e.g., an Fc region of an immunoglobulin sequence)). In some embodiments, the PD-1 inhibitor is AMP-224. In some embodiments, the PD-L1 inhibitor is anti-PD-L1 antibody such durvalumab (IMFINZI®, Astrazeneca, Wilmingon, Del.), atezolizumab (TECENTRIQ®, Roche, Zurich, CH), or avelumab (BAVENCIO®, EMD Serono, Billerica, Mass.). In some embodiments, the anti-PD-L1 binding antagonist is chosen from YW243.55.S70, MPDL3280A, MEDI-4736, MSB-0010718C, or MDX-1105.


MDX-1105, also known as BMS-936559, is an anti-PD-L1 antibody described in WO2007/005874. Antibody YW243.55.S70 is an anti-PD-L1 described in WO 2010/077634 (heavy and light chain variable region sequences shown in SEQ ID NOs. 20 and 21, respectively).


Nivolumab, also known as OPDIVO®, MDX-1106-04, ONO-4538, or BMS-936558, is a fully human IgG4 anti-PD-1 antibody described in WO2006/121168 and U.S. Pat. No. 8,008,449.


Pembrolizumab, also known as KEYTRUDA®, lambrolizumab, MK-3475 or SCH-900475, is a humanized anti-PD-1 antibody described in U.S. Pat. No. 8,354,509 and WO2009/114335 and disclosed, e.g., in Hamid, et al., New England J. Med. 369 (2): 134-144 (2013). The heavy and light chains for prembrolizumab are shown by the amino acid sequences set forth in SEQ ID Nos: 225 and 226, respectively.


Pidilizumab, also known as CT-011 (Cure Tech) is a humanized IgG1 monoclonal antibody that binds to PD-1. Pidilizumab and other humanized anti-PD-1 monoclonal antibodies are disclosed in WO2009/101611. Other anti-PD-1 antibodies include AMP 514 (Amplimmune), among others, e.g., anti-PD-1 antibodies disclosed in U.S. Pat. No. 8,609,089; U.S Publication No. 2010028330; and U.S Publication No. 20120114649.


AMP-224 (137-DCIg; Amplimmune; e.g., disclosed in WO2010/027827 and WO2011/066342), is a PD-L2 Fc fusion soluble receptor that blocks the interaction between PD-1 and B7-H1.


MDPL3280A (Genentech/Roche) is a human Fc optimized IgG1 monoclonal antibody that binds to PD-L1. MDPL3280A and other human monoclonal antibodies to PD-L1 are disclosed in U.S. Pat. No. 7,943,743 and U.S Publication No. 20120039906.


Other anti-PD-L1 binding agents include YW243.55.570 (heavy and light chain variable regions are shown in SEQ ID NOs 20 and 21 in WO2010/077634) and MDX-1105 (also referred to as BMS-936559). It and other anti-PD-L1 binding agents are disclosed in WO2007/005874).


Kits


Further provided are kits comprising one or more components that include, but are not limited to, the anti-ILT3 antibodies or antigen binding fragments thereof, as discussed herein in association with one or more additional components including, but not limited to, a further therapeutic agent, as discussed herein. The antibody or fragment and/or the therapeutic agent can be formulated as a pure composition or in combination with a pharmaceutically acceptable carrier, in a pharmaceutical composition.


In one embodiment, the kit includes the anti-ILT3 antibodies or antigen binding fragments thereof or a pharmaceutical composition thereof in one container (e.g., in a sterile glass or plastic vial) and a further therapeutic agent in another container (e.g., in a sterile glass or plastic vial).


In another embodiment, the kit comprises a combination of the anti-ILT3 antibodies or antigen binding fragments thereof or pharmaceutical composition thereof in combination with one or more therapeutic agents formulated together, optionally, in a pharmaceutical composition, in a single, common container.


If the kit includes a pharmaceutical composition for parenteral administration to a subject, the kit can include a device for performing such administration. For example, the kit can include one or more hypodermic needles or other injection devices as discussed above. Thus, the present invention includes a kit comprising an injection device and t the anti-ILT3 antibodies or antigen binding fragments thereof, e.g., wherein the injection device includes the antibody or fragment or wherein the antibody or fragment is in a separate vessel.


The kit can include a package insert including information concerning the pharmaceutical compositions and dosage forms in the kit. Generally, such information aids patients and physicians in using the enclosed pharmaceutical compositions and dosage forms effectively and safely. For example, the following information regarding a combination of the invention may be supplied in the insert: pharmacokinetics, pharmacodynamics, clinical studies, efficacy parameters, indications and usage, contraindications, warnings, precautions, adverse reactions, overdosage, proper dosage and administration, how supplied, proper storage conditions, references, manufacturer/distributor information and patent information.


Methods of Making Antibodies and Antigen Binding Fragments Thereof


The anti-ILT3 antibodies or antigen binding fragments thereof disclosed herein may also be produced recombinantly. In this embodiment, nucleic acid molecules encoding the antibody molecules may be inserted into a vector (plasmid or viral) and transfected or transformed into a host cell where it may be expressed and secreted from the host cell. There are several methods by which to produce recombinant antibodies which are known in the art.


In particular aspects, the present invention provides nucleic acid molecules encoding an HC and an LC wherein the HC comprises at least the HC-CDR3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein the HC-CDR3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the HC and/or LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the present invention provides nucleic acid molecules encoding an HC and an LC wherein the HC comprises the HC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and wherein the LC comprises the LC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the HC and/or LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the present invention provides a first expression vector comprising a nucleic acid molecule encoding an HC comprising at least the HC CDRs of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of the three HC CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the HC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and a second expression vector comprising a nucleic acid molecule encoding an LC comprising at least the LC CDRs of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of the three LC CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the present invention provides nucleic acid molecules encoding a VH and a VL wherein the VH comprises at least the HC-CDR3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein the HC-CDR3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the VH and/or VL variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the present invention provides nucleic acid molecules encoding a VH and a VL wherein the HC comprises the HC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and wherein the VL comprises the LC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the VH and/or VL variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the present invention provides nucleic acid molecules encoding a VH comprising at least the HC CDRs of an anti-ILT3 disclosed herein or embodiment thereof wherein one or more of the three HC CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the VH and/or VL variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and nucleic acid molecules encoding a VL comprising at least the LC CDRs of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of the three LC CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the VH and/or VL variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


Mammalian cell lines available as hosts for expression of the antibodies or fragments disclosed herein are well known in the art and include many immortalized cell lines available from the American Type Culture Collection (ATCC). These include, inter alia, Chinese hamster ovary (CHO) cells, NSO, SP2 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human hepatocellular carcinoma cells (e.g., Hep G2), A549 cells, 3T3 cells, human embryo kidney 293 (HEK-293) cells and a number of other cell lines. Cell lines of particular preference are selected through determining which cell lines have high expression levels. Other cell lines that may be used are insect cell lines, such as Sf9 cells, amphibian cells, bacterial cells, plant cells, filamentous fungus cells (e.g. Trichoderma reesei), and yeast cells (e.g., Saccharomyces cerevisiae or Pichia pastoris). In particular aspects, the host cell may be a prokaryote host cell such as E. coli.


When recombinant expression vectors comprising a nucleic acid molecule encoding the heavy chain or antigen-binding portion or fragment, the light chain and/or antigen-binding fragment are introduced into host cells, the antibodies are produced by culturing the host cells under conditions and for a period of time sufficient to allow for expression of the antibody in the host cells or, more preferably, secretion of the antibody into the culture medium in which the host cells are grown. The antibodies may be recovered from the culture medium and further purified or processed to produce the antibodies of the invention.


In particular aspects, the host cells are transfected with an expression vector comprising nucleic acid molecules encoding an HC and an LC wherein the HC comprises at least the HC-CDR3 of an anti-ILT3 antibody or embodiment thereof wherein the HC-CDR3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the HC and/or LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the host cells are transfected with an expression vector comprising nucleic acid molecules encoding an HC and an LC wherein the HC comprises the HC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and wherein the LC comprises the LC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the HC and/or LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the host cells are transfected with a first expression vector comprising a nucleic acid molecule encoding an HC comprising at least the HC CDRs of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of the three HC CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the HC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and a second expression vector comprising a nucleic acid molecule encoding an LC comprising at least the LC CDRs of an antibody disclosed herein or embodiment thereof wherein one or more of the three LC CDRs has one, two, or three amino acid s substitutions, additions, deletions, or combinations thereof and/or wherein the LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the host cells are transfected with an expression vector comprising nucleic acid molecules encoding a VH and a VL wherein the VH comprises at least the HC-CDR3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein the HC-CDR3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the VH and/or VL variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the host cells are transfected with an expression vector comprising nucleic acid molecules encoding a VH and a VL wherein the VH comprises the HC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and wherein the VL comprises the LC-CDR1, 2, and 3 of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of HC-CDR1, 2, and 3 has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof. In further embodiments, the VH and/or VL variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular aspects, the host cells are transfected with a first expression vector comprising a nucleic acid molecule encoding a VH comprising at least the HC CDRs of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of the three HC CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the VH variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and a second expression vector comprising a nucleic acid molecule encoding a VL comprising at least the LC CDRs of an anti-ILT3 antibody disclosed herein or embodiment thereof wherein one or more of the three LC CDRs has one, two, or three amino acid s substitutions, additions, deletions, or combinations thereof and/or wherein the VL variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


In particular embodiments, the HC and LC or VH and VL are expressed as a fusion protein in which the N-terminus of the HC and the LC are fused to a leader sequence to facilitate the transport of the antibody through the secretory pathway. Examples of leader sequences that may be used include MSVPTQVLGLLLLWLTDARC (SEQ ID NO: 12) or MEWSWVFLFFLSVTTGVHS (SEQ ID NO: 11).


The present invention further provides a plasmid or viral vector comprising a nucleic acid molecule encoding an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof. The present invention further provides a plasmid or viral vector comprising a nucleic acid molecule encoding the HC of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of the antibody or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the HC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and a nucleic acid molecule encoding the LC of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of the antibody or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


The present invention further provides a plasmid or viral vector comprising a nucleic acid molecule encoding the HC of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof and a plasmid or viral vector comprising a nucleic acid molecule encoding the LC of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof.


The present invention further provides a host cell comprising a plasmid or viral vector comprising a nucleic acid molecule encoding the HC of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the HC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and a plasmid or viral vector comprising a nucleic acid molecule encoding the LC of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the LC variable region framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof. In particular embodiments, the host cell is a CHO or HEK-293 host cell.


The present invention further provides a plasmid or viral vector comprising a nucleic acid molecule encoding an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof. The present invention further provides a plasmid or viral vector comprising a nucleic acid molecule encoding the VH of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of the antibody or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the VH framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and a nucleic acid molecule encoding the VL of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of the antibody or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the LC framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.


The present invention further provides a plasmid or viral vector comprising a nucleic acid molecule encoding the VH of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof and a plasmid or viral vector comprising a nucleic acid molecule encoding the VL of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof.


The present invention further provides a host cell comprising a plasmid or viral vector comprising a nucleic acid molecule encoding the VH of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the VH framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof and a plasmid or viral vector comprising a nucleic acid molecule encoding the VL of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof or embodiment of an anti-ILT3 antibody disclosed herein or antigen binding fragment thereof wherein one or more of the three CDRs has one, two, or three amino acid substitutions, additions, deletions, or combinations thereof and/or wherein the VL framework comprises 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof. In particular embodiments, the host cell is a CHO or HEK-293 host cell.


The anti-ILT3 antibodies or antigen binding fragments thereof can be recovered from the culture medium using standard protein purification methods. Further, expression of antibodies of the invention (or other moieties therefrom) from production cell lines can be enhanced using a number of known techniques. For example, the glutamine synthetase gene expression system (the GS system) is a common approach for enhancing expression under certain conditions.


In general, glycoproteins produced in a particular cell line or transgenic animal will have a glycosylation pattern that is characteristic for glycoproteins produced in the cell line or transgenic animal (See for example, Croset et al., J. Biotechnol. 161: 336-348 (2012)). Therefore, the particular glycosylation pattern of an antibody will depend on the particular cell line or transgenic animal used to produce the antibody. However, all antibodies encoded by the nucleic acid molecules provided herein, or comprising the amino acid sequences provided herein, comprise the instant invention, independent of the glycosylation pattern the antibodies may have.


The following examples are intended to promote a further understanding of the present invention.


General Methods

Standard methods in molecular biology are described Sambrook, Fritsch and Maniatis (1982 & 1989 2nd Edition, 2001 3rd Edition) Molecular Cloning, A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Sambrook and Russell (2001) Molecular Cloning, 3rd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Wu (1993) Recombinant DNA, Vol. 217, Academic Press, San Diego, Calif.). Standard methods also appear in Ausbel, et al. (2001) Current Protocols in Molecular Biology, Vols. 1-4, John Wiley and Sons, Inc. New York, N.Y., which describes cloning in bacterial cells and DNA mutagenesis (Vol. 1), cloning in mammalian cells and yeast (Vol. 2), glycoconjugates and protein expression (Vol. 3), and bioinformatics (Vol. 4).


Methods for protein purification including immunoprecipitation, chromatography, electrophoresis, centrifugation, and crystallization are described (Coligan, et al. (2000) Current Protocols in Protein Science, Vol. 1, John Wiley and Sons, Inc., New York). Chemical analysis, chemical modification, post-translational modification, production of fusion proteins, glycosylation of proteins are described (see, e.g., Coligan, et al. (2000) Current Protocols in Protein Science, Vol. 2, John Wiley and Sons, Inc., New York; Ausubel, et al. (2001) Current Protocols in Molecular Biology, Vol. 3, John Wiley and Sons, Inc., NY, NY, pp. 16.0.5-16.22.17; Sigma-Aldrich, Co. (2001) Products for Life Science Research, St. Louis, Mo.; pp. 45-89; Amersham Pharmacia Biotech (2001) BioDirectory, Piscataway, N.J., pp. 384-391). Production, purification, and fragmentation of polyclonal and monoclonal antibodies are described (Coligan, et al. (2001) Current Protcols in Immunology, Vol. 1, John Wiley and Sons, Inc., New York; Harlow and Lane (1999) Using Antibodies, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Harlow and Lane, supra). Standard techniques for characterizing ligand/receptor interactions are available (see, e.g., Coligan, et al. (2001) Current Protocols in Immunology, Vol. 4, John Wiley, Inc., New York).


Monoclonal, polyclonal, and humanized antibodies can be prepared (see, e.g., Sheperd and Dean (eds.) (2000) Monoclonal Antibodies, Oxford Univ. Press, New York, N.Y.; Kontermann and Dubel (eds.) (2001) Antibody Engineering, Springer-Verlag, New York; Harlow and Lane (1988) Antibodies A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., pp. 139-243; Carpenter, et al. (2000) J. Immunol. 165:6205; He, et al. (1998) J. Immunol. 160:1029; Tang et al. (1999) J. Biol. Chem. 274:27371-27378; Baca et al. (1997) J. Biol. Chem. 272:10678-10684; Chothia et al. (1989) Nature 342:877-883; Foote and Winter (1992) J. Mol. Biol. 224:487-499; U.S. Pat. No. 6,329,511).


An alternative to humanization is to use human antibody libraries displayed on phage or human antibody libraries in transgenic mice (Vaughan et al. (1996) Nature Biotechnol. 14:309-314; Barbas (1995) Nature Medicine 1:837-839; Mendez et al. (1997) Nature Genetics 15:146-156; Hoogenboom and Chames (2000) Immunol. Today 21:371-377; Barbas et al. (2001) Phage Display: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.; Kay et al. (1996) Phage Display of Peptides and Proteins: A Laboratory Manual, Academic Press, San Diego, Calif.; de Bruin et al. (1999) Nature Biotechnol. 17:397-399).


Antibodies can be conjugated, e.g., to small drug molecules, enzymes, liposomes, polyethylene glycol (PEG). Antibodies are useful for therapeutic, diagnostic, kit or other purposes, and include antibodies coupled, e.g., to dyes, radioisotopes, enzymes, or metals, e.g., colloidal gold (see, e.g., Le Doussal et al. (1991) J. Immunol. 146:169-175; Gibellini et al. (1998) J. Immunol. 160:3891-3898; Hsing and Bishop (1999) J. Immunol. 162:2804-2811; Everts et al. (2002) J. Immunol. 168:883-889).


Methods for flow cytometry, including fluorescence activated cell sorting (FACS), are available (see, e.g., Owens, et al. (1994) Flow Cytometry Principles for Clinical Laboratory Practice, John Wiley and Sons, Hoboken, N.J.; Givan (2001) Flow Cytometry, 2nd ed.; Wiley-Liss, Hoboken, N.J.; Shapiro (2003) Practical Flow Cytometry, John Wiley and Sons, Hoboken, N.J.). Fluorescent reagents suitable for modifying nucleic acids, including nucleic acid primers and probes, polypeptides, and antibodies, for use, e.g., as diagnostic reagents, are available (Molecular Probes (2003) Catalogue, Molecular Probes, Inc., Eugene, Oreg.; Sigma-Aldrich (2003) Catalogue, St. Louis, Mo.).


Standard methods of histology of the immune system are described (see, e.g., Muller-Harmelink (ed.) (1986) Human Thymus: Histopathology and Pathology, Springer Verlag, New York, N.Y.; Hiatt, et al. (2000) Color Atlas of Histology, Lippincott, Williams, and Wilkins, Phila, PA; Louis, et al. (2002) Basic Histology: Text and Atlas, McGraw-Hill, New York, N.Y.).


Software packages and databases for determining, e.g., antigenic fragments, leader sequences, protein folding, functional domains, glycosylation sites, and sequence alignments, are available (see, e.g., GenBank, VECTOR NTI® Suite (Informax, Inc, Bethesda, Md.); GCG Wisconsin Package (Accelrys, Inc., San Diego, Calif.); DECYPHER® (TimeLogic Corp., Crystal Bay, Nev.); Menne, et al. (2000) Bioinformatics 16: 741-742; Menne, et al. (2000) Bioinformatics Applications Note 16:741-742; Wren, et al. (2002) Comput. Methods Programs Biomed. 68:177-181; von Heijne (1983) Eur. J. Biochem. 133:17-21; von Heijne (1986) Nucleic Acids Res. 14:4683-4690).


Purity determinations: Size-exclusion ultra-high performance liquid chromatography (SE-UPLC) or (SEC) was carried out on an ACQUITY® UPLC® H-Class system. Column used was an ACQUITY® UPLC® Protein BEH SEC column (Part No. 186005225, 1.7 μm, 200 Å, 4.6 mm×150 mm) from Waters (Milford, Mass.). Column temperature used was 25C and 10 μl sample at 1 mg/mL was injected using a system flow rate of 0.5 ml/min. Mobile phase used was 100 mM sodium phosphate, 200 mM sodium chloride and 0.02% sodium azide, pH 7.0. Data was quantified at both 214 and 280 nm and analyzed using Empower 3 software. A BEH200 SEC Protein Standard Mix (Part No. 186006518) from Waters (Milford, Mass.) was utilized and injected at 10 ug and USP Resolution, Theoretical plates, and Tailing was measured.


NANO-DSF™ (tradename for modified differential scanning fluorimetry method to determine protein stability employing intrinsic tryptophan or tyrosin fluorescence): the temperature mid-point of a thermal unfolding curve, Tm, and mid-point of a thermal aggregation curve, Tagg, were determined by NANO-DSF® using a PROMETHEUS™ NT.48 Differential Scanning Fluorimeter (Nanotemper Technologies) controlled by PR THERMCONTROL™ v2.0.4 software. Excitation power was 40% and temperature was increased from 20° C. to 95° C. at a rate of 1 C/minute. Tm and Tagg were automatically measured. Samples were prepared by diluting to 1 mg/mL in 20 mM sodium acetate pH 5.5 buffer and drawn by capillary action into a PROMETHEUS™ glass capillary (PR-L002).


Capillary Isoelectric Focusing (cIEF): cIEF was conducted on a iCE3™ system from Protein Simple (San Jose, Calif.) using iCE CFR™ software 4.1.1 for instrument control and data analysis. cIEF Cartridge used was Fc-coated (Protein Simple, 101701) and prepared according to manufacturer's instruction. A 200 μL sample consisting of 40 μg of analyte and 1% v/v 3-10 PHARMALYTE®, 0.5% v/v 8-10.5 PHARMALYTE®, 0.5% v/v 5-8 PHARMALYTE® (GE Healthcare), 37.5% v/v 8.0 M Urea (Sigma-Aldrich), 35% v/v 1% methyl cellulose and 1 μL each of 5.85 and 9.22 pI markers (Protein Simple), was prepared. Samples were injected for 60 seconds. Isoelectric focusing parameters were 1500 V for 1 minute and 3000 V for 8 minutes. pI was automatically measured using the internal pI markers serving as a two-point calibration standard. Calibrated data was further analyzed and quantified by conversion to Empower format and analyzed using Empower 3.


Example 1

Hybridoma clone 52B8 was identified via standard mouse and rat immunization and hybridoma selections. In general, Balb/C mice or rats were immunized with human ILT3-HIS recombinant protein in a standard four week footpad immunization to generate a hyperimmune response. Electrofusion of bulk lymphocytes from draining lymph nodes with the P3 myeloma fusion partner produced immortalized hybridomas. Hybridoma supernatant fluid was screened in a primary cell-based ELISA binding assay on human CHO-human ILT3 cells. A secondary screen on CHO parental, CHO-ILT3 SNP, CHO-rhesus ILT3, CHO-ILT5, CHO-ILT8, and CHO-1LT11 cells was performed in a cell-based ELISA format (See Example 2). Subcloning by limited dilution was performed on the ILT3 specific and rhesus positive hybridoma cells. Subclones were expanded to generate purified protein to enable additional tests of Biacore analyses and functional screening. Table 5 shows 10 hybridoma clones that produced antibodies that binned together and had high affinity for human ILT3 as shown by CELISA and Biacore preformed as disclosed in Examples 2 and 4, respectively.














TABLE 5







cELISA -







human
cELISA -






ILT3
rhesus ILT3

Biacore Kd



Parental
EC50
EC50
Biacore Kd
(M) -


Clone
species
(ng/mL)
(ng/mL)
(M) - ILT3_H
ILT3_MM




















LB181.52A8.1A1
Mouse
18.4
25
8.55 × 10−10
 1.3 × 10−8


LB181.52B8.1B1
Mouse
15.5
23.2
6.58 × 10−10
2.44 × 10−8


LB182.11D1.1A1
Mouse
50.5
No Binding
1.41 × 10−08
No binding


LB182.1G12.1B1
Mouse
39.2
No Binding
1.69 × 10−08
No binding


LB184.16B1.1D2
Rat
64.9
67.9
9.57 × 10−11
2.59 × 10−10


LB184.20E4.1E1.1D1
Rat
2
18
6.99 × 10−9 
 1.8 × 10−8


LB184.24A4.1A1
Rat
21.4
23.1
2.05 × 10−11
1.26 × 10−10


LB184.37C8.1A3.1B1
Rat
7.7
9.5
1.18. × 10−11
 1.5 × 10−10


LB184.40A6.1C1
Rat
17.9
25.9
1.79 × 10−09
9.46 × 10−10


LB190.17H12.1A1
Rat
139.2
No Binding
5.92 × 10−10
No binding





H = human


MM = rhesus monkey (Macaca mulatta)






Table 6 shows the amino acid sequences for the heavy chain and light chain variable domains for the mAbs obtained from the above clones.










TABLE 6








SEQ ID NO:












Heavy Chain
Light Chain


mAb

Variable
Variable


No.
Description
domain
Domain













p52B8
Mouse anti-ILT3 mAb 52B8 IgG2a/Kappa
15
16


p40A6
Rat anti-ILT3 mAb 40A6 IgG2a/Kappa
45
46


p16B1
Rat anti-ILT3 mAb 16B1 IgG2a/Kappa
53
54


p49C6
Mouse anti-ILT3 mAb 49C6 IgG2a/Kappa
Not sequenced
Not sequenced


p11D1
Mouse anti-ILT3 mAb 11D1 IgG2b/Kappa
61
62


p17H12
Rat anti-ILT3 mAb 17H12 IgG1/Kappa
69
70


p37C8
Rat anti-ILT3 mAb 37C8 IgG2a/Kappa
77
78


p1G12
Mouse anti-ILT3 mAb IG12 IgG2a/Kappa
85
86


p20E4
Rat anti-ILT3 mAb 20E4 IgG2a/Kappa
93
94


p24A4
Rat ant-ILT3 mAb 24A4 IgG2a/Kappa
101
102









To ultimately guide the selection of a lead antibody, antibodies were further analyzed and re-evaluated in a set of bio-functional, biophysical, and physicochemical assays. Finally, antibodies were tested in an in vivo, proof of biology tumor regression study using human SKMEL5 melanoma-challenged humanized mice.


Example 2

Selectivity of various anti-ILT3 Antibodies Cell-based ELISA (cELISA) was used to show the selectivity of the various parental anti-ILT3 antibodies shown in Table 5 and humanized anti-ILT3 monoclonal antibody 9B11disclosed in U.S. Pat. No. 7,777,008 as having the amino acid sequences of SEQ ID NO: 33 (light chain) and SEQ ID NO: 34 (heavy chain).


Mouse anti-human ILT3 antibodies were tested for binding to human ILT3, and cross-reactivity to Rhesus monkey ILT3, human ILT5, human ILT7, human ILT8, and human ILT11 expressing CHO-K1 cells using a cell-based ELISA format. CHO-K1 cells were plated in 96-well tissue-culture plates in 50 μL of DMEM/F12, 10% BCS and gentamycin (CHO-K1 media). Cells were plated at either 2×104 cells/well two days prior to the assay or 4×104 cells/well one day prior to the assay. Media was removed from the wells prior to adding the test samples. Purified antibody was serially-diluted in CHO-K1 media and added to the CHO-K1 plates. The samples were incubated at room temperature for 30-60 minutes and plates were washed three times with PBS/05% Tween-20 using the cell wash program on the Biotek EL405x Select CW plate washer. Binding was detected using an HRP-conjugated goat anti-mouse IgG (Southern Biotech cat #1031-05) secondary antibody added at a 1:2000 dilution in CHO-K1 media and incubated at room temperature for 30-60 minutes. Assay plates were washed as above and developed with TMB and stopped with TMB stop solution (KPL cat #50-85-06). The absorbance at 450 nm-620 nm was determined. Mouse IgG1 (MIgG1) served as a control


The results are shown in FIGS. 1A, 1B, 1C, 1D, and 1E. The figures show that representative antibodies from clones p40B5, p49C6, and p52B8 were specific for ILT3 and did not cross-react with or bind ILT5, ILT7, ILT8, and ILT11. Antibodies from clones p49C6 and p52B8 as were the antibodies from the other clones were capable of binding Rhesus monkey ILT3. The p52B8 clone was chosen for in vivo characterization based on (1) its high affinity to human ILT3, (2) lack of binding to other ILT family members, and (3) cross-reactivity to rhesus ILT3.


Example 3

Parental mouse 52B8 heavy chain (VH) and light chain (VL) variable domain sequences were compared to human germline sequences. Human framework sequences closely homologous to the framework of the mouse antibody were chosen.


The mouse VH domain of mouse anti-human ILT3 mAb 52B8 clone scored highly against human heavy chain germline 3-07 in subgroup III and JH4 for the J region. Based on structural considerations, two framework substitutions (R87K and A97G) were incorporated to maintain binding equivalent to the parental antibody. The mouse VL domain of the antibody clone scored highly against human light chain germline 1-O2 in kappa subgroup I. Mouse 52B8 CDRs were engineered onto the variable light chain sequence of 1-O2 and JK2 for the J region. Based on structural considerations, three framework substitutions (M4L, S64 Å, and G72R) were incorporated.


To generate humanized variants, the humanized VH sequence was cloned into a vector encoding human IgG4 S228P heavy chain constant domain and the humanized VL domain was cloned into a vector encoding for a kappa light chain constant domain. A total of two humanized VH (VH1 and VH2) and 8 humanized VL were designed. In silico sequence and structural analysis of mouse 52B8 revealed six potential “hot spots” on the molecule: two potential oxidation sites in VH-CDR2 (M64) and in VH-CDR3 (W101), one potential isomerization site in VH-CDR2 (D62), one potential deamidation site in VL-CDR1 (N34), two potential isomerization sites in VL-CDR1 (D30) and VL-CDR2 (D59). M64 was modified to V64 or L64, which maintained favorable physicochemical attributes and binding/functionality.



FIG. 2A provides a table showing data characteristics on binding affinity, isoelectric point, purity of monomer species, and thermal stability measurements for humanized variants that were designed. Biacore was used to measure binding affinity, cIEF was used to measure pI, purity was determined by SE-UPLC, Tm and Tgg was determined by NANO-DSF™. FIG. 2B shows the relationship of SEC purity and melting temperature of various humanized light chain variants. Data is plotted as values obtained from each of the eight humanized light chain variants demonstrating that VL5 has both the highest purity and thermal stability. Based on the data in FIG. 2A and FIG. 2B, VL5 was selected for the light chain.


Initial studies were performed on the humanized VH1 M64V/VL5 produced in transient CHO cells. Forced deamidation conditions employing both 50° C. incubation and high pH stress performed on unformulated humanized 52B8 VH1 M64V/VL5 revealed deamidation of LC N34 in VL-CDR1 (4.0 and 7.2%, respectively) and W101 oxidation in HC-CDR3 with 1× light stress exposure was 15.4%. Substitution of N34 to Q34 maintained binding affinity to human and rhesus ILT3 assessed by a Biacore SPR assay and functional activity assessed by a DC TNFα production assay; however, substitution of the W101 residue resulted in significant loss in binding as determined by a Biacore SPR assay.


In summary, the humanized 52B8 was anti-ILT3 mAb (52B8 VH1 M64V/VL5 N34Q IgG4 S228P/Kappa), contains one framework substitution in VL (M4L) and one framework substitution in VH (A97G).


Example 4

Binding Kinetics and Affinities for the Anti-Human ILT3 Antibodies to Recombinant Human or Rhesus ILT3


The binding kinetics and affinities of anti-human ILT3 clones for human or rhesus ILT3-His tagged recombinant protein were measured by surface plasmon resonance using a Biacore T200 system (GE Healthcare, Piscataway, N.J.). HBS-EP+ buffer (BR-1006-69) was used as the running buffer. Anti-human Fc antibody (Human Fc Capture Kit, BR100839, GE Healthcare) was immobilized via amine coupling chemistry in all four flow cells on a Series S CMS sensor chip (BR100530 or 29149603, GE Healthcare) following manufacturer instructions. Flow cell 1 was used as reference for background subtraction and was not used for capture. Anti-human ILT3 antibodies listed above (diluted to 1 μg/mL in HBS-EP+ buffer) were injected over the anti-human Fc capture surfaces in flow cells 2, 3 and 4 at 10 μL/mL for 10 seconds which resulted in antibody capture levels in the range of 60-70 RU Six-point, two-fold dilution series of human or rhesus ILT3-His protein ranging from 20 nM to 0.31 nM and two zeros (HBS-EP+) were injected at 50 μL/mL over the reference and captured antibody surfaces for 180 seconds of association followed by 600 seconds of dissociation. Following each injection cycle, all four flow cells were regenerated using 30 second injection of 3M MgCl2 solution at a flow rate of 10 μL/minute. Reference subtracted sensorgrams were fit to a 1:1 Langmuir Binding Model in the Biacore T200 Evaluation Software (Version 2.0) to determine the association (ka) and dissociation (kd) rate constants and the equilibrium dissociation constant KD (=kd/ka).


Table 7 summarizes the binding kinetics and affinities for the anti-human ILT3 antibodies to recombinant human or rhesus ILT3.
















TABLE 7







cELISA
cELISA
Biacore
Biacore






(human
(rhesus
KD
KD
Purity




ILT3-
ILT3-
(human
(rhesus
by SEC




CHO)
CHO)
ILT3-
ILT3-
(%


mAb

EC50
EC50
His)
His)
main


No.
Description
(μg/mL)
(μg/mL)
(nM)
(nM)
peak)
pI






















63
Chimeric anti-
0.064
0.091
0.46
9.5
95.9
n.d.



ILT3 52B8



mouse



VH/human IgG4



(S228P):mouse



VL/human



Kappa


64
Chimeric anti-
0.075
0.096
0.44
9.2
95.3
n.d.



ILT3 52B8



mouse VH



M64V/human



IgG4



(S228P):mouse



VL/human



Kappa


65
Chimeric anti-
0.086
0.137
0.41
9.3
93.5
n.d.



ILT3 52B8



mouse VH



M64L/human



IgG4



(S228P):mouse



VL/human



Kappa


1
Humanized anti-
n.d.
n.d.
0.99
25
93.1
n.d.



ILT3 mAb (52B8



VH1/VL1)



IgG4 S228P/



Kappa


2
Humanized anti-
0.7
0.109
1.1
20
96.2
n.d.



ILT3 mAb (52B8



VH1/VL2)



IgG4 S228P/



Kappa


3
Humanized anti-
n.d.
n.d.
1.1
26
90
n.d.



ILT3 mAb (52B8



VH1/VL3)



IgG4 S228P/



Kappa


4
Humanized anti-
n.d.
n.d.
1.4
29
93.3
n.d.



ILT3 mAb (52B8



VH1/VL4)



IgG4 S228P/



Kappa


5
Humanized anti-
n.d.
n.d.
0.94
25
93.1
n.d.



ILT3 mAb (52B8



VH2/VL1)



IgG4 S228P/



Kappa


6
Humanized anti-
0.1
0.118
1.1
21
96.6
n.d.



ILT3 mAb (52B8



VH2/VL2)



IgG4 S228P/



Kappa


7
Humanized anti-
n.d.
n.d.
0.96
26
89.6
6.33



ILT3 mAb (52B8



VH2/VL3)



IgG4 S228P/



Kappa


8
Humanized anti-
n.d.
n.d.
1.3
27
92.8
n.d.



ILT3 mAb (52B8



VH2/VL4)



IgG4 S228P/



Kappa


9
Humanized anti-
n.d.
n.d.
0.94
26
92.1
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL1) IgG4



S228P/Kappa


10
Humanized anti-
0.085
0.148
1.1
22
95.1
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL2) IgG4



S228P/Kappa


11
Humanized anti-
n.d.
n.d.
1.1
27
89.6
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL3) IgG4



S228P/Kappa


12
Humanized anti-
n.d.
n.d.
1.5
29
92.4
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL4) IgG4



S228P/Kappa


13
Humanized anti-
n.d.
n.d.
0.94
25
85.9
n.d.



ILT3 mAb (52B8



VH2 M64V/



VL1) IgG4



S228P/Kappa


14
Humanized anti-
0.077
0.126
1
22
92.8
n.d.



ILT3 mAb (52B8



VH2 M64V/



VL2) IgG4



S228P/Kappa


15
Humanized anti-
n.d.
n.d.
1
26
88.7
n.d.



ILT3 mAb (52B8



VH2 M64V/



VL3) IgG4



S228P/Kappa


16
Humanized anti-
n.d.
n.d.
1.4
29
93
n.d.



ILT3 mAb (52B8



VH2 M64V/



VL4) IgG4



S228P/Kappa


17
Humanized anti-
n.d.
n.d.
0.87
24
90.2
n.d.



ILT3 mAb (52B8



VH1 M64L/



VL1) IgG4



S228P/Kappa


18
Humanized anti-
0.079
0.137
1
22
92.2
n.d.



ILT3 mAb (52B8



VH1 M64L/



VL2) IgG4



S228P/Kappa


19
Humanized anti-
n.d.
n.d.
0.99
26
87.4
n.d.



ILT3 mAb (52B8



VH1 M64L/



VL3) IgG4



S228P/Kappa


20
Humanized anti-
n.d.
n.d.
1.3
29
90.8
n.d.



ILT3 mAb (52B8



VH1 M64L/



VL4) IgG4



S228P/Kappa


21
Humanized anti-
0.079
0.112
0.88
27
91.2
n.d.



ILT3 mAb (52B8



VH2 M64L/



VL1) IgG4



S228P/Kappa


22
Humanized anti-
0.057
0.081
0.97
21
96.8
n.d.



ILT3 mAb (52B8



VH2 M64L/



VL2) IgG4



S228P/Kappa


23
Humanized anti-
n.d.
n.d.
0.96
24
88.5
n.d.



ILT3 mAb (52B8



VH2 M64L/



VL3) IgG4



S228P/Kappa


24
Humanized anti-
n.d.
n.d.
1.2
27
91.9
n.d.



ILT3 mAb (52B8



VH2 M64L/



VL4) IgG4



S228P/Kappa


25
Humanized anti-
n.d.
n.d.
0.74
8.7
94.9
7.76



ILT3 mAb



((52B8 VH1



M64V/VL2)



L234A L235A



D265S) IgG1/



Kappa


26
Humanized anti-
n.d.
n.d.
0.61
4.9
96.05
8.62



ILT3 mAb



((52B8 VH1



M64V/VL5)



L234A L235A



D265S) IgG1/



Kappa


27
Humanized anti-
n.d.
n.d.
0.92
10
90.17
8.84



ILT3 mAb



((52B8 VH1



M64V/VL6)



L234A L235A



D265S) IgG1/



Kappa


28
Humanized anti-
n.d.
n.d.
0.57
5.6
94.4
8.8



ILT3 mAb



((52B8 VH1



M64V/VL7)



L234A L235A



D265S) IgG1/



Kappa


29
Humanized anti-
n.d.
n.d.
0.56
5.7
94.14
8.85



ILT3 mAb



((52B8 VH1



M64V/VL8)



L234A L235A



D265S) IgG1/



Kappa


30
Humanized anti-
n.d.
n.d.
0.60
4.8
98.22
7.21



ILT3 mAb (52B8



VH1 M64V/



VL5) IgG4



S228P/Kappa


31
Humanized anti-
n.d.
n.d.
0.88
10
91.74
7.45



ILT3 mAb (52B8



VH1 M64V/



VL6) IgG4



S228P/Kappa


32
Humanized anti-
n.d.
n.d.
0.53
5.6
97.79
7.45



ILT3 mAb (52B8



VH1 M64V/



VL7) IgG4



S228P/Kappa


33
Humanized anti-
n.d.
n.d.
0.54
5.6
97.29
7.45



ILT3 mAb (52B8



VH1 M64V/



VL8) IgG4



S228P/Kappa


34
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V



W101F/VL2)



IgG4 S228P/



Kappa


35
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V



W101Y/VL2)



IgG4 S228P/



Kappa


36
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V



W101Q/VL2)



IgG4 S228P/



Kappa


37
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb



((52B8 VH1



M64V W101F/



VL2) L234A



L235A D265S)



IgG1/Kappa


38
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb



((52B8 VH1



M64V W101Y/



VL2) L234A



L235A D265S)



IgG1/Kappa


39
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb



((52B8 VH1



M64V W101Q/



VL2) L234A



L235A D265S)



IgG1/Kappa


40
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL2 S35A) IgG4



S228P/Kappa


41
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL2 S35N) IgG4



S228P/Kappa


42
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL2 N34Q)



IgG4 S228P/



Kappa


43
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL2 N34D)



IgG4 S228P/



Kappa


44
Humanized anti-
n.d.
n.d.
2.6
34
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL5 S35A) IgG4



S228P/Kappa


45
Humanized anti-
n.d.
n.d.
4.7
NB
n.d.
n.d.



ILT3 mAb (52B8



(No



VH1 M64V/



Binding)



VL5 S35N) IgG4



S228P/Kappa


46
Humanized anti-
0.088
0.12
0.77
15
97.9
7.1



ILT3 mAb (52B8



VH1 M64V/



VL5 N34Q)



IgG4 S228P/



Kappa


47
Humanized anti-
n.d.
n.d.
3.8
115
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V/



VL5 N34D)



IgG4 S228P/



Kappa


48
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V



W101F/VL5)



IgG4 S228P/



Kappa


49
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V



W101Y/VL5)



IgG4 S228P/



Kappa


50
Humanized anti-
n.d.
n.d.
n.d.
n.d.
n.d.
n.d.



ILT3 mAb (52B8



VH1 M64V



W101Q/VL5)



IgG4 S228P/



Kappa


51
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101F/VL5



S35A) IgG4



S228P/Kappa


52
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101F/VL5



S35N) IgG4



S228P/Kappa


53
Humanized anti-
n.d.
n.d.
35
NB
n.d.
n.d.



ILT3 mAb (52B8



(No



VH1 M64V



Binding)



W101F/VL5



N34Q) IgG4



S228P/Kappa


54
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101F/VL5



N34D) IgG4



S228P/Kappa


55
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Y/VL5



S35A) IgG4



S228P/Kappa


56
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Y/VL5



S35N) IgG4



S228P/Kappa


57
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Y/VL5



N34Q) IgG4



S228P/Kappa


58
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Y/VL5



N34D) IgG4



S228P/Kappa


59
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Q/VL5



S35A) IgG4



S228P/Kappa


60
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Q/VL5



S35N) IgG4



S228P/Kappa


61
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Q/VL5



N34Q) IgG4



S228P/Kappa


62
Humanized anti-
n.d.
n.d.
NB
NB
n.d.
n.d.



ILT3 mAb (52B8


(No
(No



VH1 M64V


Binding)
Binding)



W101Q/VL5



N34D) IgG4



S228P/Kappa


p52B8
Clone 52B8
15.5
23.2
0.658
24.4
98
n.d.



Hybridoma



extract


p40A6
Clone 40A6
17.9
25.9
0.713
0.995
n.d.
n.d.



Hybridoma



extract


p16B1
Clone 16B1
n.d.
n.d.
0.096
0.259
98.1
n.d.



Hybridoma



extract


p49C6
Clone 49C6
13.8
19.8
n.d.
n.d.
n.d.
n.d.



Hybridoma



extract (not



sequenced)


p11D1
Clone 11D1
50.46
2028
n.d.
n.d.
n.d.
n.d.



Hybridoma



extract


p17H12
Clone 17H12
139.2
NB
n.d.
n.d.
95.7
n.d.



Hybridoma



extract


p37C8
Clone 37C8
7.719
9.478
0.012
0.145
98.4
n.d.



Hybridoma



extract


p1G12
Clone 1G12
39.2
NB
n.d.
n.d.
n.d.
n.d.



Hybridoma



extract


p20E4
Clone 20E4
1.992
18.04
6.99
18.2
98.5
n.d.



Hybridoma



extract


p24A4
Clone 24A4
21.4
21.3
0.021
0.126
n.d.
n.d.



Hybridoma



extract









Example 5
Epitope Mapping of a Chimeric Anti-ILT3 52B8 Mouse VH/Human IgG4 (S228P):Mouse VL/Human Kappa (“c58B8”; mAb 73) Binding to Human ILT3 by Hydrogen Deuterium Exchange (HDX) Mass Spectrometry

Contact areas of the antibody to human ILT3 extracellular domain were determined by use of hydrogen deuterium exchange mass spectrometry (HDX-MS) analysis. HDX-MS measures the incorporation of deuterium into the amide backbone of the protein and changes in this incorporation are influenced by the hydrogen's solvent exposure. A comparison of the deuterium exchange levels in antigen-alone samples and antibody-bound samples was done to identify regions on the ILT3 extracellular domain that may be in contact with the antibody. Human ILT3 extracellular domain with a C-terminal His tag (human ILT3-His) has the amino acid sequence shown in SEQ ID NO: 1.


His-tagged human ILT3-His extracellular domain was pre-incubated with antibody c58B8 (mAb 73), a chimeric anti-ILT3 52B8 mouse VH M64V/human IgG4 (S228P):mouse VL/human Kappa comprising a HC having the amino acid sequence of SEQ ID NO: 113 and a LC having the amino acid sequence shown in SEQ ID NO: 116, before incubation in a deuterium buffer. Human ILT3-His and the antibody were buffer exchanged to PBS pH 7.4 using 3 k MWCO spin columns. Human ILT3-His (80 pmol/μL) was mixed with an equal volume of the antibody (40 pmol/μL) or, as the unbound control, PBS pH 7.4. The antibody bound samples and the unbound control were incubated at room temperature for one hour before beginning the labeling experiment.


To deuterium label the samples, 2 μL of sample was mixed with 25 μL of PBS in deuterium oxide pH 7.6. Labeling time points were 30, 300, 3000, 6000 or 12000 seconds. After the set time, 25 μL of the labeling mixture was added to 30 μL of cold quench buffer (8M Urea, 150 mM TCEP). The quenched sample was incubated at 1.5° C. for 2 minutes. 53 μL, was then injected into the column cooling chamber where the sample was passed over the pepsin/protease XIII column and the resulting peptides loaded onto the trapping column. After three minutes, the analytical gradient and the mass spectrometer were started. A fully deuterated sample was generated by incubating 2 μL of human ILT3-His with 108 μL of deuterated denaturing buffer (4M Urea, 150 mM TCEP in 99.5% deuterium oxide). The sample was incubated at 37° C. overnight. Then 55 μL was directly injected into the column chamber and the data acquired.


LC-MS/MS data was acquired of an unlabeled sample and searched before deuterium labeling to verify successful digestion of the proteins and to generate a list of peptides. Data was database searched using Proteome Discoverer 1.4 and the SEQUEST HT search algorithm (ThermoFisher Scientific). The protein database used was the human ILT3-His sequence concatenated to the yeast Saccharomycese cerevisiae database.


Following labeling, 55 μL sample aliquotes were applied to a NovaBioAssays Pepsin/Protease XIII column followed by chromatography on Waters CSH C18 Guard column and Waters CSH C18 1×50 mm Analytical column in a loading buffer containing 2% Acetonitrile, 0.1% TFA. Deuterium incorporation into the human ILT3-His extracellular domain was measured by mass spectrometry. Quench: 8M Urea, 150 mM TCEP; Labeling buffer: PBS, pH 7.6; Blank buffer: PBS, pH 7.4. The mass spectrometer was a Thermo Scientific ORBITRAP-ELITE™. For the measurement of deuterium labeled samples, the mass spectrometer was set to acquire one full scan MS data in the orbitrap at 120,000 resolving power, a target ion count of 1E6 and a maximum ion injection time of 500 millisecond. For the acquisition of MS/MS data for peptide identifications, the mass spectrometer was set to acquire one full scan spectrum at 120,000 resolving power followed by ten data-dependent MS/MS spectra in the ion trap.


The liquid chromatography system used was a Waters NANOACQUITY® for the analytical column gradient and a Waters 515 isocratic pump for the sample digestion and loading. For sample digestion and loading, the buffer used was 2% acetonitrile and 0.1% trifluoroacetic acid at a flow rate of 100 μL/min For the analytical gradient, the buffers were Buffer A) 0.1% formic acid in water and Buffer B) 0.1% formic acid in acetonitrile. The gradient was at 40 μL/min from 2% B to 36% B in 10 minutes, followed by a wash of 80% B for 1.5 minute and a re-equilibration at 2% B for 3 minutes. The column was then washed by cycling the gradient between 2% and 80% B, three times with 1 minute at each step, followed by a final equilibration at 2% B for 5 minutes. The trapping column was a Waters VANGUARD™ C18 BEH 1.7 μm Guard Column and the analytical column was a Waters C18 BEH300, 1.7 μm 1×50 mm column.


Sample handling for the deuterium labeling was done by a Leaptec H/D-X PAL™ system. The labeling sample tray was set to a temperature of 25° C., the quenching tray was set to 1.5 C and the trap and analytical column chamber was set to 1.5° C. The immobilized pepsin column (Pepsin/Protease XIII column NBA2014002, 2.1×30 mm, NovaBioAssay) was kept outside the column chamber at room temperature.


A deuterium labeling difference heatmap of the human ILT3-His amino acid residues bound by the antibody is shown in FIG. 3A. The HDX mass spectrometry shows that the antibody and the other antibody families disclosed herein that cross-compete with the antibody bind an epitope comprising or consisting of at least one amino acid in one or more of amino acid residues 18-23 (ISWGNS; SEQ ID NO: 3), 64-69 (IPSMTE; SEQ ID NO: 4), 96-101 (MTGAYS; SEQ ID NO: 5), 124-131 (QSRSPMDT; SEQ ID NO: 6), 152-159 (AQQHQAEF; SEQ ID NO: 7) and 184-187 (LLSH; SEQ ID NO: 8) of ILT3. FIG. 3B shows a first-view and a second view of a three-dimensional surface structure model of the human ILT3 extracellular domain with the protected amino acid residues shown. These protected amino acid residues comprise a split or non-contiguous epitope that spans the border between the D1 and D2 domains of the extracellular domain. FIG. 3C is a ribbon diagram showing the placement of the epitope on the human ILT3 extracellular domain. Residues in black were protected from labeling by the antibody. Residues in white showed no changes in labeling and residues in dark gray did not have data acquired for them. The deuterium labeling difference for each residue was averaged and mapped onto a crystal structure of ILT3 (Cheng et al., “Crystal structure of leukocyte Ig-like receptor LILRB4 (ILT3/LIR-5/CD85 k): a myeloid inhibitory receptor involved in immune tolerance.” J Biol Chem 286:18013-25 (2011)).


Similar HDX mapping experiments were preformed using antibodies ZM4.1, DX439, DX446, and 9B11. Antibody ZM4.1 is commercially available from ThermoFisher Scientific, Carlsbad, Calif. or BioLegend, San Diego, Calif. Antibodies DX439 and DX446 have been disclosed in WO2018089300 and Antibody 9B11 has been disclosed in U.S. Pat. No. 7,777,008. Of these antibodies, only antibody ZM4.1 was observed to bind an epitope that partially overlapped with the epitope bound by the antibodies of the present invention; however, binning studies showed that antibody ZM4.1 did not cross block binding of the antibodies of the present invention. FIGS. 3D, 3E, 3F, and 3G show heatmaps of the binding of antibodies ZM4.1, DX439, DX446, and 9B11 to human ILT3.


Example 6

Pharmacokinetics of Chimeric Anti-ILT3 52B8 Mouse VH/Human IGg4 (S228P):Mouse VL/Human Kappa (“C58B8”; mAb 73) in NSG Mice


The pharmacokinetics of chimeric anti-ILT3 52B8 mouse VH/human IgG4 (S228P):mouse VL/human Kappa (c85B8, mAb 73) was evaluated in Panc08.13 human-NSG mice model and SK-MEL-5 human CD34+-NSG mice model.


SK-MEL-5 is a human melanoma-derived line that can grow as a subcutaneous tumor. Panc 08.13 is a human pancreatic carcinoma-derived tumor line. Panc 08.13 human-NSG model has been shown to be sensitive to pembrolizumab and ipilimumab treatment. SK-MEL-5 model has a robust and diverse myeloid infiltrate in the tumor compared to Panc 08.13 model. Both models show increased ILT3 expression on human CD14+ myeloid cells in the tumor and spleen.


An ECL-based target capture immunoassay was used to quantify the antibody in humanized mice plasma. The assay was established with biotinylated recombinant ILT3 as capture reagent, and sulfoTAG labeled mouse anti-huIgG (Fc specific) from Southern Biotech (cat #9190-01) for detection reagent. Both calibrators and QCs were prepared in neat C57BL/6 plasma and diluted 100 times when testing in plate. This assay has been qualified and the LLOQ of the assay was determined to be 40 ng/mL with an MRD of 100.


In Panc08.13 hu-NSG mice model, 20 mg/kg of antibody was administered with and without pembrolizumab (5 mg/kg) via IP weekly for the first three doses and two weeks after the 3rd dose for the 4th dose. Blood samples were collected before the third dose (Ctrough) and 24 hours after the third dose (Cmax). Terminal blood samples on day 5 and 6 after the fourth dose were also collected. In SK-MEL-5 huCD34+NSG mice model, the antibody was administered at 2 and 20 mg/kg via IP weekly. Blood samples were collected before the third dose (Ctrough) and 24 h after the third dose (Cmax). Terminal blood samples on day 3 and 7 after the third dose were also collected. The free (unbound) antibody concentrations were determined by an antigen-capture assay.


Pharmacokinetic parameters are generated from historical IgG4 antibody data (IV bolus administration of 1, 3, 10, 30 mg/kg of humanized IgG4 antibody in C57BL/6J mice) with Phoenix NLME. PK profiles at the studied dose of the antibody were simulated based on the generated pharmacokinetic parameters.


PK analysis of historical IgG4 antibody data showed a linear relationship between AUC and studied dose (See FIG. 4). With the assumptions including linear PK across different tested doses of c52B8, no PK difference among different mouse strains, rapid absorption and 100% bioavailable after IP administration of the antibody, PK profiles at the studied dose of c52B8 were simulated based on historical IgG4 antibody data. The results showed that the simulated profile at 20 mg/kg in both Panc08.13 human-NSG model and SK-MEL-5 huCD34+-NSG model follow the observed c52B8 concentrations.


Example 7

Anti-ILT3 Monoclonal Antibodies Activate Dendritic Cells and Reduces Suppressive Capacity of Myeloid-Derived Suppressor Cells (MDSCs)


Human PBMCs isolated from fresh leukopacs were frozen, thawed and CD14+ monocytes were purified by negative selection. The purified cells were cultured for 5 days with GM-CSF (1000 U/mL) and IL4 (1000 U/mL). These immature DCs were then further cultured for 42 hours with addition of IL-10 (50 ng/mL) and LPS (1 ug/mL) with or without anti-ILT3 antibody. TNFα is measured in the culture supernatant.


Titration experiments showed that c52B8 caused a dose-dependent increase in TNFα secretion in the culture medium when added during the polarization step, whereas a control IgG4 did not (the control is an variant of a commercial antibody against RSV, trade name Synagis) (FIG. 5A). The concentration of antibody required to produce half of the maximal increase in TNFα levels (EC50) was approximately 1.9 ng/mL. This was not different for chimeric variants in which VH and VL of p58B8 were fused to Fc with a human IgG1 framework (mAb 78) or a N297A mutated human IgG1 framework (mAb 76). These data indicate that in this assay Fc receptor binding does not play any role in the functional activity. The independence from Fc receptor binding controls for the possibility that the mechanism of activation in this assay is DCs becoming activated through recognition of other DCs in the culture being decorated with antibody which would be a mechanism unrelated to ILT3.



FIGS. 5B and 5C show there was no significant difference in functional activity between c52B8 (mAb 73) and humanized anti-ILT3 mAb 52B8 VH1 M64V/VL5 N34Q) IgG4 S228P/Kappa (mAb 46) in two donors. As shown, with antibody c52B8 added during polarization of the DCs, but not during T cell priming, DCs were better able to activate T cells to proliferate, similar to DCs not tolerized with IL10. When antibody c52B8 was added during T cell priming but not during DC polarization, T cells were better able to respond to subsequent re-stimulation. Following humanization, variants that retained binding comparable to the chimera were tested in this same assay and found to be active, with no meaningful differences in potency among them. These data indicate that data generated with c52B8 is representative of what the data would be if humanized mAb 46 had been used.


Example 8

Anti-ILT3 Antibodies Reduce Suppressive Capacity of Myeloid-Derived Suppressor Cells (MDSCs)


Without ascribing to any particular theory or hypothesis, we hypothesize that a productive T cell response to tumor can be limited in some cases by the presence of immature and suppressive myeloid cells. These cells express ILT3 and we hypothesize that ILT3 functions as an inhibitory manner to maintain an immature state characterized by low HLA-DR expression, IL-10 production, and effective suppression of T cell activation and proliferation. Establishment of a model based on co-culture of human PBMCs with SKMEL5 tumor cells in vitro, followed by purification of MDSCs and testing of their ability to suppress proliferation of autologous CD8+ T cells enabled exploration of this aspect of ILT3 biology. This example shows that c52B8 and humanized 52B8 (mAb 46) are able to impair the acquisition (or maintenance) of a T cell-suppressive phenotype.


To generate MDSCs, healthy human PBMCs were cultured with SKMEL5 cells and 20 ng/mL GM-CSF for 7 days. CD33+ cells were collected by positive antibody-based magnetic bead selection and then co-cultured at the indicated ratios with purified autologous CD8+ T cells for 3 days in the presence of a polyclonal stimulus. Cultures included c52B8 (mAb 73), humanized 52B8 (mAb 46), or isotype control antibody (1 μg/mL) in both the co-culture and T cell suppression steps. The T cell suppression assay was conducted with a T cell to MDSC ratio of 4:1 and measuring the amount of interferon gamma (INFγ) produced.



FIG. 6A and FIG. 6B exemplifies the activity of both humanized 52B8 and c52B8 in the MDSC model at a ratio of T cells to MDSCs where the effect of these antibodies was most evident show that the antibodies reduce the suppressive capacity of MDSCs in a comparable manner. These data further indicate that data generated with c52B8 is representative of what would be found with humanized mAb 46.


Example 9

Anti-ILT3 Antibody cC52B8 Inhibits Growth of SK-MEL-5 Tumors in SK-MEL-5 Hu-NSG Mice Bearing SK-MEL-5 Subcutaneous Tumors


Systemic administration of c52B8 once weekly to mice bearing established subcutaneous tumors afforded inhibition of tumor growth (FIG. 7). Animals were randomized to treatment on the basis of tumor volume on day 21 post-implantation and dosed s.c. with 20 mg/kg of c52B8 (mAb 73) or isotype control once weekly beginning on day 21. Data shown in the left panel are means and std. error (nine per group). Individual animal tumor growth curves are shown at right. Body weight decreased to a similar degree in both control and 52B8 groups. This study is representative of three independent studies.


The degree of inhibition of tumor growth was consistent and similar in three separate studies and was very similar to the effect of anti-ILT4. None of the other mechanisms tested to date (e.g. anti-PD-1, anti-ILT4, anti-CD27, anti-GITR) have afforded regressions leading us to speculate that tumor stasis may represent a floor for this model. This is clearly different from the mouse syngenic models commonly used for preclinical efficacy assays.


Example 10

Immune Activation in SK-MEL-5 Hu-NSG after c52B8 Treatment


To understand immune mechanism that mediates the tumor efficacy, tumor infiltrating immune cells were profiled and measured sHLA-G levels were measured in the blood. Mice were treated with c52B8 (2 and 20 mg/kg i.p. QW). Antibody doses were selected based on Cmax and Ctrough levels detected in a mini-PK and simulations using historical studies. Blood samples were collected for PK, sHLA-G, and cytokine analyses. TILs profiling was performed using CyTOF to detect 36 markers simultaneously. Terminal tumor samples were fixed and used for human CD3+ T cell IHC analysis. Thirty percent tumor growth inhibition was observed in mice treated with 20 mpk 52B8. However, no statistical significant difference was detected due to big variability associated with the humanized tumor model. 52B8 modest tumor efficacy was associated with a modest decrease in tumor CD4+CD127-CD25+T suppressor cells (21% vs. 14%) and blood sHLA-G levels and an increase in activation of T cells (CD69 intensity, 14 vs. 23) in the tumor. No cytokine change was detected with c52B8 treatment as seen in FIG. 8.


Example 11

Effect of Anti-ILT3 Antibody c52B8 in Combination with Pembrolizumab in Panc 08.13 Hu-NSG Model: Tumor Efficacy and Immune Activation


Anti-ILT3 antibody c52B8 was evaluated in Panc 08.13 hu-NSG model. 52B8 used as a single agent showed minimum effect on tumor growth inhibition. When 52B8 was used in combination with pembrolizumab, one in five cohorts (five different human donors) of humanized mice had 50% tumor growth inhibition (TGI) and the TGI was associated with increased T cell activation and IFNγ production and decreased blood sHLA-G level as seen in FIG. 9A, FIG. 9B, FIG. 9C, and FIG. 9D.


Example 12

Effect of Anti-ILT3 Antibody 52B8 in Combination with Pembrolizumab in an MDSC/T Cell Suppression Assay


Humanized anti-ILT3 antibody 52B8 (mAb 46) with and without pembrolizumab effected an increase T-Cell activity in MDSC/T-cell suppression assays. The effect was additive when mAb 46 was used in combination with pembrolizumab.


To generate MDSCs, healthy human PBMCs from a particular donor were cultured with SKMEL5 cells and 20 ng/mL GM-CSF for seven days. Cultures were treated with 52B8 (1 μg/mL) or isotype control antibody (1 μg/mL). CD33+ cells were collected anti-CD33 magnetic microbeads and LS column separation (Miltenyi Biotec, Germany) and then co-cultured at the indicated ratios with purified autologous CD8+ T cells for 3 days in the presence of a polyclonal stimulus. Autologous CD8+ T cells were isolated from healthy human PBMCs using negative antibody-based magnetic bead selection (Stem Cell Technologies, Canada) then co-cultured in 96 well plates with CD33+ myeloid cells at the ratio of 8:1 (Tcell:MDSC) for 2 days. Cultures included humanized 52B8 (mAb 46) or isotype control antibody (IgG4) (1 μg/mL) alone or in combination with pembrolizumab (2 μg/mL) in both the co-culture and T cell suppression steps. Total antibody concentration in each treatment is adjusted to 3 ug/mL with isotype control antibody. T cell proliferation was induced by a polyclonal stimulus anti-CD3/CD28 beads and IL2. IFNγ levels were determined in culture supernatants using MSD ELISA (Mesoscale Discovery, MD). The T cell suppression assay was conducted with a T cell to MDSC ratio of 4:1 or 8:1 and measuring the amount of interferon gamma (INFγ) produced. The results are shown in FIGS. 10-14.



FIG. 10 shows that humanized anti-ILT3 antibody 52B8 (mAb 46) reduces the suppressive capacity of MDSCs to an extent comparable to chimeric anti-ILT3 antibody c52B8 (mAb 73; lot 26AVY) in MDSC/T-cell suppression assays using MDSCs obtained from PBMCs from two different human donors (D00100385 and D001003507, respectively).


As shown in FIGS. 11-14 humanized anti-ILT3 antibody 52B8 (mAb 46) in combination with pembrolizumab reduced MDSC inhibition of T cell activation at a higher level compared to either alone in an MDSC/T cell suppression assay (a) at either a 4:1 or 8:1 ratio of T cell to MDSC using MDSCs obtained from PBMCs from human donor D001003835 (FIG. 11); (b) at either a 4:1 or 8:1 ratio of MDSC to T cell using MDSCs obtained from PBMCs from human donor D001003180 (FIG. 12); (c) at a 4:1 or 8:1 ratio of ratio of T cell to MDSC using MDSCs obtained from PBMCs from human donor D001003507 (FIG. 13); and an 8:1 ratio of ratio of T cell to MDSC using MDSCs obtained from PBMCs from human donor (FIG. 14). The results are summarized in Tables 8 and 9. As shown in FIGS. 10-13 and Tables 8 and 9, combining an anti-ILT3 antibody 52B8 with pembrolizumab resulted in an additive effect of increasing the activation of T cells over that achievable using pembrolizumab or 52B8 alone. As shown, increases in IFNγ for the combination relative to the other treatments ranged from 41% to 74%. These results indicate that the combination of pembrolizumab with 52B8 does not result in an excessive or uncontrolled escalation of T cell activation.









TABLE 8







Summary of the humanized anti-ILT3 antibody 52B8 and pembrolizumab combination data









Mean Avg ± SD









T cell + MDSC














T Cell:MDSC
T cell
hIgG4 +
hIgG4 +
hIgG4 +
52B8 +


Donor
ratio
only
hIgG4
Pembrolizumab
52B8
Pembrolizumab





D001003835
4:1
19439 ± 4191
3667 ± 795
4676 ± 1162
 6380 ± 1187
10438 ± 1132



8:1
32644 ± 4146
17386 ± 1628
20556 ± 5028 
28280 ± 4643
38163 ± 7817


D001003180
4:1
38166 ± 7574
1482 ± 646
1781 ± 295 
 3983 ± 1528
 3606 ± 1864



8:1
33250 ± 6021
 6823 ± 2170
6768 ± 1287
 9532 ± 3025
14896 ± 2932


D001003507
4:1
56836 ± 5777
 7364 ± 2977
8111 ± 5220
12202 ± 3221
18422 ± 4135



8:1
55376 ± 6310
23417 ± 8640
23981 ± 3135 
26204 ± 3075
36992 ± 1856


D001003428
8:1
159127 ± 10552
 81071 ± 13458
87413 ± 15061
98902 ± 9884
123920 ± 22448
















TABLE 9







52B8 Antibody + Pembrolizumab Combination -


T cell:MDSC ratio (8:1)













Ratios





Condition
of GM
95% CI
P-value






(52B8 + pembrolizumab)/
1.84
1.35, 2.53
0.0043



IgG4






(52B8 + pembrolizumab)/
1.73
1.26, 2.36
0.0057



pembrolizumab






(52B8 + pembrolizumab)/
1.39
1.20, 1.61
0.0028



52B8





The p-values are from one-sided paired t-tests comparing the 52B8 + pembrolizumab combination to each of the other groups, using logs of IFNγ values.


GM = geometric mean






Example 13

Effect of Anti-ILT3 Antibody 52B8 in Combination with Pembrolizumab in Mixed Lymphocyte Reaction of Polarized IL-10 DCs and Allogenic CD8+ T Cells


In this example, a mixed lymphocyte reaction of IL-10-polarized human monocyte-derived dendritic cells and allogenic CD8+ T cells, incubated for four days followed by measurement of interferon gamma (IFNγ) in the culture supernatant as a read out of T cell activation. In this experiment, the activities of pembrolizumab, 52B8, or the combination of the two were compared to isotype control antibody (IgG4 in both cases), in nine allogenic donor pairs.


Monocyte derived dendritic cells (DCs) —IL10 DCs from three CD14+ monocyte donors were differentiated for seven days (Granulocyte-macrophage colony-stimulating factor (GMCSF) and IL4 for five days and then two days with IL10, with and without IgG4 (lot 92ASJ), with and without 52B8 (Lot 41BAB) at 1 μg/mL) to produce DC129, DC226, and DC196. CD8+ cells from three donors were isolated and mixed leukocyte reactions (MLR) were established at 1:5 DC:T cell ratio from the three donors in a 96 well format (30 k DC vs 150 k CD8+ T cells) where cells were treated with and without IgG4 (lot 92 ASJ); with and without Pembrolizumab (lot 42ASN) at 2 μg/mL. IgG4 or 52B8 was also added back in the MLR at 1 μg/mL. Wound up with nine MLR pairs of IL10 DCs:CD8+ T cells:


DC129 vs T30, T3788 and T3259


DC226 vs T30, T3788 and T3259


DC196 vs T30, T3788 and T3259


IFNγ supernatant was collected at day four and quantified using Meso Scale Discovery (MSD). Additional supernatant fraction was collected at day five and cells were collected and stained for PD1 and PDL1 expression. Dendritic Cell Staining on Day seven of differentiation (just prior to MLR setup). T cell Staining of CD8+ T cells at day five of MLR assay.



FIG. 15 shows the results for all donor pairs combined into one figure (each mark is a donor pairing). As shown, 52B8 in combination with pembrolizumab effected a reverse of T cell tolerization, resulting in a statistically significant increase in activation of CD8+ T cells.











TABLE OF SEQUENCES





SEQ




ID




NO:
Description
Sequence







  1
Human ILT3
QAGPLPKPTLWAEPGSVISWGNSVTIWCQGTLEAREYRLDK



(LILRB4)
EESPAPWDRQNPLEPKNKARFSIPSMTEDYAGRYRCYYRSP



extracellular
VGWSQPSDPLELVMTGAYSKPTLSALPSPLVTSGKSVTLLC



domain with C-

QSRSPMDTFLLIKERAAHPLLHLRSEHGAQQHQAEFPMSPV




terminal His Tag;
TSVHGGTYRCFSSHGFSHYLLSHPSDPLELIVSGSLEDPRPSP



epitope domains
TRSVSTAAGPEDQPLMPTGSVPHSGLRRHWEHHHHHHHH



identified by bold-




face type






  2

Macaca mulatta

QAGPLPKPTIWAEPGSVISWGSPVTIWCQGTLDAQEYYLDKE



(Rhesus) ILT3
GSPAPWDTQNPLEPRNKAKFSIPSMTQHYAGRYRCYYHSHP



(LILRB4)
DWSEDSDPLDLVMTGAYSKPILSVLPSPLVTSGESVTLLCQS



extracellular
QSPMDTFLLFKEGAAHPLPRLRSQHGAQLHWAEFPMGPVTS



domain
VHGGTYRCISSRSFSHYLLSRPSDPVELTVLGSLESPSPSPTRSI



(sequence obtained
SAAGPEDQSLMPTGSDPQSGLRRHWE



from GenBank




NP_001035766)






  3
Human ILT3
ISWGNS



peptide A






  4
Human ILT3
IPSMTE



peptide B






  5
Human ILT3
MTGAYS



peptide C






  6
Human ILT3
QSRSPMDT



peptide D






  7
Human ILT3
AQQHQAEF



peptide E






  8
Human ILT3
LLSH



peptide F






  9
Human IgG4 HC

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




Constant domain

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




(S228P; shown in

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




bold-face type)

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLGK






 10
Human IgG4 HC

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




Constant domain

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




(S228P; shown in

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




bold-face type)

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS




(lacks C-terminal K

TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP




(herein referred to

REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP




as “K−”))

ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLG






 11
Human IgG1 HC

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




constant domain

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN






TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL






MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE






QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






 12
Human IgG1 HC

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Constant domain

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(L234A, L235A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDTL




D265S; shown in

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




bold-face type)

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK






GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






 13
Human IgG1 HC

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Constant domain

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(K−)(L234A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDTL




L235A, D265S;

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




shown in bold-face

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK




type)

GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






 14
Human LC Kappa

RTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVD




Constant domain

NALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEV






THQGLSSPVTKSFNRGEC






 15
Anti-ILT3 52B8
EVQLVESGGDLVKPGGSLKLSCAASGFTFSNYGMSWVRQTP



parental HC
DRRLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNTLYLQ



variable domain
MSSLKSEDTAMYYCGRRLWFRSLYYAMDYWGQGTSVTVSS





 16
Anti-ILT3 52B8
NIVLTQSPASLAVSLGQRATISCRASEKVDSFGNSFMHWYQQ



parental LC
KPGQPPKLLIYLTSNLDSGVPARFSGSGSRTDFALTIDPVEAD



variable domain
DAATYYCQQNNEDPYTFGGGTKLEIK





 17
52B8 HC-CDR1
NYGMS





 18
52B8 HC-CDR2
TISGGGDYTNYPDSXRG



(Wherein Xaa15 is




M, V, or L)






 19
52B8 HC-CDR2 M
TISGGGDYTNYPDSMRG





 20
52B8 HC-CDR2 V
TISGGGDYTNYPDSVRG





 21
52B8 HC-CDR2 L
TISGGGDYTNYPDSLRG





 22
52B8 HC-CDR3
RLXFRSLYYAMDY



(Wherein Xaa3 is




W, Y, Q, or F)






 23
52B8 HC-CDR3
RLWFRSLYYAMDY





 24
52B8 HC-CDR3
RLYFRSLYYAMDY





 25
52B8 HC-CDR3
RLQFRSLYYAMDY





 26
52B8 HC-CDR3
RLFFRSLYYAMDY





 27
52B8 LC-CDR1
RASEKVDSFGXXFMH



(Wherein Xaa11 is




N, D, or Q and




Xaa12 is S, N, or




A)






 28
52B8 LC-CDR1 N
RASEKVDSFGNXFMH



(WhereinXaa12 is




S, N, or A)






 29
52B8 LC-CDR1 D
RASEKVDSFGDXFMH



(WhereinXaa12 is




S, N, or A)






 30
52B8 LC-CDR1 Q
RASEKVDSFGQXFMH



(WhereinXaa12 is




S, N, or A)






 31
52B8 LC-CDR1 S
RASEKVDSFGXSFMH



(Wherein Xaa11 is




N, D, or Q)






 32
52B8 LC-CDR1 N
RASEKVDSFGXNFMH



(Wherein Xaa11 is




N, D, or Q)






 33
52B8 LC-CDR1 A
RASEKVDSFGXAFMH



(Wherein Xaa11 is




N, D, or Q)






 34
52B8 LC-CDR1
RASEKVDSFGNNFMH



(NN)






 35
52B8 LC-CDR1
RASEKVDSFGDNFMH



(DN)






 36
52B8 LC-CDR1
RASEKVDSFGQNFMH



(QN)






 37
52B8 LC-CDR1
RASEKVDSFGNSFMH



(NS)






 38
52B8 LC-CDR1
RASEKVDSFGDSFMH



(DS)






 39
52B8 LC-CDR1
RASEKVDSFGNAFMH



(NA)






 40
52B8 LC-CDR1
RASEKVDSFGDAFMH



(DA)






 41
52B8 LC-CDR1
RASEKVDSFGQSFMH



(QS)






 42
52B8 LC-CDR1
RASEKVDSFGQAFMH



(AF)






 43
52B8 LC-CDR2
LTSNLDS





 44
52B8 LC-CDR3
QQNNEDPYT





 45
Anti-ILT3 40A6
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYSINWVRQSSG



parental HC
KGPEWMGRFWYDEGIAYNLTLESRLSISGDTSKNQVFLKMN



variable domain
SLRTGDTGTYYCTRDRDTVGITGWFAYWGQGTLVTVSS





 46
Anti-ILT3 40A6
ETVMTQSPTSLSASIGERVTLNCKASQSVGVNVDWYQQTPG



parental LC
QSPKLLIYGSANRHTGVPDRFTGSGFGSDFTLTISDVEPEDLG



variable domain
VYYCLQYGSVPYTFGAGTKLELK





 47
40A6 HC-CDR1
SYSIN





 48
40A6 HC-CDR2
RFWYDEGIAYNLTLES





 49
40A6 HC-CDR3
DRDTVGITGWFAY





 50
40A6 LC-CDR1
KASQSVGVNVD





 51
40A6 LC-CDR2
GSANRHT





 52
40A6 LC-CDR3
LQYGSVPYT





 53
Anti-ILT3 16B1
QVQLKESGPGLVQASETLSLTCTVSGFSLTNYCVNWVRQPS



parental HC
GKGPEWLGRFWFDEGKAYNLTLESRLSISGDTSKNQVFLRM



variable domain
NSLRADDTGTYYCTRDRDTVGITGWFAYWGQGTLVTVSS





 54
Anti-ILT3 16B1
ETVMTQSPTSLSASIGERVTLNCKASQSVGINVDWYQQTPGQ



parental LC
SPKLLIYGSANRHTGVPDRFTGSGFGSDFTLTISNVEPEDLGV



variable domain
YYCLQYGSVPYTFGPGTKLELK





 55
16B1 HC-CDR1
NYCVN





 56
16B1 HC-CDR2
RFWFDEGKAYNLTLES





 57
16B1 HC-CDR3
DRDTVGITGWFAY





 58
16B1 LC-CDR1
KASQSVGINVD





 59
16B1 LC-CDR2
GSANRHT





 60
16B1 LC-CDR3
LQYGSVPYT





 61
Anti-ILT3 11D1
QVQLQQSGAELMKPGASVKISCKATGYTFRTYWIEWVKQRP



parental HC
GHGLEWIGEILPGNGNTHFNENFKDKATFTADTSSNAAYMQ



variable domain
LSSLTSEDSAVYYCVRRLGRGPFDFWGQGTTLTVSS





 62
Anti-ILT3 11D1
DIQMTQSPSSLSVSLGGKVTITCKASQDINEYIGWYQRKPGK



parental LC
GPRLLIHYTSTLQSGIPSRFSGSGSGRDYSLSISNLEPEDIATYY



variable domain
CLQYANPLPTFGGGTKLEIK





 63
11D1 HC-CDR1
TYWIE





 64
11D1 HC-CDR2
EILPGNGNTHFNENFKD





 65
11D1 HC-CDR3
RRLGRGPFDF





 66
11D1 LC-CDR1
KASQDINEYIG





 67
11D1 LC-CDR2
YTSTLQS





 68
11D1 LC-CDR3
LQYANPLPT





 69
Anti-ILT3 17H12
EVQLVESGGGLVQPGRSMKLSCAASGFTFSNFDMAWVRQA



parental HC
PTRGLEWVSSITYDGGSTSYRDSVKGRFTISRDNAKGTLYLQ



variable domain
MDSLRSEDTATYYCTTVESIATISTYFDYWGQGVMVTVSS





 70
Anti-ILT3 17H12
DIVLTQSPALAVSLGQRATISCRASQSVSMSRYDLIHWYQQK



parental LC
PGQQPKLLIFRASDLASGIPARFSGSGSGTDFTLTINPVQADDI



variable domain
ATYYCQQTRKSPPTFGGGTRLELK





 71
17H12 HC-CDR1
NFDMA





 72
17H12 HC-CDR2
SITYDGGSTSYRDSVKG





 73
17H12 HC-CDR3
VESIATISTYFDY





 74
17H12 LC-CDR1
RASQSVSMSRYDLIH





 75
17H12 LC-CDR2
RASDLAS





 76
17H12 LC-CDR3
QQTRKSPPT





 77
Anti-ILT3 37C8
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYCVNWVRQPSG



parental HC
KGPEWLGRFWYDEGKVYNLTLESRLSISGDTSKNQVFLKMN



variable domain
RLRTDDTGTYYCTRDRDTMGITGWFAYWGQGTLVTVSS





 78
Anti-ILT3 37C8
ETVMTQSPTSLSASIGERVTLNCKASQSVGINVDWYQQTPGQ



parental LC
SPKLLIYGSANRHTGVPDRFTGSGFGSGFTLTISNVEPEDLGV



variable domain
YYCLQYGSVPYTFGPGTKLELK





 79
37C8 HC-CDR1
SYCVN





 80
37C8 HC-CDR2
RFWYDEGKVYNLTLES





 81
37C8 HC-CDR3
DRDTMGITGWFAY





 82
37C8 LC-CDR1
KASQSVGINVD





 83
37C8 LC-CDR2
GSANRHT





 84
37C8 LC-CDR3
LQYGSVPYT





 85
Anti-ILT3 1G12
QVQMQQSGTELMKPGASMKISCKATGYTFSTYWIQWIKQRP



parental HC
GHGLEWIGEILPGSGTTNYNENFKGKATFSADTSSNTAYIHLS



variable domain
SLTSEDSAVFYCARRLGRGPFDYVVGQGTTLTVSS





 86
Anti-ILT3 1G12
DIQMTQSPSSLSASLGGKVTITCEASQDINKHIDWYQHQPGR



parental LC
GPSLLIHYASILQPGIPSRFSGSGSGRDYSFSITSLEPEDIATYY



variable domain
CLQYDNLLPTFGGGTKLEIK





 87
1G12 HC-CDR1
TYWIQ





 88
1G12 HC-CDR2
EILPGSGTTNYNENFKG





 89
1G12 HC-CDR3
RLGRGPFDY





 90
1G12 LC-CDR1
EASQDINKHID





 91
1G12 LC-CDR2
YASILQP





 92
1G12 LC-CDR3
LQYDNLLPT





 93
Anti-ILT3 20E4
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYSVNWVRQPSG



parental HC
KGLEWMGRFWYDGGTAYNSTLESRLSISGDTSKNQVFLKM



variable domain
NSLQTDDTGTYYCTRDRDTMGITGWFAYWGQGTLVTVSP





 94
Anti-ILT3 20E4
ETVMTQSPTSLSASIGERVTLNCKASQSVGVNVDWYQQTPG



parental LC
QSPKLLIYGSANRHTGVPDRFTGSGFGSDFTLTISNVEPEDLG



variable domain
VYYCLQYGSVPYTFGAGTKLELK





 95
20E4 HC-CDR1
SYSVN





 96
20E4 HC-CDR2
RFWYDGGTAYNSTLES





 97
20E4 HC-CDR3
DRDTMGITGWFAY





 98
20E4 LC-CDR1
KASQSVGVNVD





 99
20E4 LC-CDR2
GSANRHT





100
20E4 LC-CDR3
LQYGSVPYT





101
Anti-ILT3 24A4
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYCVNWVRQPSG



parental HC
KGPEWLGRFWYDEGKVYNLTLESRLSISGDTSKNQVFLKMN



variable domain
RLRTDDTGTYYCTRDRDTLGITGWFAYWGQGTLVTVSS





102
Anti-ILT3 24A4
ETVMTQSPTSLSASIGERVTLNCKASQSVGINVDWYQQTPGQ



parental LC
SPKLLIYGSANRHTGVPDRFTGSGFGSGFTLTISNVEPEDLGV



variable domain
YYCLQYGSVPYTFGPGTKLELK





103
24A4 HC-CDR1
SYCVN





104
24A4 HC-CDR2
RFWYDEGKVYNLTLES





105
24A4 HC-CDR3
DRDTLGITGWFAY





106
24A4 LC-CDR1
KASQSVGINVD





107
24A4 LC-CDR2
GSANRHT





108
24A4 LC-CDR3
LQYGSVPYT





109
Leader sequence A
MEWSWVFLFFLSVTTGVHS





110
Leader sequence B
MSVPTQVLGLLLLWLTDARC





111
Mouse Anti-ILT3
EVQLVESGGDLVKPGGSLKLSCAASGFTFSNYGMSWVRQTP



p52B8 parental HC:
DRRLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNTLYLQ



Murine IgG2a
MSSLKSEDTAMYYCGRRLWFRSLYYAMDYWGQGTSVTVSS



heavy chain
AKTTAPSVYPLAPVCGDTTGSSVTLGCLVKGYFPEPVTLTW




NSGSLSSGVHTFPAVLQSDLYTLSSSVTVTSSTWPSQSITCNV




AHPASSTKVDKKIEPRGPTIKPCPPCKCPAPNLLGGPSVFIFPP




KIKDVLMISLSPIVTCVVVDVSEDDPDVQISWFVNNVEVHTA




QTQTHREDYNSTLRVVSALPIQHQDWMSGKEFKCKVNNKD




LPAPIERTISKPKGSVRAPQVYVLPPPEEEMTKKQVTLTCMV




TDFMPEDIYVEWTNNGKTELNYKNTEPVLDSDGSYFMYSKL




RVEKKNWVERNSYSCSVVHEGLHNHHTTKSFSRTPGK





112
Mouse Anti-ILT3
NIVLTQSPASLAVSLGQRATISCRASEKVDSFGNSFMHWYQQ



p52B8 parental LC:
KPGQPPKLLIYLTSNLDSGVPARFSGSGSRTDFALTIDPVEAD



murine Kappa light
DAATYYCQQNNEDPYTFGGGTKLEIKRADAAPTVSIFPPSSE



chain
QLTSGGASVVCFLNNFYPKDINVKWKIDGSERQNGVLNSWT




DQDSKDSTYSMSSTLTLTKDEYERHNSYTCEATHKTSTSPIV




KSFNRNEC





113
Chimeric Anti-
EVQLVESGGDLVKPGGSLKLSCAASGFTFSNYGMSWVRQTP



ILT3 mouse 52B8
DRRLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNTLYLQ



VH parental/human
MSSLKSEDTAMYYCGRRLWFRSLYYAMDYWGQGTSVTVSS



IgG4 (S228P)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA






LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN






TKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR






TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDLIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLGK






114
Chimeric Anti-
EVQLVESGGDLVKPGGSLKLSCAASGFTFSNYGMSWVRQTP



ILT3 mouse 52B8
DRRLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNTLYLQ



VH M64V/human
MSSLKSEDTAMYYCGRRLWFRSLYYAMDYWGQGTSVTVSS



IgG4 (S228P)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA






LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN






TKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR






TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDLIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLGK






115
Mouse Anti-ILT3
EVQLVESGGDLVKPGGSLKLSCAASGFTFSNYGMSWVRQTP



52B8 VH
DRRLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNTLYLQ



M64L/human IgG4
MSSLKSEDTAMYYCGRRLWFRSLYYAMDYWGQGTSVTVSS



(S228P)

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA






LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN






TKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKPKDTLMISR






TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDLIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLGK






116
Chimeric Anti-
NIVLTQSPASLAVSLGQRATISCRASEKVDSFGNSFMHWYQQ



ILT3 mouse 52B8
KPGQPPKLLIYLTSNLDSGVPARFSGSGSRTDFALTIDPVEAD



parental VL /
DAATYYCQQNNEDPYTFGGGTKLEIKRTVAAPSVFIFPPSDEQ



human Kappa

LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS






KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE






C






117
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS




S





118
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)
S





119
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)
S





120
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLFFRSLYYAMDYWGQGTLVTVSS



(M64V, W101F)






121
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLYFRSLYYAMDYWGQGTLVTVSS



(M64V, W101Y)






122
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLQFRSLYYAMDYWGQGTLVTVSS



(M64V, W101Q)






123
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS




S





124
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)
S





125
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)
S





126
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSRTDFTLTISSLQAED



domain VL1
VAVYYCQQNNEDPYTFGQGTKLEIK





127
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAED



domain VL2
VAVYYCQQNNEDPYTFGQGTKLEIK





128
Humanized 52B8
EIVLTQSPATLSLSPGERATLSCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQAPRLLIYLTSNLDSGVPARFSGSGSRTDFTLTISSLEPED



domain VL3
FAVYYCQQNNEDPYTFGQGTKLEIK





129
Humanized 52B8
EIVLTQSPATLSLSPGERATLSCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQAPRLLIYLTSNLDSGIPARFSGSGSGTDFTLTISSLEPEDF



domain VL4
AVYYCQQNNEDPYTFGQGTKLEIK





130
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5
FATYYCQQNNEDPYTFGQGTKLEIK





131
Humanized 52B8
DIQMTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSRTDFTLTISSLQPED



domain VL6
FATYYCQQNNEDPYTFGQGTKLEIK





132
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSRTDFTLTISSLQPED



domain VL7
FATYYCQQNNEDPYTFGQGTKLEIK





133
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPARFSGSGSRTDFTLTISSLQPED



domain VL8
FATYYCQQNNEDPYTFGQGTKLEIK





134
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNAFMHWYQ



LC variable
QKPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAE



domain VL2,
DVAVYYCQQNNEDPYTFGQGTKLEIK



(S35A)






135
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNNFMHWYQ



LC variable
QKPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAE



domain VL2,
DVAVYYCQQNNEDPYTFGQGTKLEIK



(S35N)






136
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGQSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAED



domain VL2,
VAVYYCQQNNEDPYTFGQGTKLEIK



(N34Q)






137
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGDSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAED



domain VL2,
VAVYYCQQNNEDPYTFGQGTKLEIK



(N34D)






138
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNAFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5,
FATYYCQQNNEDPYTFGQGTKLEIK



(S35A)






139
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNNFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5,
FATYYCQQNNEDPYTFGQGTKLEIK



(S35N)






140
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGQSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5
FATYYCQQNNEDPYTFGQGTKLEIK



(N34Q)






141
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGDSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5,
FATYYCQQNNEDPYTFGQGTKLEIK



(N34D)






142
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



VH1/Human IgG4
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



(S228P) constant

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLGK






143
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (S228P)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLGK






144
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (S228P)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLGK






145
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLFFRSLYYAMDYWGQGTLVTVSS



(M64V,

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




W101F)/Human

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




IgG4 (S228P)

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLGK






146
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLYFRSLYYAMDYWGQGTLVTVSS



(M64V,

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




W101Y)/Human

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




IgG4 (S228P)

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLGK






147
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLQFRSLYYAMDYWGQGTLVTVSS



(M64V,

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




W101Q)/Human

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




IgG4 (S228P)

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLGK






148
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



VH2/Human IgG4
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



(S228P) constant

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLGK






149
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (5228P)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLGK






150
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (S228P)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLGK






151
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSRTDFTLTISSLQAED



domain VL1/kappa
VAVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



constant domain

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK






DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






152
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAED



domain VL2/kappa
VAVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



constant domain

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK






DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






153
Humanized 52B8
EIVLTQSPATLSLSPGERATLSCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQAPRLLIYLTSNLDSGVPARFSGSGSRTDFTLTISSLEPED



domain VL3/kappa
FAVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



constant domain

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK






DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






154
Humanized 52B8
EIVLTQSPATLSLSPGERATLSCRASEKVDSFGNSFMHWYQQ



LC variable
KPGQAPRLLIYLTSNLDSGIPARFSGSGSGTDFTLTISSLEPEDF



domain VL4/kappa
AVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQLK



constant domain

SGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKD






STYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






155
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5/kappa
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



constant domain

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK






DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






156
Humanized 52B8
DIQMTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSRTDFTLTISSLQPED



domain VL6/kappa
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



constant domain

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK






DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






157
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSRTDFTLTISSLQPED



domain VL7/kappa
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



constant domain

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK






DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






158
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPARFSGSGSRTDFTLTISSLQPED



domain VL8/kappa
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



constant domain

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK






DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






159
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNAFMHWYQ



LC variable
QKPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAE



domain VL2
DVAVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQ



(S35A)/kappa

LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS




constant domain

KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE






C






160
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGNNFMHWYQ



LC variable
QKPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAE



domain VL2
DVAVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQ



(S35N)/kappa

LKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDS




constant domain

KDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGE






C






161
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGQSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAED



domain VL2
VAVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



(N34Q)/kappa

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK




constant domain

DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






162
Humanized 52B8
DIVLTQSPDSLAVSLGERATINCRASEKVDSFGDSFMHWYQQ



LC variable
KPGQPPKLLIYLTSNLDSGVPDRFSGSGSGTDFTLTISSLQAED



domain VL2
VAVYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



(N34D)/kappa

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK




constant domain

DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






163
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNAFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



(S35A)/kappa

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK




constant domain

DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






164
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGNNFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



(S35N)/kappa

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK




constant domain

DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






165
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGQSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



(N34Q)/kappa

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK




constant domain

DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






166
Humanized 52B8
DIQLTQSPSSLSASVGDRVTITCRASEKVDSFGDSFMHWYQQ



LC variable
KPGKAPKLLIYLTSNLDSGVPSRFSGSGSGTDFTLTISSLQPED



domain VL5
FATYYCQQNNEDPYTFGQGTKLEIKRTVAAPSVFIFPPSDEQL



(N34D)/kappa

KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSK




constant domain

DSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC






167
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain VH1/
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



Human IgG1 HC
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



(L234A L235A

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




D265S) constant

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GPSVFLFPPKPKDT




domain

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE






QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






168
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265S) constant

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






169
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265S) constant

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV





MHEALHNHYTQKSLSLSPGK





170
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLFFRSLYYAMDYWGQGTLVTVSS



(M64V, W101 F)/

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Human IgG1 HC

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(L234A, L235A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDTL




D265S) constant

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




domain

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK






GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






171
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLYFRSLYYAMDYWGQGTLVTVSS



(M64V, W101Y)/

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Human IgG1 HC

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(L234A, L235A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLEPPKPKDTL




D265S) constant

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




domain

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK






GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






172
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLQFRSLYYAMDYWGQGTLVTVSS



(M64V, W101Q)/

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Human IgG1 HC

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(L234A, L235A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDTL




D265S) constant

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




domain

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK






GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






173
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain VH2/
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



Human IgG1 HC
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



(L234A, L235A,

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




D265S) constant

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




domain

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE






QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






174
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265S) constant

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






175
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265S) constant

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






176
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



VH1/Human IgG4
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



(S228P)(K−)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE





ALHNHYTQKSLSLSLG





177
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (S228P)(K−)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLG






178
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (S228P)(K−)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLG






179
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLFFRSLYYAMDYWGQGTLVTVSS



(M64V),

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




W101F/Human

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




IgG4 (S228P)(K−)

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLG






180
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLYFRSLYYAMDYWGQGTLVTVSS



(M64V,

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




W101Y)/Human

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




IgG4 (S228P)(K−)

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLG






181
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLQFRSLYYAMDYWGQGTLVTVSS



(M64V,

ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSGA




101Q)/Human IgG4

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPSN




(S228P)(K−)

TKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQP






REPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHEA






LHNHYTQKSLSLSLG






182
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



VH2/Human IgG4
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



(S228P)(K−)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLG






183
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (S228P)(K−)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLG






184
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)/Human
SASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWNSG



IgG4 (S228P)(K−)

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCNVDHKPS




constant domain

NTKVDKRVESKYGPPCP
custom character
CPAPEFLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNAKTKPREEQFN






STYRVVSVLTVLHQDWLNGKEYKCKVSNKGLPSSIEKTISKAKGQ






PREPQVYTLPPSQEEMTKNQVSLTCLVKGFYPSDIAVEWESNGQ






PENNYKTTPPVLDSDGSFFLYSRLTVDKSRWQEGNVFSCSVMHE






ALHNHYTQKSLSLSLG






185
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain VH1/
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



Human IgG1 HC
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



(L234A, L235A,

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




D265S)(K−)

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




constant domain

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE






QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






186
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265S)(K−)

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




constant domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






187
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64L)/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265S)(K−)

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




constant domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






188
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLFFRSLYYAMDYWGQGTLVTVSS



(M64V, W101F)/

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Human IgG1 HC

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(L234A, L235A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDTL




D265S)(K−)

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




constant domain

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK






GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






189
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLYFRSLYYAMDYWGQGTLVTVSS



(M64V, W101Y)/

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Human IgG1 HC

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(L234A, L235A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDTL




D265S)(K−)

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




constant domain

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK






GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






190
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLQFRSLYYAMDYWGQGTLVTVSS



(M64V, W101Q)/

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




Human IgG1 HC

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(L234A, L235A,

TKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDTL




D265S)(K−)

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREEQ




constant domain

YNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAK






GQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESN






GQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






191
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSMRGRFTISRDNAKNSLYLQ



domain VH2/
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



Human IgG1 HC
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



(L234A, L235A,

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




D265S)(K−)

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




constant domain

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE






QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






192
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



M64V/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265s)(K−)

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




constant domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






193
Humanized 52B 8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSLRGRFTISRDNAKNSLYLQ



domain VH2
MNSLKAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



M64L/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(L234A, L235A,

NTKVDKKVEPKSCDKTHTCPPCPAPE
custom character
GGPSVFLFPPKPKDT




D265 S) (K−)

LMISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




constant domain

QYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPG






194
Chimeric Anti-
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYSINWVRQSSG



ILT3 rat 40A6
KGPEWMGRFWYDEGIAYNLTLESRLSISGDTSKNQVFLKMN



parental HC
SLRTGDTGTYYCTRDRDTVGITGWFAYWGQGTLVTVSSAST



variable

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS




domain/human

GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV




IgG4 (S228P)

DKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST






YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






195
Chimeric Anti-
ETVMTQSPTSLSASIGERVTLNCKASQSVGVNVDWYQQTPG



ILT3 rat 40A6
QSPKLLIYGSANRHTGVPDRFTGSGFGSDFTLTISDVEPEDLG



parental LC
VYYCLQYGSVPYTFGAGTKLELKRTVAAPSVFIFPPSDEQLKS



variable

GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS




domain/human

TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






196
Chimeric Anti-
QVQLKESGPGLVQASETLSLTCTVSGFSLTNYCVNWVRQPS



ILT3 rat 16B1
GKGPEWLGRFWFDEGKAYNLTLESRLSISGDTSKNQVFLRM



parental HC
NSLRADDTGTYYCTRDRDTVGITGWFAYWGQGTLVTVSSAS



variable

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT




domain/human

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK




IgG4 (S228P)

VDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMIS




constant domain

RTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






197
Chimeric Anti-
ETVMTQSPTSLSASIGERVTLNCKASQSVGINVDWYQQTPGQ



ILT3 rat 16B1
SPKLLIYGSANRHTGVPDRFTGSGFGSDFTLTISNVEPEDLGV



parental LC
YYCLQYGSVPYTFGPGTKLELKRTVAAPSVFIFPPSDEQLKSGT



variable

ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY




domain/human

SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






198
Chimeric Anti-
QVQLQQSGAELMKPGASVKISCKATGYTFRTYWIEWVKQRP



ILT3 mouse 11D1
GHGLEWIGEILPGNGNTHFNENFKDKATFTADTSSNAAYMQ



parental HC
LSSLTSEDSAVYYCVRRLGRGPFDFWGQGTTLTVSSASTKGP



variable

SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH




domain/human

TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK




IgG4 (S228P)

VEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPE




constant domain

VTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRV






VSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREP






QVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENN






YKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHN






HYTQKSLSLSPGK






199
Chimeric Anti-
DIQMTQSPSSLSVSLGGKVTITCKASQDINEYIGWYQRKPGK



ILT3 mouse 11D1
GPRLLIHYTSTLQSGIPSRFSGSGSGRDYSLSISNLEPEDIATYY



parental LC
CLQYANPLPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTAS



variable

VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL




domain/human

SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






200
Chimeric Anti-
EVQLVESGGGLVQPGRSMKLSCAASGFTFSNFDMAWVRQA



ILT3 rat 17H12
PTRGLEWVSSITYDGGSTSYRDSVKGRFTISRDNAKGTLYLQ



parental HC
MDSLRSEDTATYYCTTVESIATISTYFDYWGQGVMVTVSSAS



variable

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT




domain/human

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK




IgG4 (S228P)

VDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMIS




constant domain

RTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






201
Chimeric Anti-
DIVLTQSPALAVSLGQRATISCRASQSVSMSRYDLIHWYQQK



ILT3 rat 17H12
PGQQPKLLIFRASDLASGIPARFSGSGSGTDFTLTINPVQADDI



parental LC
ATYYCQQTRKSPPTFGGGTRLELKRTVAAPSVFIFPPSDEQLKS



variable

GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS




domain/human

TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






202
Chimeric Anti-
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYCVNWVRQPSG



ILT3 rat 37C8
KGPEWLGRFWYDEGKVYNLTLESRLSISGDTSKNQVFLKMN



parental HC
RLRTDDTGTYYCTRDRDTMGITGWFAYWGQGTLVTVSSAST



variable

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS




domain/human

GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV




IgG4 (S228P)

DKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST






YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






203
Chimeric Anti-
ETVMTQSPTSLSASIGERVTLNCKASQSVGINVDWYQQTPGQ



ILT3 rat 37C8
SPKLLIYGSANRHTGVPDRFTGSGFGSGFTLTISNVEPEDLGV



parental LC
YYCLQYGSVPYTFGPGTKLELKRTVAAPSVFIFPPSDEQLKSGT



variable

ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY




domain/human

SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






204
Chimeric Anti-
QVQMQQSGTELMKPGASMKISCKATGYTFSTYWIQWIKQRP



ILT3 mouse 1G12
GHGLEWIGEILPGSGTTNYNENFKGKATFSADTSSNTAYIHLS



parental HC
SLTSEDSAVFYCARRLGRGPFDYWGQGTTLTVSSASTKGPSV



variable

FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF




domain/human

PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE




IgG4 (S228P)

PKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISRTPEVT




constant domain

CVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVS






VLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQV






YTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKT






TPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYT






QKSLSLSPGK






205
Chimeric Anti-
DIQMTQSPSSLSASLGGKVTITCEASQDINKHIDWYQHQPGR



ILT3 mouse 1G12
GPSLLIHYASILQPGIPSRFSGSGSGRDYSFSITSLEPEDIATYY



parental LC
CLQYDNLLPTFGGGTKLEIKRTVAAPSVFIFPPSDEQLKSGTAS



variable

VVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSL




domain/human

SSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






206
Chimeric Anti-
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYSVNWVRQPSG



ILT3 rat 20E4
KGLEWMGRFWYDGGTAYNSTLESRLSISGDTSKNQVFLKM



parental HC
NSLQTDDTGTYYCTRDRDTMGITGWFAYWGQGTLVTVSPAS



variable

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT




domain/human

SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK




IgG4 (S228P)

VDKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMIS




constant domain

RTPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL





HNHYTQKSLSLSPGK





207
Chimeric Anti-
ETVMTQSPTSLSASIGERVTLNCKASQSVGVNVDWYQQTPG



ILT3 rat 20E4
QSPKLLIYGSANRHTGVPDRFTGSGFGSDFTLTISNVEPEDLG



parental LC
VYYCLQYGSVPYTFGAGTKLELKRTVAAPSVFIFPPSDEQLKS



variable

GTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDS




domain/human

TYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






208
Chimeric Anti-
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYCVNWVRQPSG



ILT3 rat 24A4
KGPEWLGRFWYDEGKVYNLTLESRLSISGDTSKNQVFLKMN



parental HC
RLRTDDTGTYYCTRDRDTLGITGWFAYWGQGTLVTVSSAST



variable

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS




domain/human

GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV




IgG4 (S228P)

DKKVEPKSCDKTHTCPPCPAPEAAGGPSVFLFPPKPKDTLMISR




constant domain

TPEVTCVVVSVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNST






YRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






209
Chimeric Anti-
ETVMTQSPTSLSASIGERVTLNCKASQSVGINVDWYQQTPGQ



ILT3 rat 24A4
SPKLLIYGSANRHTGVPDRFTGSGFGSGFTLTISNVEPEDLGV



parental LC
YYCLQYGSVPYTFGPGTKLELKRTVAAPSVFIFPPSDEQLKSGT



variable

ASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTY




domain/human

SLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC




kappa






210
Humanized 52B8
EVQLVESGGGLVQPGGSLRLSCAASGFTFSNYGMSWVRQAP



HC variable
GKGLEWVATISGGGDYTNYPDSVRGRFTISRDNAKNSLYLQ



domain VH1
MNSLRAEDTAVYYCGRRLWFRSLYYAMDYWGQGTLVTVS



(M64V)/ Human
SASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSG



IgG1 HC

ALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPS




(N297A) constant

NTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL




domain

MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE






QYASTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






211
Human IgG1 HC

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




constant domain

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(N297A; shown in

TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL




bold-face type)

MISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREE






QY  STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






212
Chimeric anti-ILT3
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYSINWVRQSSG



40A6 rat VH/
KGPEWMGRFWYDEGIAYNLTLESRLSISGDTSKNQVFLKMN



human IgG1
SLRTGDTGTYYCTRDRDTVGITGWFAYWGQGTLVTVSSAST



(N297A)

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS






GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV






DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR






TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






213
Chimeric anti-ILT3
QVQLKESGPGLVQASETLSLTCTVSGFSLTNYCVNWVRQPS



16B1 rat VH/
GKGPEWLGRFWFDEGKAYNLTLESRLSISGDTSKNQVFLRM



human IgG1
NSLRADDTGTYYCTRDRDTVGITGWFAYWGQGTLVTVSSAS



(N297A)

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT






SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK






VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYA






STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ






PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA






LHNHYTQKSLSLSPGK






214
Chimeric anti-ILT3
QVQLQQSGAELMKPGASVKISCKATGYTFRTYWIEWVKQRP



11D1 mouse VH/
GHGLEWIGEILPGNGNTHFNENFKDKATFTADTSSNAAYMQ



human IgG1
LSSLTSEDSAVYYCVRRLGRGPFDFWGQGTTLTVSSASTKGP



(N297A)

SVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVH






TFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKK






VEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPE






VTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYR






VVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPRE






PQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPEN






NYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALH






NHYTQKSLSLSPGK






215
Chimeric anti-ILT3
EVQLVESGGGLVQPGRSMKLSCAASGFTFSNFDMAWVRQA



17H12 rat VH/
PTRGLEWVSSITYDGGSTSYRDSVKGRFTISRDNAKGTLYLQ



human IgG1
MDSLRSEDTATYYCTTVESIATISTYFDYWGQGVMVTVSSAS



(N297A)

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT






SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK






VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYA






STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ






PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA






LHNHYTQKSLSLSPGK






216
Chimeric anti-ILT3
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYCVNWVRQPSG



37C8 rat VH/
KGPEWLGRFWYDEGKVYNLTLESRLSISGDTSKNQVFLKMN



human IgG1
RLRTDDTGTYYCTRDRDTMGITGWFAYWGQGTLVTVSSAST



(N297A)

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS






GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV






DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR






TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






217
Chimeric anti-ILT3
QVQMQQSGTELMKPGASMKISCKATGYTFSTYWIQWIKQRP



1G12 mouse VH/
GHGLEWIGEILPGSGTTNYNENFKGKATFSADTSSNTAYIHLS



human IgG1
SLTSEDSAVFYCARRLGRGPFDYWGQGTTLTVSSASTKGPSV



(N297A)

FPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTF






PAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVE






PKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVT






CVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYASTYRVV






SVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQ






VYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYK






TTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHY






TQKSLSLSPGK






218
Chimeric anti-ILT3
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYSVNWVRQPSG



20E4 rat VH/
KGLEWMGRFWYDGGTAYNSTLESRLSISGDTSKNQVFLKM



human IgG1
NSLQTDDTGTYYCTRDRDTMGITGWFAYWGQGTLVTVSPAS



(N297A)

TKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALT






SGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTK






VDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMIS






RTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYA






STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQ






PREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQP






ENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEA






LHNHYTQKSLSLSPGK






219
Chimeric anti-ILT3
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYCVNWVRQPSG



24A4 rat VH/
KGPEWLGRFWYDEGKVYNLTLESRLSISGDTSKNQVFLKMN



human IgG1
RLRTDDTGTYYCTRDRDTLGITGWFAYWGQGTLVTVSSAST



(N297A)

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS






GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV






DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR






TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






220
Chimeric anti-ILT3
QVQLKESGPGLVQASETLSLTCTVSGFSLTSYSINWVRQSSG



40A6 rat VH/
KGPEWMGRFWYDEGIAYNLTLESRLSISGDTSKNQVFLKMN



human IgG1
SLRTGDTGTYYCTRDRDTVGITGWFAYWGQGTLVTVSSAST



(N297A)

KGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTS






GVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKV






DKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISR






TPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYAS






TYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQP






REPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPE






NNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEAL






HNHYTQKSLSLSPGK






221
Residues after LC-
FGXG



CDR3




Xaa is any amino




acid






222
Residues before
CXXX



HC-CDR1




Xaa is any amino




acid






223
Residues before
LEWIG



HC-CDR1






224
Residues after HC-
WGXG



CDR3




Xaa is any residue






225
Pembrolizumab
QVQLVQSGVEVKKPGASVKVSCKASGYTFTNYYMYwVRQ



Heavy Chain
APGQGLEWMGGINPSNGGTNFNEKFKNRVTLTTDSSTTTAY




MELKSLQFDDTAVYYCARRDYRFDMGFDYWGQGTTVTVSS




ASTKGPSVFPLAPCSRSTSESTAALGCLVKDYFPEPVTVSWN




SGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTKTYTCN




VDHKPSNTKVDKRVESKYGPPCPPCPAPEFLGGPSVFLFPPKP




KDTLMISRTPEVTCVVVDVSQEDPEVQFNWYVDGVEVHNA




KTKPREEQFNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKG




LPSSIEKTISKAKGQPREPQVYTLPPSQEEMTKNQVSLTCLVK




GFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSRLTV




DKSRWQEGNVFSCSVMHEALHNHYTQKSLSLSLGK





226
Pembrolizumab
EIVLTQSPATLSLSPGERATLSCRASKGVSTSGYSYLHWYQQ



Light Chain
KPGQAPRLLIYLASYLESGVPARFSGSGSGTDFTLTISSLEPED




FAVYYCQHSRDLPLTFGGGTKVEIKRTVAAPSVFIFPPSDEQL




KSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTE




QDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTK




SFNRGEC





227
Human IgG1 HC

ASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGA




constant domain

LTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSN




(N297A, D265A;

TKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTL




shown in bold-face

MISRTPEVTCVVV
custom character
VSHEDPEVKFNWYVDGVEVHNAKTKPREE




type)

QY
custom character
STYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKA






KGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWES






NGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSV






MHEALHNHYTQKSLSLSPGK






Constant regions are shown in italics.


Amino acid sequences underlined are CDRs.






While the present invention is described herein with reference to illustrated embodiments, it should be understood that the invention is not limited hereto. Those having ordinary skill in the art and access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Therefore, the present invention is limited only by the claims attached herein.

Claims
  • 1. An antibody or antigen binding fragment that binds the extracellular domain of human immunoglobulin-like transcript 3 (ILT3) having amino acids 1-238 of SEQ ID NO: 1, wherein the antibody or antigen binding fragment comprises (a) a heavy chain complementarity determining region 1 (HC-CDR1), wherein the HC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 17; an HC-CDR2, wherein the HC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 19, 20, or 21; an HC-CDR3, wherein the HC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 23; and(b) a light chain complementarity determining region 1 (LC-CDR1), wherein the LC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 34, 35, 36, 37, 38, 39, 40, 41, or 42; an LC-CDR2, wherein the LC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 43; and an LC-CDR3, wherein the LC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 44.
  • 2. The antibody or antigen binding fragment of claim 1, wherein (a) the HC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 17; the HC-CDR2 has the amino acid sequence set forth in SEQ ID NO:20; and the HC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 23; and(b) the LC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 41; the LC-CDR2 has the amino acid sequence set forth in SEQ ID NO:43; and, the LC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 44.
  • 3. The antibody or antigen binding fragment of claim 2, wherein the antibody comprises: (i) a VH having a framework selected from the group consisting of human VH1, VH2, VH3, VH4, VHS, and VH6 and a human IgG1 or IgG4 HC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native IgG1 or IgG4 isotype HC constant domain; and,(ii) a VL having a framework selected from the group consisting of human Vκ1, Vκ2, Vκ3, Vκ4, Vκ5, Vκ6, Vλ1, Vλ2, Vλ3, Vλ4, Vλ5, Vλ6, Vλ7, Vλ8, Vλ9, and Vλ10 and a human kappa or lambda LC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa or lambda LC constant domain.
  • 4. The antibody or antigen binding fragment of claim 3, wherein the antibody comprises a heavy chain (HC) constant domain comprising the amino acid sequence set forth in SEQ ID NO: 9, 10, 11, 12, or 13.
  • 5. The antibody or antigen binding fragment of claim 3, wherein the antibody comprises a light chain (LC) constant domain comprising the amino acid sequence set forth in SEQ ID NO: 14.
  • 6. The antibody or antigen binding fragment of claim 3, wherein the antibody comprises a heavy chain (HC) comprising the amino acid sequence set forth in SEQ ID NO: 142, 143, 144, 148, 149, 150, 167, 168, 169, 170, 174, 175, 176, 177, 178, 182, 183, 184, 185, 186, 187, 191, 192, or 193.
  • 7. The antibody or antigen binding fragment of claim 3, wherein the antibody comprises a light chain (LC) comprising the amino acid sequence set forth in SEQ ID NO: 151, 152, 153, 154, 155, 156, 157, 158, 159, 160, 161, 162, 163, 164, 165, or 166.
  • 8. The antibody or antigen binding fragment of claim 3, wherein the antibody comprises a heavy chain (HC) comprising the amino acid sequence set forth in SEQ ID NO: 143 and a light chain (LC) comprising the amino acid sequence set forth in SEQ ID NO: 165, and variants thereof wherein the HC lacks a C-terminal Lysine residue or a C-terminal glycine-lysine.
  • 9. The antibody or antigen binding fragment of claim 1, wherein the VH comprises a framework selected from the group consisting of human VH1, VH2, VH3, VH4, VH5, and VH6, and variants thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof; and, the VL comprises a framework selected from the group consisting of human Vκ1, Vκ2, Vκ3, Vκ4, Vκ5, Vκ6, Vλ1, Vλ2, Vλ3, Vλ4, Vλ5, Vλ6, Vλ7, Vλ8, Vλ9, and Vλ10, and variants thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof.
  • 10. The antibody or antigen binding fragment of claim 9, wherein the antibody or antigen binding fragment comprises a VH and a VL having the amino acid sequences set forth in SEQ ID NO: 15 and SEQ ID NO: 16, respectively; SEQ ID NO:45 and SEQ ID NO: 46, respectively; SEQ ID NO: 53 and SEQ ID NO: 54, respectively; SEQ ID NO: 61 and SEQ ID NO: 62, respectively; SEQ ID NO: 69 and SEQ ID NO: 70, respectively; SEQ ID NO: 77 and SEQ ID NO: 78, respectively; SEQ ID NO: 85 and SEQ ID NO: 86, respectively; SEQ ID NO: 93 and SEQ ID NO: 94, respectively; or SEQ ID NO:101 and SEQ ID NO: 102, respectively.
  • 11. The antibody or antigen binding fragment of claim 9, wherein the antibody or antigen binding fragment comprises a VH having the amino acid sequence set forth in SEQ ID NO: 117, 118, 119, 123, 124, or 125 and a VL having the amino acid sequence set forth in SEQ ID NO: 126, 127, 128, 129, 130, 131, 132, 133, 134, 135, 136, 137, 138, 139, 140, or 141.
  • 12. The antibody or antigen binding fragment of claim 11, wherein the antibody or antigen binding fragment comprises a VH having the amino acid sequence set forth in SEQ ID NO: 118 and a VL having the amino acid sequence set forth in SEQ ID NO: 140.
  • 13. The antibody or antigen binding fragment of claim 1, wherein the antibody comprises an HC having a human IgG1, IgG2, IgG3, or IgG4 HC constant domain or variant thereof having 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native IgG1, IgG2, IgG3, or IgG4 isotype constant domain.
  • 14. The antibody or antigen binding fragment of claim 13, wherein the antibody comprises an LC having a human kappa or lambda LC constant domain or variant thereof comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 amino acid substitutions, additions, deletions, or combinations thereof compared to the amino acid sequence of the native human kappa or lambda light chain constant domain.
  • 15. A composition comprising: an antibody or antigen binding fragment of claim 1 and a pharmaceutically acceptable carrier.
  • 16. An antibody or antigen binding fragment that binds the extracellular domain of human immunoglobulin-like transcript 3 (ILT3) having amino acids 1-238 of SEQ ID NO: 1, wherein the antibody or antigen binding fragment comprises (a) a heavy chain complementarity determining region 1 (HC-CDR1), wherein the HC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 17; an HC-CDR2, wherein the HC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 20; an HC-CDR3, wherein the HC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 23; and(b) a light chain complementarity determining region 1 (LC-CDR1), wherein the LC-CDR1 has the amino acid sequence set forth in SEQ ID NO: 41; an LC-CDR2, wherein the LC-CDR2 has the amino acid sequence set forth in SEQ ID NO: 43; and an LC-CDR3, wherein the LC-CDR3 has the amino acid sequence set forth in SEQ ID NO: 44.
  • 17. The antibody or antigen binding fragment of claim 16, wherein the antibody or antigen binding fragment comprises a VH and a VL having the amino acid sequences set forth in SEQ ID NO: 118 and SEQ ID NO: 140, respectively.
  • 18. The antibody or antigen binding fragment of claim 17, wherein the antibody comprises a heavy chain (HC) comprising the amino acid sequence set forth in SEQ ID NO: 143 and a light chain (LC) comprising the amino acid sequence set forth in SEQ ID NO: 165, and variants thereof wherein the HC lacks a C-terminal Lysine residue or a C-terminal glycine-lysine.
  • 19. A composition comprising: an antibody or antigen binding fragment of claim 16 and a pharmaceutically acceptable carrier.
  • 20. A composition comprising: an antibody or antigen binding fragment of claim 17 and a pharmaceutically acceptable carrier.
  • 21. A composition comprising: an antibody or antigen binding fragment of claim 18 and a pharmaceutically acceptable carrier.
CROSS REFERENCE TO RELATED APPLICATIONS

The present application claims benefit of U.S. Provisional Patent Application No. 62/587,604 filed Nov. 17, 2017, and which is herein incorporated by reference in its entirety.

US Referenced Citations (35)
Number Name Date Kind
4439196 Higuchi Mar 1984 A
4447224 DeCant, Jr. et al. May 1984 A
4487603 Harris Dec 1984 A
4596556 Morrow et al. Jun 1986 A
4741900 Alvarez May 1988 A
4790824 Morrow et al. Dec 1988 A
4816567 Cabilly et al. Mar 1989 A
4941880 Burns Jul 1990 A
5064413 McKinnon et al. Nov 1991 A
5312335 McKinnon et al. May 1994 A
5383851 McKinnon, Jr. et al. Jan 1995 A
5399163 Peterson et al. Mar 1995 A
5591828 Bosslet et al. Jan 1997 A
6096002 Landau Aug 2000 A
6329511 Vasquez et al. Dec 2001 B1
6620135 Weston et al. Sep 2003 B1
7777008 Ponath Aug 2010 B2
7943743 Korman et al. May 2011 B2
8008449 Korman et al. Aug 2011 B2
8354509 Carven et al. Jan 2013 B2
8609089 Langermann Dec 2013 B2
8691730 Vasquez Apr 2014 B2
8877688 Vasquez Nov 2014 B2
8901281 Ponath Dec 2014 B2
8969526 Baehner Mar 2015 B2
9296815 D'angelo Mar 2016 B2
9708406 Zhang Jul 2017 B2
20090202544 Suciu-foca Aug 2009 A1
20100028330 Collins et al. Feb 2010 A1
20120039906 Olive Feb 2012 A1
20120114649 Langermann May 2012 A1
20130071403 Rolland et al. Mar 2013 A1
20150110714 Suciu Foca et al. Apr 2015 A1
20150139986 Ponath et al. May 2015 A1
20170267759 Liang Sep 2017 A1
Foreign Referenced Citations (25)
Number Date Country
404097 Dec 1990 EP
1964852 Sep 2008 EP
WO199311161 Jun 1993 WO
WO199428027 Dec 1994 WO
2003093474 Nov 2003 WO
2004099249 Nov 2004 WO
2006121168 Nov 2006 WO
2006138739 Dec 2006 WO
2007005874 Jan 2007 WO
2008117049 Oct 2008 WO
WO2009101611 Aug 2009 WO
2009114335 Sep 2009 WO
2010027827 Mar 2010 WO
2010077634 Jul 2010 WO
2011066342 Jun 2011 WO
2011127543 Oct 2011 WO
2013033734 Mar 2013 WO
WO2013043569 Mar 2013 WO
WO2013181438 Dec 2013 WO
WO2014116846 Oct 2014 WO
WO2016049641 Mar 2016 WO
WO2016127427 Aug 2016 WO
WO2017015227 Jan 2017 WO
2018089300 May 2018 WO
WO2018148494 Aug 2018 WO
Non-Patent Literature Citations (95)
Entry
Brummell et al. (Biochemistry 32:1180-1187 (1993)).
Kobayashi et al. (Protein Engineering 12:879-844 (1999)).
Burks et al. (PNAS 94:412-417 (1997)).
Jang et al. (Molec. Immunol. 35:1207-1217 (1998)).
Brorson et al. (J. Immunol. 163:6694-6701 (1999)).
Coleman (Research in Immunol. 145:33-36 (1994)).
Dufner (Trends Biotechnol. 24(11):523-29 (2006)).
Rudikoff et al (Proc Natl Acad Sci USA 1982 vol. 79 p. 1979).
MacCallum et al. (J. Mol. Biol. (1996) 262:732-745).
De Pascalis et al. (The Journal of Immunology (2002) 169, 3076-3084).
Gasset et al. ((2003) BBRC 307, 198-205).
Vajdos et al. ((2002) J. Mol. Biol. 320, 415-428).
Holm et al ((2007) Mol. Immunol. 44: 1075-1084).
Chen et al. (J. Mol. Bio. (1999) 293, 865-881).
Wu et al. (J. Mol. Biol. (1999) 294, 151-162).
Ward et al. (Nature 341:544-546 (1989)).
Smith-Gill et al. (J. Immunol. 139:4135-4144 (1987)).
Kumar et al. (J. Biol. Chem. 275:35129-35136 (2000)).
Song et al. (Biochem Biophys Res Comm 268:390-394 (2000)).
USPTO , TC1600 , BCPM Kolker “Antibodies and the written description requirement of 35 U.S.C.112(a)” pp. 1-36 (Sep. 17, 2020).
Agata et al., Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytes, International Immunology, 1996, pp. 765-772, vol. 8, No. 5.
Armour et al., Recombinant Human IgG Molecules Lacking Fcy receptor I Binding and Monocyte Triggering Activities, Eur. J. Immunol., 1999, pp. 2613-2624, vol. 29.
Baca et al., Antibody Humanization Using Monovalent Phage Display, J. Biol. Chem., 1997, pp. 10678-10684, vol. 272.
Baert et al., Influence of Immunogenicity on the long term efficacy of Infliximab in Crohns disease, New England Journal Med., 2003, pp. 601-608, vol. 348.
Barbas et al., Synthetic Human Antibodies, Nature Medicine, 1995, pp. 837-839, vol. 1.
Beiboer, Sigrid H. W. et al., Guided Selection of a Pan Carcinoma Specific Antibody Reveals Similar Binding Characteristics yet Structural Divergence Between the Original Murine Antibody and its Human Equivalent, J. Mol. Biol., 2000, pp. 833-849, vol. 296.
Beniaminovitz et al., Prevention of rejection in cardiac transplantation by blockade of the interleukin 2 receptor with a monoclonal antibody, New England Journal of Medicine, 2000, pp. 613-619, vol. 342.
Bennett et al., Program Death-1 Engagement Upon TCR Activation Has Distinct Effects on Costimulation and Cytokine-Driven Proliferation: Attenuation of ICOS, IL-4, and IL-21, But Not CD28, IL-7, and IL-15 Responses, The Journal of Immunology, 2003, pp. 711-718, vol. vol. 170.
Blank et al., Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections, Cancer Immunol. Immunother., 2007, pp. 739-745, vol. 56(5).
Blank, Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy, Cancer Immunol. Immunother., 2005, pp. 307-314, vol. 54.
Brown, Blockade of Programmed Death-1 Ligands on Dendritic Cells Enhances T Cell Activation and Cytokine Production, J. Immunol., 2003, pp. 1257-1266, vol. vol. 170.
Carpenter et al., Non-Fc Receptor-Binding Humanized Anti-CD3 Antibodies Induce Apoptosis of Activated Human T Cells, J. Ummunol., 2000, pp. 6205-6213, vol. 165.
Carter et al., PD-1:PD-L Inhibitory Pathway Affects Both CD4 Plus and CD8 Plus and CD8 Plus T Cells and is overcome by IL-2, Eur. J. Immunol., 2002, pp. 634-643, vol. 32.
Cella et al., A Novel Inhibitory Receptor (ILT3) Expressed on Monocytes, Macrophages, and Dendritic Cells Involved in Antigen Processing, J. Exp. Med., 1997, Issue 10, pp. 1743-1751, vol. 185.
Cheung et al., Epitope-specific antibody response to the surface antigen of duck hepatitis B virus in infected ducks, Virology, 1990, pp. 546-552, vol. 176.
Chothia et al, Canonical Structures for the Hypervariable Regions of Imrnunoglobins, J. Mol. Biol., 1987, pp. 901-917, vol. 196.
Chothia et al., Conformations of immunoglobin hypervariable regions, Nature, 1989, pp. 877-883, vol. 342.
Clackson et al., Making Antibody Fragments Using Phage Display Libraries, Nature, 1991, pp. 624-628, vol. 352.
Cunningham et al., High resolution Epitope mapping of hgH-receptor interactions by alanine-scanning mutagenesis, Science, 1985, pp. 1081-1085, vol. 244.
Dong et al., B7-H1 pathway and its role in the evasion of tumor immunity, J. Mol. Med., 2003, pp. 281-287, vol. 81.
Everts et al., Selective Intracellular Delivery ofDexamethasone into Activated Endothelial Cells Using an E-Selectin-Directed Immunoconjugate, J. Immunol., 2002, pp. 883-889, vol. 168.
Foote et al., Antibody Framework Residues Affecting the Conformation of the Hypervariable Loops, J. Mol. Biol., 1992, pp. 487-499, vol. 224.
Freeman et al., Engagement of the PD-1 Immunoinhibitory Receptor by a Novel B7 Family Member Leads to Negative Regulation of Lymphocyte Activation, J. Exp. Med., 2000, pp. 1027-1034, vol. 192.
Ghosh et al., Natalizumab for active Crohns disease, New England J. Med., 2003, pp. 24-32, vol. 348.
Gibellini et al., Extracellular HIV-1 Tat Protein Induces the Rapid Ser 133 Phosphorylation and Activation of CREB Transcription Factor in Both Jurkat Lymphoblastoid T Cells and Primary Peripheral Blood Mononuclear Cells, J. Immunol., 1998, pp. 3891-3898, vol. 160.
Hamid et al., Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma, New Eng. J. Med., 2013, pp. 134-144, vol. 369(2).
He et al., Humanization and Pharmacokinetics of a Monoclonal Antibody with Specificity for both E- and P-Selectin, J. Immunol. 1998, pp. 1029-1035, vol. 160.
Herold, New England Journal of Medicine, New England Journal of Medicine, 2002, pp. 1692-1698, vol. 346.
Holliger et al., Diabodies, Proc. Natl. Acad. Sci. USA, 1993, No. 14, pp. 6444-6448, vol. 90.
Holliger et al., Engineered antibody fragments and the rise of single domains, Nat. Biotechnol., 2005, pp. 1126-1136, vol. 23.
Hoogenboom et al., Natural and designer binding sites made by phage display technology, Immunol. Today, 2000, pp. 371-377, vol. 21.
Hsing et al., Requirement for Nuclear Factor-κBActivation by a Distinct Subset of CD40-Mediated Effector Functions in B Lymphocytes, J. Immunol., 1999, pp. 2804-2811, vol. 162.
Ishida et al., Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death, The EMBO Journal, 1992, pp. 3887-3895, vol. 11(11).
Iwai, Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade, Proc. Natl. Acad. Sci. USA, 2002, pp. 12293-12297, vol. 99.
Kabat, The Structural Basis of Antibody Complementarity, Adv. Prot. Chem., 1978, pp. 1-75, vol. 32.
Kabat, Unusual Distributions of Amino Acids in Complementarity-determining (Hypervriable) Segment of Heavy and Light Chains of Immunoglobulins and Their Possible Roles in Specificity of Antibody-combining Sites, J. Biol. Chem., 1977, pp. 6609-6616, vol. 252.
Kirkland et al., Analysis of the fine specificity and cross-reactivity of monoclonal anti-lipid A antibodies, J. Immunol., 1986, pp. 3614-3619, vol. 137.
Klimka, A. et al., Human anti-CD30 recombinant antibodies by guided phage antibody selection using cell panning, British Journal of Cancer, 2000, pp. 252-260, vol. 83(2).
Kohler et al., Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity, Nature, 1975, pp. 495-497, vol. 256.
Konishi et al., B7-H1 Expression on Non-Small Cell Lung Cancer Cells and Its Relationship with Tumor-Infiltrating Lymphocytes and Their PD-1 Expression, Clin. Cancer Res., 2004, pp. 5094-5100, vol. 10.
Kostelny et al., Formation of a bispecific antibody by the use of leucine zippers, J. Immunol., 1992, pp. 1547-1553, vol. 148.
Le Doussal et al., Enhanced in vivo targeting of an asymmetric bivalent hapten to double-antigen-positive mouse B cells with monoclonal antibody conjugate cocktails, J. Immunol., 1991, pp. 169-175, vol. 146.
Lipsky et al., Infliximab and methotrexate in the treatment of rheumatoid arthritis, New England Journal of Medicine, 2000, pp. 1594-1602, vol. 343.
Liu et al., J. Neurol. Neurosurg. Psych., N. Neurol. Neurosurg. Psych., 1999, pp. 451-456, vol. 67.
Marks et al., By passing Immunization, J. Mol. Biol., 1991, pp. 581-597, vol. 222.
Meene et al., A comparison of signal sequence prediction methods using a test set of signal peptides, Bioinformatics, 2000, pp. 741-742, vol. 16.
Mendez et al., Functional Transplant of Megabase Human Immunoglobulin loc Recapitulates Human Antibody Response in Mice, Nature Genetics, 1997, pp. 146-156, vol. 15.
Milgrom et al., Treatment of allergic asthma with monoclonal anti IgE antibody, New England Journal Med., 1999, pp. 1966-1973, vol. 341.
Moldenhauer et al., Identity of HML-1 Antigen on Intestinal Intra Epithelial T Cells and of B-1y7 Antigen on Hairy Cell Leukemia, Scan. J. Immunol., 1990, pp. 77-82, vol. 32.
Morel et al., Monoclonal Antibodies to Bovine Serum Albumin: Affinity and Specificity Determinations, Mol. Immunol., 1988, Issue No. 1, pp. 7-15, vol. 25.
Morrison, Sherie L. et al., Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains, Proc. Natl. Acad. Sci. USA, 1984, pp. 6851-6855, vol. 81.
Okazaki et al., New regulatory co-receptors: inducible co-stimulator and PD1, Curr. Opin. Immunol., 2002, pp. 779-782, vol. 14.
Portielje, IL-12: a promising adjuvant for cancer vaccination, Cancer Immunol Immunother, 2003, pp. 133-144, vol. 52.
Presta, Leonard G. et al., Selection, design, and engineering of therapeutic antibodies, J. Allergy Clin. Immunol., 2005, pp. 731-736, vol. 116(4).
Rader et al., A phage display approach for rapid antibody humanization: Designed combinatorial V gene libraries, Proc. Natl. Acad. Sci. USA, 1998, pp. 8910-8915, vol. 95.
Samaridis et al., Cloning of novel immunoglobulin superfamily receptors expressed on human myeloid and lymphoid cells: structural evidence for new stimulatory and inhibitory pathways, Eur. J. Immunol., 1997, Issue 3, pp. 660-665, vol. 27.
Shields, High Resolution Mapping of the Binding Site on Human IgG1 for FcyRI, FcyRII, FcyRIII, and FcRn and Design of IgG1 Variants with Improved Binding to the FeyR, J. of Biol. Chem., 2001, pp. 6591-6604, vol. 276, No. 9.
Slamon et al., Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2, New England J. Med., 2001, pp. 783-792, vol. 344.
Sondermann et al., The 3.2-Angstrom Crystal Structure of the Human IgG1 Fc Fragment-Fc gamma RIII Complex, Nature, 2000, pp. 267-273, vol. 406.
Songsivilai et al., Bispecific antibody: a tool for diagnosis and treatment of disease, Clin. Exp. Immunol, 1990, pp. 315-321, vol. 79.
Stahli et al., Distinction of Epitopes by monoclonal antibodies, Methods in Enzymology, 1983, pp. 242-253, vol. 9.
Tang et al., Use of a Peptide Mimotope to Guide the Humanization of MRK-16, an Anti-P-glycoprotein Monoclonal Antibody, J. Biol. Chem., 1999, pp. 27371-27378, vol. 274.
Traunecker et al., Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells, EMBO J., 1991, pp. 3655-3659, vol. 10.
Traunecker et al., Janusin: New Molecular Design for Bispecific Reagents, Int. J. Cancer Suppl., 1992, pp. 51-52, vol. 7.
Vaughan et al., Human Antibodies with Sub-nanomolar affinities isolated from a large non-immunized phage display library, Nature Biotechnology, 1996, pp. 309-314, vol. vol. 14.
Von Heijne et al., A new method for predkting signal sequence cleavage sites, Nucleic Acids Res., 1986, pp. 4683-4690, vol. 14.
Von Heijne, Patterns of Amino Acids near Signal-Sequence Cleavage Sites, Eur. J. Biochem., 1983, pp. 17-21, vol. 133.
Watson et al., The fine structure of bacterial and phage genes, Molecular biology of the gene, 1987, pp. 224-238, vol. 4.
Wren et al., SIGNAL-Sequence Information and GeNomic AnaLysis, Comput. Methods Programs Biomed., 2002, pp. 177-181, vol. 68.
Xu, JL et al., Diversity in the CDR3 region of Vh is sufficient for most antibody specificities, Immunity, 2000, pp. 37-45, vol. 13.
Yang et al., Identification of the ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury, Natl. Med., 2000, pp. 886-889, vol. 6.
Yang et al., New England J. Med., New England Journal of Medicine, 2003, pp. 427-434, vol. 349.
Columbia University in the City of New York, Recombinant ILT3 protein for the treatment of cancer, Columbia Technology Ventures, 2015, 1-2, N/A.
Kang, Xunlei et al., Inhibitory leukocyte immunoglobulin-like receptors: Immune checkpoint proteins and tumor sustaining factors, Cell Cycle, 2015, 25-40, 15(1).
Xu, Zheng et al., ILT3.Fc-CD166 Interaction Induces Inactivation of p70 S6 Kinase and Inhibits Tumor Cell Growth, The Journal of Immunology, 2017, 1207-1219, 200.
Related Publications (1)
Number Date Country
20190153093 A1 May 2019 US
Provisional Applications (1)
Number Date Country
62587604 Nov 2017 US